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Neuronal signaling in the central nervous system (CNS) requires a highly controlled 
microenvironment.1,2 The blood-brain barrier (BBB) is separating circulating blood 
from the neural tissue of the CNS. This barrier is formed by capillary endothelial 
cells which are connected by tight junctions (Figure 1). The main function of BBB is 
to control molecular traffic, keep out toxins, contribute to ion homeostasis and 
maintain low protein environment in CNS.2 The movement of molecules across the 
BBB is either passive, driven by a concentration gradient from plasma to brain, with 
more lipid-soluble substances entering most easily, facilitated by passive or active 
transporters in the endothelial cell membranes or mediated by receptors via 
transcytosis.   
 
Figure 1. Blood-brain barrier structure and cell association. Figure from reference 1, 
reprinted with permission.  
ABC transporters 
The ATP-binding cassette (ABC) transporters are the largest transporter gene family 
at the BBB. ABC transporters use energy from ATP hydrolysis to actively transport 
endogenous and exogenous compounds across cell membranes.3–5 To date, there 
are 48 ABC transporters divided in seven subfamilies based on the structural 




 1 carry also sugars, amino acids, metal ions, fatty acids, peptides and proteins.4,5 Efflux 
transporters at the BBB are essential for tissue detoxification but they also present a 
major barrier for pharmacotherapy in the treatment of brain diseases. ABC 
transporters strongly contribute to the development of the multidrug resistance 
(MDR) phenotype in neurological diseases.6–9  
P-glycoprotein 
ABCB1, also called MDR1 or P-glycoprotein (P-gp), was the first ABC transporter 
described and is the most studied efflux transporter so far. P-gp is located in the body 
in a wide range of tissues, particularly in epithelial cells of lower gastrointestinal tract 
(GIT), canalicular surface of hepatocytes and luminal surface of proximal tubule in 
kidney and placenta.3,10 P-gp is expressed in many blood-tissue barriers such as in 
blood-brain, blood-cerebrospinal fluid, blood-retina and blood-testis barriers.11–13 
Originally P-gp was thought to reside only on the luminal, blood-facing side, of the 
BBB capillary endothelial cells, but more recent data has identified P-gp also on the 
abluminal membrane and in adjacent pericytes, astrocytes and microglia.14–16 Inside 
the cells, P-gp is distributed along the nuclear envelope, caveolae, cytoplasmic 
vesicles, Golgi complex and rough endoplasmic reticulum (RER).16 P-gp is 1280 
amino acids long (molecular weight ∼170 kDa) glycoprotein, expressed as a single 
chain containing two ATP binding regions and two homologous portions each 
containing six transmembrane domains (Figure 2).17 The first extracellular loop of P-
gp is highly N-glycosylated.18 Inside the lipid bilayer of BBB and transmembrane 
domain is a large cavity open to both the cytoplasm and the inner lipid leaflet.19 The 
volume of this internal cavity is substantial (~6000 Å3) and at least two compounds 
could bind there simultaneously.19–21 The upper half of this drug-binding pocket 
contains mostly hydrophobic and aromatic residues whereas the lower half of the 
pocket has more polar and charged residues.  




Figure 2. Schematic representation of P-gp, BCRP and MRP1 structure. Figure from 
reference 66, reprinted with permission.  
Different mechanisms have been proposed to describe the P-gp efflux. The lipid 
bilayer of the BBB is generally considered important for the transport. In the flippase 
model, drug interacts with the membrane before it interacts with the transport 
protein. The drug in the inner leaflet will either diffuse into the cytoplasm or is flipped 
by P-gp into the outer leaflet.22 In the hydrophobic vacuum cleaner model, P-gp can 
efflux drugs directly from the inner leaflet out to the extracellular space.23 ATP 
binding and release of energy by ATP hydrolysis into ADP was found to be essential 
for efflux of P-gp.24 The three-dimensional conformation of P-gp changes upon 
binding of nucleotides to the intracellular nucleotide-binding domains.25 One 
molecule of drug is effluxed at the expense of two molecules of ATP. Release of 
ADP from nucleotide binding sites reverts P-gp back to its native conformation. It 
has been suggested based on the crystal structure, that in the inward-facing 
conformation, P-gp provides access to drugs to the internal cavity through two 
portals.19 These portals form a contiguous space allowing P-gp to scan the inner 
leaflet to select and bind its substrates. Substrate release could be either facilitated 
by ATP hydrolysis or result from decreased binding affinity caused by changes in 
specific residue contacts between the protein and drug during the conformational 
change. This change from open inward conformation to closed outward-facing 






Figure 3. The ATP-switch model of mouse P-gp efflux describing the conformational 
change from inward- to outward-facing conformation and hydrolysis of ATP. Figure 
from reference 27, reprinted with permission.  
Breast cancer resistance protein 
Breast cancer resistance protein (BCRP in humans, Bcrp in rodents, ABCG2) is an 
ABC efflux transporter named after its discovery in a multidrug resistant breast 
cancer cell line.28,29 Substrate specificity is largely overlapping with P-gp. In addition 
to many chemotherapeutics, BCRP is transporting physiological substances such as 
estrone-3-sulfate, 17β-estradiol 17-(β-D-glucuronide) and uric acid. As well as P-gp, 
BCRP is also highly expressed on the luminal membranes of the placenta, intestinal 
epithelium, liver hepatocytes, endothelial cells of brain microvessels and renal 
proximal tubular cells. However, structurally BCRP is distinct, as it is only a half 
transporter with only one nucleotide binding domain and one bundle of six 
transmembrane domains (Figure 2). Therefore, BCRP dimerizes in order to form a 
functional transporter.30 This structure suggests an inward-facing configuration 
similar to P-gp, with the nucleotide-binding domains of the dimer widely separated 
from each other. 
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P-gp is encoded by a small multigene family (Mdr class I, II and III). All three 
isoforms are present in rodents (Mdr1a, Mdr1b and Mdr2), while humans express 
only MDR1 and MDR3.31,32 In the rat brain endothelial cells, Mdr1a was found to 
be principally expressed.33 Mouse P-gp has 87 % sequence identity to human P-gp.19 
However, the expression levels of transporter proteins demonstrate considerable 
species differences in the BBB.34,35 In a proteomic LC-MS analysis, BCRP was found 
to be the most abundant transporter protein in the human brain. Its expression level 
was 1.8-fold greater in humans than in mice.36 In contrast, P-gp protein expression in 
humans was 2.3-fold smaller than that of Mdr1a in mice. These species differences 
complicate the translation of pharmacological findings from one animal strain to 
another, as well as from animals to humans. In addition, LC-MS analysis measures 
total transporter protein and does not distinguish between active and inactive forms. 
BCRP is suggested to be active only as a dimer, but in the LC-MS analysis also 
monomer is measured. Another complicating observation is, that low affinity 
substrates may still be significantly effluxed if low affinity is compensated by higher 
expression of a transporter. Therefore, although BCRP expression in the human 
brain is higher than P-gp expression, it is impossible to say which transporter is more 
important in the drug delivery.37  
Multidrug resistance proteins 
Multidrug resistance proteins (MRP) are another abundant subfamily of ABC 
transporters at the BBB. MRP1 (ABCC1), MRP4 (ABCC4) and MRP5 (ABCC5) 
have been identified on the luminal side of the capillary endothelial cells of the 
human brain, but their function is less studied compared to P-gp and BCRP.38 MRP1 
has been found to favor lipophilic compounds conjugated with glutathione, 
glucuronate or sulfate as its substrates, whereas MRP4 and MRP5 transport 
intracellular signaling molecules such as cyclic AMP, cyclic GMP and other 
nucleotide analogues. Compared to P-gp structure, MRP1 has additional bundle of 
transmembane domains in the N-terminus (Figure 2).39   
Neuropathological conditions involving P-gp at the BBB 
P-gp and other ABC transporters are affected in many neuropathological conditions. 




 1 common form of dementia. Accumulation of amyloid-beta (Aβ) protein plaques is 
thought to be the primary cause in AD pathogenesis.40 In a healthy brain Aβ is 
cleared via several ways: (i) enzymatic degradation by variety of proteases, (ii) 
perivascular drainage, (iii) continuous slow removal of Aβ through the interstitial 
fluid bulk flow into cerebrospinal fluid (CSF) and from there into the bloodstream 
and (iv) transport (efflux) of Aβ across the BBB into the bloodstream. The receptor 
for advanced glycation end products (RAGE) is the primary transporter of Aβ from 
the blood stream across the BBB into the brain, whereas the low-density lipoprotein 
receptor-related protein-1 (LRP-1) is one the transporters involved in Aβ transport 
out of the brain into the blood. Several studies suggest also ABC transporters, P-gp 
particularly, to be involved in the efflux of Aβ.41,42 Decreased P-gp function has been 
found in AD patients and increased accumulation of Aβ in the mice brains where P-
gp was inhibited or knocked out.40 P-gp function is decreasing with increasing age, 
which is the main risk factor for sporadic AD.43–45   
Parkinson´s disease (PD) is a neurodegenerative disease associated with neuronal 
cell death in the midbrain where large amounts of neurotransmitters such as 
dopamine, noradrenaline, serotonin and acetylcholine normally are produced.46 
Genetic susceptibility and exposure to environmental toxins increase the risk of 
PD.47,48 Decreased P-gp function has been proposed as one reason for increased 
toxin accumulation in the brain and polymorphism in the ABCB1 gene has also been 
found in many PD patients.49 P-gp substrate (R)-[11C]verapamil uptake was 
significantly increased in the midbrain of PD patients compared to controls indicating 
decreased P-gp function.50 However, this was not observed in the early stage PD 
patients, suggesting that P-gp dysfunction is probably not involved in the initial 
pathogenesis of the disease, but develops in later disease stages.51,52  
Epilepsy is a neurological disorder characterized by seizures due to abnormal nerve 
cell activity in the brain cortex.53–55 Approximately a third of all epileptics do not 
respond to antiepileptic drugs. It is not clear whether pharmacoresistance develops 
as a result of the disease process or exists at the time of initial seizure. P-gp 
overexpression has been proposed to be a major contributor in the drug resistance. 
Many antiepileptic drugs are substrates for P-gp and some of them have been 
reported to induce P-gp function via neuronal receptors.56,57 P-gp overexpression 
may be a consequence of (i) this upregulation by antiepileptic drugs or 
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neurotransmitters, (ii) seizures themselves or (iii) genetic variation.58,59 
Overexpression of many ABC transporter genes has been found in patients with 
refractory epilepsy.60 Also, the expression of P-gp protein was greater in drug-
resistant than in drug-responsive patients and P-gp expression in patients with 
recurrent seizures was significantly higher than in seizure free patients at BBB in 
temporal lobe.61,62 In a pilot imaging study with (R)-[11C]verapamil, no significant 
difference in the P-gp function was observed between epileptogenic and 
nonepileptogenic regions in patients with drug-resistant unilateral temporal lobe 
epilepsy.63 In another study, however, pharmacoresistant patients had lower (R)-
[11C]verapamil influx corresponding to higher P-gp function than seizure free 
patients.64 Higher seizure frequency was also associated with higher P-gp function.  
Positron emission tomography 
Positron emission tomography (PET) and single-photon emission computed 
tomography (SPECT) are molecular imaging techniques used to measure in vivo 
processes noninvasively. These techniques are often combined with magnetic 
resonance imaging (MRI) or computed tomography (CT) to provide better 
anatomical information. In PET and SPECT imaging, radioactive isotopes are 
introduced into biologically active molecules which are injected at tracer 
(subpharmacological) doses into the body. Radionuclides used in PET scanning are 
typically isotopes with short half-lives such as 11C (~20 min), 15O (~2 min), 18F (~110 
min) and 68Ga (~68 min). Unstable radioactive atoms decay by positron emission to 
become stable. The decay of radionuclides occurs by emission of a positively 
charged particle called positron (β+). The positron passes a short distance (1–5 mm), 
dependent on the positron energy of the isotope, in the surrounding tissue before it 
annihilates by combining with an electron. Then, the mass of the positron and 
electron is converted to energy resulting in two 511 keV γ-rays which are emitted 
simultaneously at approximately 180° to each other. The pair of γ-rays is detected 
by ring of detectors in the PET scanner. The acquisition of a large number of 
coincident events provides data which can be reconstructed to an image with 





 1 P-gp substrates and inhibitors  
Both P-gp substrate and inhibitor molecules can be labeled with positron emitters, 
such as 11C or 18F, and used in the PET imaging. PET tracers can provide information 
of in vivo functionality of P-gp, which cannot be obtained with in vitro tests. 
Substrates bind in a substrate site, usually in a reversible noncovalent manner, and 
get transported out of the brain. Radiolabeled substrates can be used to image P-gp 
function. Since currently available PET tracers (Figure 4) are high-affinity substrates 
for P-gp, they are efficiently transported out of the brain by P-gp which results in low 
brain uptake. Low brain uptake makes it difficult to use these tracers for measuring 
cerebral P-gp overexpression, which is expected to occur, for example, in medically 
refractory epilepsy.65 Inhibitor molecules binding to P-gp would be therefore 
preferred to measure P-gp expression, but so far efforts in developing such a tracer 
have not been very successful. Inhibitor tracers are expected to show a signal 
increase rather than a signal reduction in brain regions that overexpress P-gp. There 
are several mechanisms of P-gp inhibition. Inhibition could be caused by (i) 
occupation of P-gp by a stronger substrate with higher affinity for P-gp than other 
substrates, so that the weaker substrates cannot be transported anymore, (ii) fast 
passive diffusion through the membrane back into the brain, thereby canceling out 
net efflux, (iii) alteration of lipids in the membrane and prevention of conformational 
changes of P-gp or (iv) inhibition of ATPase activity.66 Only the last option refers to 
actual inhibitors, which are binding to P-gp and thereby preventing binding of ATP 
to nucleotide binding sites. Problem is also, that inhibitor capacity is usually 
concentration dependent. Inhibition of P-gp can be observed at a pharmacological 
dose but substrate behavior at a tracer concentration.67  
(R)-[11C]Verapamil 
The L-type calcium channel blocker verapamil has been widely used in the treatment 
of hypertension, angina pectoris and cardiac arrhythmias.68 Today, (R)-
[11C]verapamil is the most extensively used P-gp substrate PET tracer (Figure 4). In 
nanomolar concentrations, [11C]verapamil is selectively transported by P-gp and not 
by MRP1 or BCRP at the BBB.69 At high doses, verapamil has P-gp inhibition activity 
but its use as an inhibitor is hampered by toxic effects.70 [11C]Verapamil has been 
used extensively in humans for example in studies related to Parkinson’s disease,50–
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52 aging,44,45 Alzheimer’s disease,42 schizophrenia71 and P-gp modulation.72–76 (R)- 
and (S)-[11C]verapamil are equally transported by P-gp, but since (R)-verapamil is 
metabolized less in man and it has lower affinity for calcium channels, it is primarily 
used in the PET imaging studies.77 Metabolic stability of verapamil is its biggest 
drawback. Verapamil metabolizes preferentially to norverapamil via N-
demethylation.78 In addition, small polar radiolabeled metabolites are formed, which 
may result in a non-P-gp-mediated 11C signal in the brain.79 Furthermore, N-
dealkylation products are formed, for example [11C]D617, which is itself a substrate 
of P-gp.80 These radioactive metabolites complicate quantification of P-gp function. 
 
Figure 4. The most commonly used P-gp PET tracers  
[11C]N-desmethyl-Loperamide 
Loperamide was developed as an antidiarrheal agent that acts through agonism of 
gut μ-opioid receptors.81 [11C]Loperamide has been used as a P-gp substrate in the 
PET imaging studies but it is avidly metabolized to [N-methyl-11C]N-desmethyl-




 1 substrate for P-gp, even at a pharmacological dose, and it is nowadays used as a PET 
tracer instead of [11C]loperamide.83 Demethylation of [11C]dLop may also occur, but 
it will lead only to single-carbon radiometabolites such as [11C]methanol. These 
metabolites will be oxidized and ultimately expired as [11C]carbon dioxide so they 
should not accumulate in the brain tissue. dLop has a pKa of 7.3 and it may be 
trapped by passive diffusion into acidic organelles, mainly lysosomes, followed by 
protonation within the organelle.84,85 This irreversible trapping amplifies the PET 
signal by accumulating the radioactivity over time so it is advantageous from an 
imaging perspective.86 [11C]dLop is a high affinity substrate for P-gp and in a normal 
condition, P-gp almost completely blocks its brain entry. When P-gp was inhibited 
with tariquidar, a significantly increased [11C]dLop brain uptake was measured in 
humans.87  
[11C]Laniquidar 
Laniquidar was developed as a P-gp inhibitor, but has been found to possess inhibitor 
properties only at a pharmacological concentration. At a tracer dose, [11C]laniquidar 
shows substrate behavior. In the rat brain in baseline conditions, [11C]laniquidar had 
a very low uptake, which was increased significantly after administration of 
cyclosporine A or tariquidar.88,89 Also addition of a high dose of unlabeled laniquidar 
lead to increased [11C]laniquidar uptake in mouse brain.83 Plasma metabolite analysis 
in rats 30 min after injection, showed 68 % of radioactivity to be still unchanged 
parent compound.89 In another report, parent compound constituted 45 % of 
radioactivity at 45 min in plasma and 72 % in brain.88 Labeled metabolites of 
[11C]laniquidar are likely to be brain entering also in humans, which complicates the 
quantification. Best fits for PET data were found by a dual-input model, which 
accounts for uptake of [11C]laniquidar and its labeled metabolites.90 Laniquidar can 
safely be administered both orally and intravenously in humans.91,92 Dosimetry study 
also declared [11C]laniquidar as a safe PET tracer in humans with highest radiation 
dose in liver, spleen, kidneys and lung.93 
[11C]Tariquidar 
Tariquidar is at low concentrations a substrate for both P-gp and BCRP, although 
affinity for P-gp is higher.67,94–96 At pharmacological concentrations tariquidar acts as 
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an inhibitor.97,98 Advantage of [11C]tariquidar is its good metabolic stability.94 One 
hour after injection in rats, 96 % of plasma radioactivity represented unchanged 
parent compound. Although tariquidar is not specific for P-gp, it could discriminate 
between high and low P-gp expressing tumors, whereas other P-gp tracers 
[11C]elacridar and (R)-[11C]verapamil could not.99 In humans, 24 % increase in 
[11C]verapamil brain uptake was measured after 2 mg/kg tariquidar inhibition.75 
Similar [11C]tariquidar brain uptake was found after 3 mg/kg dose of unlabeled 
tariquidar.100 A maximum increase of 2.7-fold in [11C]verapamil brain uptake was 
observed after 8 mg/kg dose.101 In rats, the [11C]verapamil brain uptake has been 
reported to increase up to 12-fold after tariquidar inhibition.98 In a dosimetry study 
in humans, highest radiation doses of [11C]tariquidar were measured in liver, spleen 
and kidney.102 Tariquidar has been labeled also with 18F to increase its applicability 
due to longer half-life. [18F]Fluoroethyl tariquidar has been synthesized and evaluated 
in vivo in mice.103 Addition of fluoroethyl did not affect the potency towards the 
transporters, as the in vivo behavior was similar to carbon-11 labeled counterpart.  
[11C]Elacridar 
[11C]Elacridar has similar properties as [11C]tariquidar, it is a substrate for P-gp and 
BCRP at tracer dose, but inhibitor at higher concentrations. Elacridar is in fact more 
potent inhibitor than tariquidar. Half-maximum effective dose (ED50) values of 3.0 ± 
0.2 and 1.2 ± 0.1 mg/kg were determined in rats for tariquidar and elacridar, 
respectively.97 A 5.4-fold increase in the [11C]elacridar brain uptake in rats was 
measured after inhibition with 5 mg/kg dose of unlabeled elacridar.104 Metabolically 
[11C]elacridar was stable in rats, after 1 h, still 70 % of radioactivity constituted of the 
parent compound in plasma. In mice, increase in [11C]elacridar brain uptake was 2.5-
fold in Mdr1a/b(-/-) knockout compared to wild type and 1.3-fold in Bcrp1(-/-) mice.104 
Uptake in Mdr1a/b(-/-)Bcrp1(-/-) mice was more than the combined uptake in single 
transporter knockouts.67 In human brain, [11C]elacridar had a very low uptake 
(standardized uptake value 0.1) which was increased 21 % after 3 mg/kg of 
tariquidar.100 Two different fluorine-18 labeled versions of elacridar have been 
prepared, [18F]fluoroethyl elacridar and 1-[18F]fluoroelacridar.103,105 Both of them had 
similar properties in vivo in rodents as the carbon-11 labeled version, but 




 1 Aim of the thesis 
Majority of the current P-gp PET tracers have been labeled with carbon-11. Due to 
the short half-life (20 min) of this radioisotope, it can only be applied in PET centers 
with on-site cyclotron and good manufacturing practice (GMP) compliant 
radiopharmaceutical production facilities. Fluorine-18 has similar positron emission 
properties as carbon-11, but the longer half-life of 110 min enables commercialization 
and use which is not possible with carbon-11. Fluorine-18 tracers can be transported 
to other imaging centers without on-site cyclotron within 4 h range, which is current 
routine practice for glucose analogue [18F]FDG, the most used PET 
radiopharmaceutical. Longer half-life also enables that more patients can be dosed 
from one production batch and longer scan times may be applied.  
The aim of this thesis was to develop new fluorine-18 labeled PET tracers for P-gp 
imaging, both substrate and inhibitor tracers. Compounds were selected from library 
of molecules synthesized by group of Professor Colabufo in the University of Bari, 
Italy. Compounds were chosen based on the in vitro screening results with non-
radioactive molecules. Fluorine-18 labeling method was developed for the selected 
candidates. Tracers were evaluated in vivo in different rodent models to assess their 
suitability for P-gp imaging. 
General requirements for a CNS PET tracer apply well also for P-gp tracers.106 Tracer 
should be brain penetrating, have high selectivity (30−100 fold) to its target and 
exhibit low nonspecific binding in order to achieve good signal-to-noise ratio. Lower 
lipophilicity generally leads to reduced nonspecific binding, but on the other hand, 
tracers need to be lipophilic in order to enter the brain. Tracer should have low to 
moderate in vivo metabolism and should not have brain penetrating radioactive 
metabolites, which would disturb the quantification by PET. Fluorine-18 tracers 
should not have extensive defluorination in vivo which would cause uptake in the 
skull and could lead to problems in the quantification due to spillover of the signal. 
P-gp substrates should have increased brain accumulation when P-gp is either 
inhibited or knocked out.  
There are also requirements for the radiochemistry and production of 
radiopharmaceuticals. Ligand candidates should have structures amenable to insert 
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a short-lived positron emitting isotope. The radiosynthesis should be relatively easy 
with high radiochemical yield, molar activity and radiochemical purity. Furthermore, 
radiosynthesis should be suitable for GMP implementation using automated 
synthesis modules. Translation into human use would also require that safety 
requirements regarding dosimetry and toxicity are met.  
Outline of the thesis 
In chapter 2, three new P-gp substrate candidates are selected: MC210, MC224 and 
MC225. Radiosynthesis using fluorine-18 is developed and their brain uptake is 
assessed with PET imaging in transporter knockout and wild-type mice. Brain uptake 
is also compared to (R)-[11C]verapamil. [18F]MC225 is chosen for further analysis in 
rats, which are reported in chapter 3. Selectivity to P-gp is studied by using P-gp and 
Bcrp inhibitors. Arterial blood samples are collected during the scans in order to 
perform metabolite analysis and to select a kinetic model for quantification of the P-
gp function in vivo.  
P-gp function can change due to many external factors, but reports suggest that P-gp 
function also follows its internal daily rhythm. In chapter 4, [18F]MC225 is used to 
study diurnal rhythm of P-gp function in the brain in rats and the effect of acute sleep 
deprivation. Separate groups of rats are scanned at different points of the light – dark 
cycle and in additional experiment rats are scanned after 10 h sleep deprivation. 
Chapter 5 explores different in vitro tests, bidirectional transport and calcein-AM 
assay, in finding P-gp ligands and their correlation with the in vivo PET studies. 
Already reported in vivo data from (R)-[11C]verapamil, [18F]MC225, [18F]MC224 and 
two different [18F]fluoroethyl verapamil analogues are used. In addition, two new 
molecules, [18F]MC198 and [18F]KE64, are evaluated in knockout and wild-type 
mice. All the molecules are labeled with tritium (3H) for the in vitro bidirectional 
transport assay. 
Chapter 6 discusses the results and conclusions of this thesis and future perspectives. 
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P-glycoprotein (P-gp), along with other transporter proteins at the blood-brain barrier 
(BBB), limits the entry of many pharmaceuticals into the brain. Altered P-gp function 
has been found in several neurological diseases. To study the P-gp function, many 
positron emission tomography (PET) radiopharmaceuticals have been developed. 
Most P-gp radiopharmaceuticals are labeled with carbon-11, while labeling with 
fluorine-18 would increase their applicability due to longer half-life. Here we present 
the synthesis and in vivo evaluation of three novel fluorine-18 labeled 
radiopharmaceuticals: 4-((6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-2-
(4-fluorophenyl)oxazole (1a), 2-biphenyl-4-yl-2-fluoroethoxy-6,7-dimethoxy-1,2,3,4-
tetrahydro-isoquinoline (2), and 5-(1-(2-fluoroethoxy))-[3-(6,7-dimethoxy-3,4-dihydro-
1H-isoquinolin-2-yl)-propyl]-5,6,7,8-tetrahydronaphthalen (3). Compounds were 
characterized as P-gp substrates in vitro, and Mdr1a/b(–/–)Bcrp1(–/–) and wild-type mice 
were used to assess the substrate potential in vivo. Comparison was made to (R)-
[11C]verapamil, which is currently the most frequently used P-gp substrate. 
Compound [18F]3 was performing the best out of the new radiopharmaceuticals; it 
had 2-fold higher brain uptake in the Mdr1a/b(–/–)Bcrp1(–/–) mice compared to wild-
type and was metabolically quite stable. In the plasma, 69% of the parent compound 
was intact after 45 min and 96% in the brain. Selectivity of [18F]3 to P-gp was tested 
by comparing the uptake in Mdr1a/b(–/–) mice to uptake in Mdr1a/b(–/–)Bcrp1(–/–) mice, 
which was statistically not significantly different. Hence, [18F]3  was found to be 
selective for P-gp and is a promising new radiopharmaceutical for P-gp PET imaging 
at the BBB. 










P-glycoprotein (P-gp) is an efflux transporter protein on the luminal membrane of 
the brain endothelial cells.1 It belongs to a family of transporters that has a similar 
function at the blood-brain barrier (BBB), where P-gp and the breast cancer resistance 
protein (BCRP) are the most important in the human brain.2 This family of 
transporters is also known as the ATP-binding cassette (ABC) transporters, as their 
function is ATP dependent.3 They recognize small hydrophobic exogenous 
compounds that have diffused through the BBB and efflux them back into the blood. 
Consequently, P-gp not only protects the brain from harmful compounds, but can 
also reduce the uptake of drugs that need to act in the brain.4 Moreover, P-gp 
function is altered in some neurological diseases. For instance, decreased P-gp 
function has been found in Alzheimer’s disease (AD)5,6 and Parkinson’s disease 
(PD),7 while it has been hypothesized that P-gp function is increased in epilepsy.8 
Positron emission tomography (PET) is a molecular imaging technique that is able 
to measure tissue concentrations of compounds labeled with positron emitting 
isotopes as a function of time in a noninvasive manner. To study P-gp function with 
PET, radiolabeled substrates as well as radiolabeled inhibitors could be applied.9 
The most widely used substrate radiopharmaceutical for P-gp imaging is 
[11C]verapamil. It has been used either as racemic mixture or as (R)-enantiomer10 
and has been utilized in clinical research.11,12 The P-gp inhibitors [11C]tariquidar and 
[11C]elacridar have been labeled with carbon-11. They were aimed to bind P-gp with 
high selectivity. However, they were proved to behave as substrates at tracer level 
and are not specific for P-gp, but are also transported by BCRP.13,14  
Most of the labeled compounds that are currently in use are labeled with carbon-11, 
while labeling with fluorine-18 would lead to a radiopharmaceutical that can be 
transported to other imaging centers without on-site cyclotron due to the longer half-
life of fluorine-18 of 110 min vs 20 min for carbon-11. In addition, the longer half-life 
would enable prolonged imaging times and also more subjects could be dosed from 
one radiopharmaceutical production. Half-life of fluorine-18 can be a disadvantage 
only if repeated scanning for the same subject during one day is desired.    
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There are only a few examples of fluorine-18 labeled P-gp radiopharmaceuticals that 
have been applied in CNS disorders. Tariquidar and elacridar analogues have been 
labeled with fluorine-18 by a fluoroalkylation method, demonstrating similar in vivo 
behavior as their carbon-11 labeled counterparts.15 An elacridar analogue has been 
labeled also via a nucleophilic aromatic fluorination, but the utilization of 1-
[18F]fluoroelacridar is limited due to the low radiochemical yield and in vivo 
defluorination.16  
 
Figure 1. Structures of [18F]1a, [18F]2, [18F]3, [18F]fluoroethyl tariquidar, 
[18F]fluoroethyl elacridar and 1-[18F]fluoroelacridar 
Clearly, there is an unmet need to develop 18F-radiolabeled compounds to study P-
gp function with PET at the BBB. We report three novel compounds: 4-((6,7-
dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-2-(4-fluorophenyl)oxazole (1a, 
MC210), 2-biphenyl-4-yl-2-fluoroethoxy-6,7-dimethoxy-1,2,3,4-tetrahydro-
isoquinoline (2, MC224), and 5-(1-(2-fluoroethoxy))-[3-(6,7-dimethoxy-3,4-dihydro-
1H-isoquinolin-2-yl)-propyl]-5,6,7,8-tetrahydronaphthalen (3, MC225), which were 
identified as P-gp substrates in in vitro experiments. All of the compounds contain 




the same basic 6,7-dimethoxytetrahydroisoquinoline moiety as tariquidar or elacridar 
also have.17,18 All three compounds were labeled with fluorine-18 (Figure 1) and their 
brain uptake was investigated with PET imaging in FVB mice as well as in the 
Mdr1a/b(–/–)Bcrp1(–/–) knockout mice, and results were compared to those of (R)-
[11C]verapamil. In addition, [18F]3 was investigated in Mdr1a/b(–/–) mice to see if the 
compound was selective for P-gp. 
2. Experimental Section 
2.1. Chemicals and cell lines 
All reagents and solvents were obtained from commercial suppliers (Merck (New 
Jersey, USA), Sigma-Aldrich (St. Louis, USA), Rathburn (Walkerburn, UK) and B. 
Braun (Melsungen, Germany)) and were used without further purification. (R)-
Norverapamil was purchased from ABX advanced biochemical compounds 
(Radeberg, Germany). Human liver microsomes were obtained from BD Gentest 
(20 mg/mL) (San Jose, USA). Cell culture reagents were purchased from Celbio s.r.l. 
(Pero Mi, Italy). CulturePlate 96/wells plates were bought from PerkinElmer Life 
Science (Waltham, USA). MDCK-MDR1, MDCK-BCRP, and MDCK-MRP1 cell 
lines were a gift from Professor P. Borst, NKI-AVL Institute, Amsterdam, 
Netherlands. Caco-2 cells were a gift from Dr. Aldo Cavallini and Dr. Caterina Messa 
from the Laboratory of Biochemistry, National Institute for Digestive Diseases, ‘S. de 
Bellis’, Bari, Italy.  
2.2. Organic synthesis 
2.2.1. General methods  
Column chromatography was performed with Merck silica gel 60 Å (63–200 μm) as 
the stationary phase. Recording of mass spectra was done on an HP 6890-5973MSD 
gas chromatograph/mass spectrometer (Santa Clara, USA); only significant m/z 
peaks, with their percentage of relative intensity in parentheses, are reported. 1H 
NMR spectra were recorded in CDCl3 at 300 MHz with Varian Mercury-VX 
spectrometer (Palo Alto, USA) or on an Avance 500 MHz spectrometer (Bruker, 
Billerica, USA). All chemical shift values are reported in ppm (δ) relative to the 
solvent peak (7.27 for CHCl3). Melting points were determined in open capillary on 
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a Gallenkamp electrothermal apparatus (Leicestershire, UK). ESI-MS analyses were 
performed on an Agilent 1100 LC/MSD trap system VL (Santa Clara, USA). 
Elemental analyses (C, H, N) were performed on Eurovector Euro EA 3000 analyzer 
(Milan, Italy); the analytical results were within ±0.4% of the theoretical values for the 
given formula.  
2.2.2. Synthesis of 4-fluorobenzamide (5a)  
4-Fluorobenzoic acid (4a, 2.0 g, 14 mmol) was refluxed with SOCl2 (2.0 mL, 28 
mmol) in the presence of Et3N (1.0 mL, 7.2 mmol) for 1 h. After evaporation of 
SOCl2, the resulting acyl chloride was added to a 45 mL mixture of NH4OH (8 M), 
H2O, and CH2Cl2 (1:1:1 v/v/v). This mixture was stirred at room temperature for 4 
h. The organic layer was separated from the aqueous layer and washed with 2 M 
NaOH (3 × 10 mL). The organic solution was dried over Na2SO4 and evaporated 
under reduced pressure. The residue was purified by silica gel column 
chromatography (CH2Cl2/MeOH 95:5 v/v). The yield of brown solid 5a was 590 mg 
(30%). GC–MS m/z: 139 (M+, 67), 123 (100), 95 (72).  
2.2.3 Synthesis of 4-(chloromethyl)-2-(4-fluorophenyl)oxazole (6a)  
Amide 5a (590 mg, 4.2 mmol) was reacted with 1,3-dichloroacetone (1.0 g, 8.4 mmol) 
at 200 ˚C for 5 h. After cooling to room temperature, water (10 mL) and CHCl3 (10 
mL) were added. The aqueous phase was extracted with CHCl3 (3 × 50 mL), and 
the combined organic layers were dried over Na2SO4 and evaporated under reduced 
pressure. The residue was purified on silica gel column chromatography 
(hexane/EtOAc 8:2 v/v) yielding 270 mg (30%) of 6a as a brown solid. GC–MS m/z: 
213 (M++2, 19), 211 (M+, 57), 176 (78). 1H NMR (300 MHz, CDCl3) δ: 8.06 (d, 1H, J 
= 8.0 Hz, phenyl-H2), 8.03 (d, 1H, J = 8.1 Hz, phenyl-H3), 7.60 (s, 1H, oxazole-H5 ), 
7.18 (d, 1H, J = 8.3 Hz, phenyl-H6), 7.16 (d, 1H, J = 8.0 Hz, phenyl-H5), 4.32 (s, 2H, 
CH2). 
2.2.4. Synthesis of 4-((6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-
2-(4-fluorophenyl)oxazole (1a) 
Compound 6a (260 mg, 1.0 mmol) was alkylated with 6,7-dimethoxy-1,2,3,4-
tetrahydroisoquinoline (460 mg, 2.4 mmol) in DMF (20 mL) using Na2CO3 as a base 




(250 mg, 2.4 mmol). The mixture was refluxed overnight. DMF was evaporated 
under reduced pressure, and the residue was partitioned between H2O (20 mL) and 
CHCl3 (20 mL). The organic phase was separated, the aqueous phase was extracted 
with CHCl3 (3 × 50 mL), and the collected organic fractions were dried over Na2SO4 
and evaporated under reduced pressure. The residue was purified on silica gel 
column chromatography (CH2Cl2/EtOAc 1:1 v/v) to obtain 270 mg of 1a as brown 
oil in 74% yield. Hydrochloride salt was dissolved in methanol while heating, Et2O 
was added, and the solution was cooled down to recrystallize the product. Mp: 232–
235 ˚ C. ESI+/MS m/z: 369 [M+H]+, 391 [M+Na]+. ESI+/MS/MS m/z: 352 (16), 230 (50), 
176 (98), 121 (100). 1H NMR (300 MHz, CDCl3) δ: 8.05 (d, 1H, J = 8.0 Hz, phenyl-
H2) 8.03 (d, 1H, J = 8.1 Hz, phenyl-H3), 7.60 (s, 1H, oxazole-H5), 7.16 (d, 1H, J = 8.0 
Hz, phenyl-H5), 7.15 (d, 1H, J = 8.2 Hz, phenyl-H6), 6.58 (s, 1H, isoquinoline-H5), 
6.50 (s, 1H, isoquinoline-H8), 3.88 (s, 3H, CH3), 3.82 (s, 3H, CH3), 3.75–3.79 (m, 4H, 
NCH2CH2), 2.94 (s, 4H, CH2NCH2). Purity of the final compound was established 
by combustion analysis of the corresponding hydrochloride salt, confirming a purity 
≥95%. (C,N,H) C21H21FN2O3HCl(H2O)0.5. 
2.2.5. Synthesis of 2-biphenyl-4-yl-2-fluoroethoxy-6,7-dimethoxy-1,2,3,4-
tetrahydro-isoquinoline (2) 
A suspension of NaH (24 mg, 1.0 mmol) in dry DMF (3.0 mL) was stirred at room 
temperature for 10 min. A solution of phenol precursor 9 (1.0 g, 1.0 mmol) in DMF 
(1.0 mL) was added, and the solution was stirred for 1 h. A solution of 2-fluoroethyl 
tosylate was added (860 mg, 2.0 mmol) in DMF (1.0 mL), and the reaction mixture 
was stirred for 4 h. Water was added until effervescence ceased. The solvent was 
evaporated and the residue was partitioned between H2O (20 mL) and CHCl3 (20 
mL). The organic phase was separated, the aqueous phase was extracted with CHCl3 
(3 × 50 mL), and the collected organic fractions were dried over Na2SO4 and 
evaporated under reduced pressure. The residue was purified on silica gel column 
chromatography (CHCl3/MeOH 19:1 v/v) and recrystallized from MeOH/Et2O to 
obtain 190 mg of 2 (45%). (C,N,H) C26H28FNO3HCl. ESI+/MS m/z: 444 [M+Na]+. 
ESI+/MS/MS m/z: 441 (100). 1H NMR (300 MHz, CDCl3) δ: 7.42 (dd, 4H, J = 7.2 Hz, 
J = 8.0 Hz phenyl-H2’,3’,5’,6’), 7.12 (d, 2H, J = 8 Hz, phenyl-H2,6), 7.01 (d, 2H, J = 7.5 
Hz, phenyl-H3,5), 6.60 (s, 1H, isoquinoline-H5), 6.45 (s, 1H, isoquinoline-H8), 4.83 (t, 
1H, J =3 Hz, FCH2CH2), 4.60 (t, 1H, J =3 Hz, FCH2CH2), 4.14 (t, 1H, J =3 Hz, 
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FCH2CH2), 4.10 (t, 1H, J =3 Hz, FCH2CH2), 3.83 (s, 3H, CH3), 3.80 (s, 3H, CH3), 
3.71 (s, 2H, NCH2), 3.57 (s, 2H, NCH2) 2.83–2.76 (m, 4H, NCH2CH2). 
2.2.6. Synthesis of 5-(1-(2-fluoroethoxy))-[3-(6,7-dimethoxy-3,4-dihydro-1H-
isoquinolin-2-yl)-propyl]-5,6,7,8-tetrahydronaphthalen (3)  
A suspension of NaH (48 mg, 2.0 mmol) in dry DMF (3.0 mL) was stirred at room 
temperature for 10 min. A solution of phenol precursor 14 (560 mg, 2.0 mmol) in 
DMF (1.0 mL) was added, and the solution was stirred for 1 h. A solution of 2-
fluoroethyl tosylate was added (1.1 g, 4.0 mmol) in DMF (1.0 mL), and the reaction 
mixture was stirred for 4 h. Water was added until effervescence ceased. The solvent 
was evaporated, and the residue was partitioned between H2O (20 mL) and CHCl3 
(20 mL). The organic phase was separated, the aqueous phase was extracted with 
CHCl3 (3 × 50 mL), and the collected organic fractions were dried over Na2SO4 and 
evaporated under reduced pressure. The residue was purified on silica gel column 
chromatography (CHCl3/MeOH 19:1 v/v) and recrystallized from MeOH/Et2O to 
yield 320 mg of 3 (38%). (C,N,H) C26H35FNO3HCl. ESI+/MS m/z: 450 [M+Na]+. 
ESI+/MS/MS m/z: 420 (47), 388 (100). 1H NMR (300 MHz, CDCl3) δ: 7.08 (dd, 1H, J 
= 7.8 Hz, J = 6 Hz, phenyl-H7), 6.82 (d, 1H, J = 7.7 Hz, phenyl-H6), 6.63 (d, 1H, J = 7 
Hz, phenyl-H8), 6.58 (s, 1H, isoquinoline-H5), 6.50 (s, 1H, isoquinoline-H8), 4.83 (t, 
1H, J =3 Hz, FCH2CH2), 4.66 (t, 1H, J =3 Hz, FCH2CH2), 4.24 (t, 1H, J =3 Hz, 
FCH2CH2), 4.14 (t, 1H, J =3 Hz, FCH2CH2), 3.84 (s, 3H, CH3), 3.83 (s, 3H, CH3), 
3.55 (s, 2H, NCH2), 2.60–2.84 (m, 9H, tetrahydronaphthalen-CH2CH2CH2CH, 
isoquinoline-NCH2CH2CH2, NCH2CH2), 1.63–1.85 (m, 8H, tetrahydronaphthalen-
CH2CH2CH2CH, isoquinoline-NCH2CH2CH2). 
2.2.7. Synthesis of 2-fluoroethyl tosylate 
Synthesis of 2-fluoroethyl tosylate was performed by making a solution of 2-
fluoroethanol (1.3 mL, 2.0 mmol) and p-toluenesulfonyl chloride (170 mg, 1.1 mmol) 
in 5 M NaOH  (5.0 mL, 1.6 mmol), which was stirred at room temperature for 24 h. 
The reaction mixture was diluted with CH2Cl2, and the organic phase was washed 
with 10% NaOH. The organic layer was dried (Na2SO4) and evaporated under 
reduced pressure. The crude product was purified by chromatography on a silica 
gel column with CH2Cl2 to give 220 mg (92%) of colorless oil that was stored in a 




freezer. ESI+/MS m/z: 241 [M+Na]+. ESI+/MS/MS m/z: 241 (74), 97 (100). 1H NMR 
(300 MHz, CDCl3) δ: 7.80 (d, 2H, J = 8 Hz, phenyl-H2,6), 7.34 (d, 2H, J = 8 Hz, 
phenyl-H3,5), 4.49 (t, 1H, J = 4 Hz, CH2), 4.64 (t, 1H, J = 4 Hz, CH2), 4.30 (t, 1H, J = 
4 Hz, CH2), 4.21 (t, 1H, J = 4 Hz, CH2), 2.45 (s, 3H, CH3). 
2.2.8. Synthesis of 2-bromoethyl tosylate (15) 
A volume of 3.0 mL of CHCl2 was added to toluenesulfonyl chloride (950 mg, 5.0 
mmol) in a round-bottom flask, and the mixture was brought to 0 °C. Triethylamine 
(680 µL, 5.0 mmol) was added, and 2-bromoethanol (280 µL, 4.0 mmol) was added 
dropwise. The mixture was stirred for 1 h at 0 °C. It was brought to room 
temperature, washed with water (10 mL), brine (10 mL), and dried over Na2SO4. 
Crude product was concentrated under reduced pressure into brown liquid. Product 
was purified by silica gel column chromatography (hexane/EtOAc 9:1 v/v). Product 
was isolated as a colorless liquid (550 mg, yield 49%). 1H NMR (500 MHz, CDCl3) 
δ: 7.84 (d, 2H, J = 5 Hz, phenyl-H2,6), 7.39 (d, 2H, J = 10 Hz, phenyl-H3,5), 4.31 (t, 
2H, J = 5 Hz, CH2), 3.50 (t, 2H, J = 7 Hz, CH2), 2.48 (s, 3H, CH3).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
2.3. Radiochemistry 
2.3.1. Production and workup of fluorine-18 
[18F]Fluoride was produced by irradiation of [18O]water with the Scanditronix MC-
17 cyclotron (Uppsala, Sweden) via the 18O(p,n)18F nuclear reaction. The [18O]water 
containing the [18F]fluoride was passed over a pretreated Sep-Pak light Accell Plus 
QMA (Waters, Milford, USA) (pretreated with 5 mL of 1.4% Na2CO3 solution (B. 
Braun, Melsungen, Germany), washed with water until pH was neutral, and dried 
using argon). The [18F]fluoride was eluted from the cartridge with solution of K2CO3 
(5.0 mg, 36 mmol in production of [18F]1a, and 3.0 mg, 22 mmol in production of 
[18F]2 and [18F]3 in 1.0 mL of water) and collected into a vial containing 
Kryptofix[2.2.2] (15 mg, 40.0 mmol). A volume of 1 mL of dry acetonitrile was added, 
and solvents were evaporated to dryness at 130 °C with a helium flow (200 mL/min). 
Next, 0.5 mL of acetonitrile was added, and the mixture was dried again under the 
same conditions. This procedure was repeated another two times.  
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2.3.2 Radiosynthesis of [18F]1a 
The precursor 1b (2.0 mg, 5.0 mmol) was dissolved in 0.5 mL of DMF and was 
added to the dried K[18F]F/Kryptofix complex. Mixture was reacted for 30 min at 
160 °C and cooled for 2 min after which 0.5 mL of HPLC eluent (0.05 M 
NaOAc/MeOH/THF 55:27:18 v/v/v) was added. The total mixture was filtered 
through an Acrodisc syringe filter (0.4 µm, Pall Life Sciences, Port Washington, USA) 
and subjected to HPLC purification utilizing a Symmetryshield RPS 5 µm 7.8 × 300 
mm column (Waters, Milford, USA) at a flow of 2 mL/min (UV detection at 254 nm, 
Rt([18F]1a) = 15 min). The product was collected into a bottle containing 80 mL of 
sterile water. After mixing with helium, the solution was passed over an Oasis HLB 
1cc (30 mg) extraction cartridge (Waters, Milford, USA) to trap [18F]1a, after which 
the cartridge was washed twice with 8 mL of water. Finally the product was eluted 
from the cartridge with 1 mL of ethanol and passed through a Millipore Millex LG 
filter (0.2 µm, Billerica, USA). The filtrate was diluted with 4 mL of 0.9% NaCl. 
Analysis of the product was performed by HPLC using an Xterra C18 5 um 4.6 × 
250 mm column (Waters, Milford, USA) and 0.05 M NaH2PO4/MeOH/THF 55:27:18 
(v/v/v) as eluent at a flow of 1 mL/min.    
2.3.3. Radiosynthesis of [18F]2 and [18F]3 
In the synthesis of [18F]2 and [18F]3, 15 µL (21 mg, 75 µmol) of 2-bromoethyl tosylate 
(15) in 1.0 ml of 1,2-dichlorobenzene (DCB) was added to the dried fluoride 
complex. Distillation of the formed [18F]bromoethyl fluoride (16) at 90 °C was started 
immediately with a helium gas flow (40 mL/min) to the second vial in room 
temperature containing 2.0 mg of precursor (5.0 mmol 9 or 14) and 3.0 mg (75 mmol) 
of 60% dispersion of NaH in mineral oil in 0.5 mL of DMF. After 15 min of distillation, 
vial 2 was reacted for 5 min at 80 °C in the synthesis of [18F]3 and 10 min in the 
synthesis of [18F]2. After completion of the reaction, 0.5 mL of HPLC eluent (0.1 M 
NaOAc/MeCN 5.5:4.5 v/v) was added. The mixture was filtered through an Acrodisc 
syringe filter (0.4 µm) and subjected to HPLC purification utilizing a Symmetryshield 
RPS 5 µm 7.8 × 300 mm column at a flow of 3 mL/min (UV detection at 254 nm, Rt 
of both [18F]2 and [18F]3 10 min). The product was collected into a bottle containing 
80 mL of sterile water. After mixing with helium, the solution was passed over an 
Oasis HLB 1cc (30 mg) extraction cartridge to trap the product, after which the 




cartridge was washed twice with 8 mL of water. Finally the product was eluted from 
the cartridge with 1 mL of ethanol and passed through a Millipore Millex LG filter 
(0.2 µm). The filtrate was diluted with 4 mL of 0.9% NaCl. Analysis of the product 
was performed by HPLC using an Alltech Alltima C18 5 um 4.6 × 250 mm as a 
column (Thermo Fisher Scientific, Waltham, USA) using the same eluent as in prep. 
HPLC for [18F]2 and MeCN/water 1:1 + 0.1% TFA (v/v) for [18F]3, both at a flow of 1 
mL/min. 
2.3.4. Radiosynthesis of (R)-[11C]verapamil 
The synthesis of (R)-[11C]verapamil was performed as described previously with 
some modifications.19 Briefly, [11C]CH4, produced directly in the target using 
14N(p,α)11C nuclear reaction, was trapped in the liquid nitrogen. [11C]Methane was 
first converted into [11C]methyl iodide and further into [11C]methyl triflate by passage 
through a silver triflate/α-alumina column (Sigma-Aldrich, St. Louis, USA).19 
[11C]Methyl triflate was bubbled into (R)-norverapamil (0.5 mg, 1.0 mmol) solution 
in 0.5 mL of acetonitrile. The reaction mixture was heated for 5 min at 120 °C. Water 
(0.5 mL) and MeCN (0.5 mL) were added, the solution was injected into preparative 
HPLC system (column Symmetryshield RPS 5 µm 7.8 × 300 mm) and purified with 
25 mM NaH2PO4 pH 7.0/MeCN/MeOH (41:37:22 v/v/v) as mobile phase (flow rate 
5 mL/min, UV detection at 210 nm, Rt((R)-[11C]verapamil) = 9 min). The eluted 
fraction containing [11C]verapamil was collected into 80 mL of sterile water. After 
mixing with helium, organic solvents were removed by passing the mixture through 
an Oasis HLB 1cc (30 mg) extraction cartridge, following rinsing of the cartridge 
(twice) with 8 mL of saline solution (0.9% NaCl). (R)-[11C]Verapamil was eluted by 
passing 0.8 mL of EtOH through the cartridge and Millipore Millex LG filter (0.2 
µm) and formulated with 4 mL of saline solution.  Analysis of the product was 
performed by HPLC using an Alltima C18 5 µm 4.6 x 250 mm column and 0.1 M 
NaH2PO4 (pH 3)/MeCN (65:35 v/v) as eluent (flow rate 1.5 mL/min, UV detection at 
210 nm). 
2.4. Distribution coefficient log D 
n-Octanol (0.5 mL) and phosphate buffered saline (PBS, pH = 7.2, 0.5 mL) were 
pipetted in 1:1 ratio into Eppendorf tubes. The radiopharmaceutical solution (~1 
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MBq, 100 µL) was added, tubes were vortexed for 1 min and centrifuged for 5 min 
at 6000 rpm. Samples (100 µL) of octanol and PBS layer were counted on a γ-counter 
(LKBG–Compugamma CS 1282, Wallac, Waltham, USA). The distribution 
coefficient log D was calculated as log(Aoctanol/APBS). Measurements were done in 
triplicate. 
2.5. Animals 
All animal studies were in compliance with the local ethical guidelines, and protocols 
were approved by the Institutional Animal Care and Use Committee of the 
University of Groningen. Male FVB wild type mice (28 ± 1.8 g), Mdr1a/b(–/–)Bcrp1(–
/–) constitutive knockout mice (29 ± 1.1 g), and Mdr1a/b(–/–) constitutive knockout 
mice (28 ± 2.3 g) developed from the FVB line were purchased from Taconic 
(Hudson, USA). After arrival, animals were acclimatized at least 7 days in the Central 
Animal Facility of the University Medical Center Groningen. Mice had access to 
food and water ad libitum and were kept under a 12 h light-dark cycle. During 
experiments, mice were anesthetized with 2% isoflurane in medical air and warmed 
with a heating pad.  
2.6. PET procedure 
Mice were injected with a fluorine-18 radiopharmaceuticals (5.3 ± 1.9 MBq, 0.1–0.2 
mL, 64 ± 22 ng of 1a, 7.0 ± 7.0 ng of 2, 0.3 ± 0.01 ng of 3) or (R)-[11C]verapamil (7.3 
± 3.2 MBq, 0.2 mL, 200 ± 180 ng of verapamil) in the penile vein under isoflurane 
anesthesia. [18F]1a was injected, and animals were transferred into the microPET 
camera (microPET Focus 220, Siemens Medical Solutions, Malvern, USA) causing a 
few minutes delay between injection and start of a 60 min dynamic emission scan. 
All the other radiopharmaceuticals were injected directly on the camera following 
the start of a 30 min dynamic emission scan. A transmission scan of 515 s with a 57Co 
point source was performed for correction of attenuation and scatter by tissue after 
an emission scan. Mice were terminated by cervical dislocation. Several organs and 
tissues were excised, weighed, and radioactivity was measured with a γ-counter. 
Radioactivity accumulation in the organs was expressed as standardized uptake value 
(SUV), using the following formula: [tissue activity concentration (MBq/g)]/[injected 
dose (MBq)/body weight (g)].  




2.7. Metabolite analysis 
In vitro metabolism was examined in human liver microsomes. A solution (4.0 mM, 
14 µL) of 1a, 2, 3, or (R)-verapamil in DMSO was pipetted into test tubes to a final 
concentration of 20.0 µM. Verapamil was used as a reference compound to check if 
the microsomes were working adequately because its metabolic pathways are 
known.20 PBS (2.6 mL) and human liver microsomes (70.0 µL, final protein 
concentration 0.5 mg/mL) were added, and tubes were preincubated at 37 °C for 5 
min. NADPH solution (20.0 mM, 140 µL) was freshly made in PBS and was added 
to tubes in final concentration of 1 mM to start the reaction, as NADPH is a cofactor 
for cytochrome P450 enzymes. The first sample (400 µL) was taken immediately, and 
proteins were precipitated by addition of acetonitrile + 0.1% formic acid (800 µL). 
Other samples were taken at time points 15, 30, 45, 60, 90, and 120 min. Three 
control tubes were also incubated for 120 min: one without microsomes, one without 
NADPH, and one without test compound. In these tubes the volume of a missing 
component was replaced by PBS. Sample tubes were vortexed and centrifuged for 
6 min at 12000 rpm. Supernatants were analyzed by Xevo QTof UPLC/MS/MS 
system (Waters, Milford, USA), mounted with ACQUITY UPLC BEH C18 1.7 µm 
column, H2O/CH3CN + 0.1% HCOOH as eluent at a flow of 0.6 mL/min, ESI positive 
mode. Metabolynx XS 4.1 software (Waters, Milford, USA) was used for the analysis 
of metabolites. Found mass peaks were integrated, and the area was converted to 
percentage considering the parent area at T = 0 min as 100%. Percentage of the parent 
compound and found metabolites were expressed as a function of time. Results from 
2–3 experiments were fitted using second order polynomial fitting in GraphPad 
Prism 5 software (La Jolla, USA). 
Metabolites formed during the in vivo experiments were analyzed from the plasma 
and brain tissue. Terminal arterial whole blood samples (0.5 mL) were taken after 
the scans, and they were centrifuged for 5 min at 6000 rpm to obtain plasma. Plasma 
samples were precipitated by 2 volume addition of acetonitrile, centrifuged, and 2.5–
10 µL samples of supernatant were applied on a thin layer chromatography (TLC) 
plate (F-254 silica gel plates, Sigma-Aldrich, St. Louis, USA). Metabolism in the brain 
was investigated by dissecting half of the brain and homogenizing it with 0.9 ml of 
acetonitrile. Brain homogenate was centrifuged, and supernatant was applied on 
TLC. Plates were eluted with ethyl acetate and methanol, ratio (v/v) 95:5 for [18F]1a 
Chapter 2  
38 
 
and [18F]3 and ratio 99:1 for [18F]2 (Rf[18F]1a = 0.57, Rf[18F]2 = 0.69, Rf[18F]3 = 0.41). 
Radioactivity of the eluted plates was analyzed by phosphor storage imaging. 
Exposed screens were scanned with a Cyclone phosphor storage system 
(PerkinElmer Life and Analytical Science, Waltham, USA). Percentage of the intact 
radiopharmaceutical and the formed metabolites were calculated by region of 
interest (ROI) analysis using OptiQuant 03.00 software (PerkinElmer, Waltham, 
USA).      
2.8. PET data analysis         
A 60 min scan, used for [18F]1a, was separated into 21 time frames: 6 × 10, 4 × 30, 2 
× 60, 1 × 120, 1 × 180, 4 × 300, and 3 × 600 s. A 30 min scan used for other 
radiopharmaceuticals consequently had the first 18 time frames. Emission sinograms 
were normalized and corrected for attenuation and radioactive decay. The sinograms 
were iteratively reconstructed (two-dimensional ordered subsets expectation 
maximization (OSEM2D) with Fourier rebinning, 4 iterations, and 16 subsets). The 
final data set consisted of 95 slices with a slice thickness of 0.8 mm and an in-plane 
image matrix of 128 x 128 pixels. The voxel size was 0.9 mm x 0.9 mm x 0.8 mm. 
The Inveon Research Workplace software version 4.0 (Siemens) was used for the 
data analysis. All the frames were summed, and a PET image was coregistered with 
an MRI template.21 Whole brain volume of interest (VOI) based on the MRI 
template was generated. Radioactivity concentration was converted to SUV values 
and plotted as a time-activity curve (TAC).  
2.9. Statistical analysis 
Differences between control (FVB) and knockout animals were calculated for 
statistical significance using either one way analysis of variance (ANOVA) with 
Bonferroni correction or two-sided unpaired Student’s t test. A p-value of less than 
0.05 was considered statistically significant. IBM SPSS Statistics version 22 (Armonk, 
USA) was used for the analysis.  
 
 





3.1. Organic synthesis 
Compounds 1a, 2, and 3 were synthesized as displayed in Schemes 1, 2, and 3, 
respectively. Synthesis of compounds 1b, 4b–6b, and 7–14  has been reported 
previously, and spectral data of these compounds were identical to those previously 
described.17,22,23 Synthesis of compound 1a was performed in the same conditions as 
the nitro derivative 1b. The key intermediate, chloromethyloxazole 6a, was obtained 
by cyclization of fluorobenzamide 5a with dichloroacetone. Compound 1a was 
obtained in a high yield (74%) by condensation of 6a with 6,7-
dimethoxytetrahydroisoquinoline. In the synthesis of fluoroethyl compounds 2 and 
3, different approaches were attempted. First, phenol precursors were alkylated with 
bromoethanol. The resulting hydroxyethyl compounds were transformed into 
mesylate or tosylate derivatives. The leaving group was attempted to substitute with 
fluoride by employing different reagents (NaF, tetrabutylammonium fluoride), but 
unfortunately the reaction was unsuccessful. Then, as a second approach, fluoroethyl 
tosylate was prepared by reaction of fluoroethanol with toluensulphonyl chloride. 
Phenol precursor was reacted with the fluoroethyl tosylate in the presence of different 
bases (NaOH, KOH, NaH) and solvents (toluene, DMF). Phenol precursors had low 
reactivity and required the use of NaH and DMF for successful synthesis.  
 
Scheme 1. Synthesis of 1a,b. (i): SOCl2, Et3N, NH4OH, CH2Cl2; (ii): 1,3-
dichloroacetone; (iii): Na2CO3, DMF 




Scheme 2. Synthesis of 2 (i): SOCl2 and Et3N; CH2Cl2 and 1.2% NaOH; 6,7-
dimethoxytetrahydroisoquinoline; (ii) LiAlH4, THF; (iii) 2-fluoroethyl tosylate, NaH, 
DMF  
 
Scheme 3. Synthesis of 3 (i): CH3SO2Cl, Et3N, CH2Cl2, T = -10 °C; (ii): 
cyclopropylmagnesium bromide, 3 N HCl, THF; (iii): 6,7-dimethoxy-1,2,3,4-
tetrahydroisoquinoline, Na2CO3, DMF; (iv): H2, Pd/C (5%); (v): 2-fluoroethyl tosylate, 
NaH, DMF 
3.2. Cell experiments 
Three different cell experiments were performed with the nonradioactive 
compounds to examine the substrate potential: apparent permeability experiment in 
Caco-2 cells, Calcein-AM assay to determine selectively the potency (EC50) toward 




each transporter, and ATP depletion assay. The experimental setup is described in 
detail elsewhere.18,24 A compound is defined as a substrate when it is transported, 
and it activates ATPase. The ratio of drug transport through Caco-2 monolayers in 
the basolateral-apical and apical-basolateral directions (Papp BA/AB) was higher than 
the cutoff value of 2 for all the compounds (9.5, 7.9, and 6.1, respectively, for 1a, 2, 
and 3) as presented in Table 1. EC50 values were determined in the Calcein-AM 
assay in Madin-Darby Canine Kidney cells overexpressing selectively each 
transporter. Potency was tested also against multidrug resistance-associated protein 1 
(Mrp1), which is another efflux transporter. All compounds showed high affinity 
toward P-gp, most active being 3 (EC50 = 0.35 µM). Only 1a had some affinity to 
Bcrp (15 µM), but none of the compounds were found to have affinity to Mrp1. All 
the compounds activated ATPase. Based on the results from all the experiments, 
compounds were classified as P-gp substrates. Affinity of the compounds to sigma-1 
and sigma-2 receptors was also tested at several concentrations in binding 
competition assays using previously published methods, as our molecules and many 
of the sigma ligands have a similar structure.25,26 The half maximal inhibitory 
concentration IC50 could not be determined, and consequently neither could 
inhibition constant Ki, because the percentage of competition in all concentrations 
was less than 50%. Therefore, the percentage of competition at the highest tested 
concentration (1 µM) is reported in parentheses for each compound in Table 1. All 
compounds were found to be inactive toward sigma-1 and sigma-2 receptors, the Ki 
values are at least 100 times higher than the values for known sigma ligands.27 




































[18F]1a was synthesized via nucleophilic aromatic substitution reaction in 90 min with 
a total radiochemical yield of 3.2 ± 2.6% (Scheme 4). The radiochemical purity was 
>96% and the specific activity 29 ± 13 GBq/µmol. Radiochemical yield (decay 
corrected) is calculated for the formulated product from the end of bombardment 
(EOB) of [18F]fluoride. The measured log D was 2.6. [18F]2 and [18F]3 were 
synthesized in a two-pot method in 70–80 min (Scheme 5). They were produced with 
a radiochemical yield of 11 ± 4.7%. Specific activity for both radiopharmaceuticals 
was >100 GBq/µmol. Radiochemical purity was >98% for [18F]2 and >95% for [18F]3. 
Log D value was measured as 2.9 for [18F]2 and 3.0 for [18F]3. (R)-[11C]Verapamil 
was produced in 39 min with a radiochemical yield of 8.2 ± 4.9%, specific activity of 
34 ± 16 GBq/µmol and over 99% radiochemical purity. Radiochemical yield is 
calculated for the formulated product from the trapped activity of [11C]CH4. Log D 
value as measured earlier was 2.7.28 
 
 
Scheme 4. Radiosynthesis of [18F]1a 





Scheme 5. Radiosynthesis of [18F]2 and [18F]3 
 
3.4. PET data and biodistribution 
In the [18F]1a scan the peak of activity in the brain was missed, due to the delay 
between radiopharmaceutical injection and start of the scan. On average, the first 7.7 
min were not recorded. However, it is clear from the time-activity curves (Figure 2) 
that there is no difference in the brain uptake between knockout and control animals. 
In the biodistribution study (Figure 3), the uptake in all the organs and tissues was 
also similar between the strains (p > 0.05).  
 




Figure 2. Cerebral kinetics of the evaluated radiopharmaceuticals. Data are SUV-
PET values for the entire brain, expressed as mean ± SEM (n = 3–6). Time point 0 
min is the start of the scan. 
Scan time of other radiopharmaceuticals was reduced to 30 min, compared to 60 
min for 1a, as it was found to be sufficient to evaluate the cerebral uptake between 
the mice strains. Injections were performed directly on the microPET camera to 
avoid the loss of data. The cerebral kinetics of [18F]2 were not significantly different 
between the strains (p = 0.092). In addition, the shape of the time-activity curve was 
different than expected. There is no initial peak of uptake, but instead the curves are 
slowly rising until reaching a plateau after 10 min. In the biodistribution data, no 
significant difference between the strains was found. In the periphery, [18F]2 had only 
some nonspecific uptake in all the collected organs and tissues. Notable is the high 
uptake in plasma, which could refer to binding in plasma proteins.  




Figure 3. Biodistribution study of all the radiopharmaceuticals performed after the 
scans. Data are SUV expressed as mean ± SEM (n = 3–6). Statistical differences (p < 
0.05) are marked with a capped line.  
[18F]3 had almost the same maximum uptake in the Mdr1a/b(–/–)Bcrp1(–/–) mice as 
[11C]verapamil, but the excretion from the brain was slower. Brain uptake of [18F]3 
in the control mice was higher than for [11C]verapamil. The area under curve (AUC) 
0–30 min of [11C]verapamil in Mdr1a/b(–/–)Bcrp1(–/–) mice was 3.7-fold higher than in 
the control mice. In comparison with [18F]3, the difference was 2-fold. Maximum 
knockout/control ratio with [18F]3 was reached in 15–20 min whereas for 
[11C]verapamil this was 5 min. There was no statistically significant difference 
between the [18F]3 uptake in Mdr1a/b(–/–)Bcrp1(–/–) and Mdr1a/b(–/–)  knockout mice 
(p = 0.316), although the SUV values are higher for Mdr1a/b(–/–)Bcrp1(–/–) mice. The 
area under the curve of Mdr1a/b(–/–) mice constitutes about 86% of the AUC of 
Mdr1a/b(–/–)Bcrp1(–/–)mice. The examples of brain images with [18F]3 in each strain 
are displayed in Figure 4.  
 





Figure 4. SUV-PET images of [18F]3 in control mouse (left), Mdr1a/b(-/-) mouse 
(middle) and Mdr1a/b(–/–)Bcrp1(–/–) mouse (right), sagittal view. Vinci 4.24 software 
(Max Planck Institute, Cologne, Germany) was used to create the images.  
In the biodistribution study the uptake of [11C]verapamil was significantly different 
between the strains in testes and brain at time point 45 min after injection. Statistical 
differences between control animals and Mdr1a/b(–/–)Bcrp1(–/–) knockouts in [18F]3 
biodistribution were found in the spleen, small intestine, testes, and brain. Between 
Mdr1a/b(–/–) knockouts and controls the statistical difference was found in whole 
blood, plasma, liver, spleen, small intestine, and brain. In contrast to the brain, the 
radioactivity uptake of [18F]3 in many P-gp containing peripheral organs was actually 
higher in control animals than in the knockouts.  
Table 2. Brain-to-plasma ratios of all groups. Data are presented as mean ± SD. 
 
Groups Brain-to-plasma 
[11C]verapamil control 0.32 ± 0.1 
[11C]verapamil Mdr1a/b(–/–)Bcrp1(–/–) 2.3 ± 0.2 
[18F]1a control 0.45 ± 0.3 
[18F]1a Mdr1a/b(–/–)Bcrp1(–/–) 0.38 ± 0.1 
[18F]2 control 0.37 ± 0.04 
[18F]2 Mdr1a/b(–/–)Bcrp1(–/–) 0.54 ± 0.1 
[18F]3 control 1.3 ± 0.2 
[18F]3 Mdr1a/b(–/–) 5.6 ± 0.8 
[18F]3 Mdr1a/b(–/–)Bcrp1(–/–) 4.2 ± 1.1 
 




In addition to TACs, we calculated brain-to-plasma radioactivity ratios from the 
biodistribution data. Therefore, the values represent only one time point after the 
scan (Table 2). Brain-to-plasma radioactivity ratios of [18F]3 suggest that radioligand 
is P-gp selective and is not transported by Bcrp. The difference in brain uptake 
between control and P-gp knockout was 4.1-fold for [18F]3 and 7.1-fold for 
[11C]verapamil. Furthermore, baseline brain uptake of [18F]3 was approximately 4-
fold higher than for [11C]verapamil. 
 
3.5. Metabolism 
Phase I metabolism of the nonradioactive compounds was investigated in the human 
liver microsomes, to study the possible metabolites and metabolism rate. Control 
tubes without microsomes and NADPH were included to see if the compound 
metabolized/degraded without them and if the microsomes were working 
adequately. Tubes without the test compound were analyzed to detect impurities in 
the chemicals or in the LC-MS system. No metabolites were observed in the control 
tubes with any of the tested compounds.  
In the experiment performed in human liver microsomes, 60% of the intact 1a was 
still present after 75 min. Decomposition of the compound caused a formation of 6,7-
dimethoxy-1,2,3,4-tetrahydroisoquinoline, which was identified by MS as a primary 
metabolite. In vivo plasma samples were analyzed by radio-TLC. Majority of the 
metabolites were hydrophilic (>85%, Rf = 0). After 75 min, 43 ± 8.0% of the parent 
radiopharmaceutical was still intact. Brain metabolism data is not available.  
Compound 2 was stable during the microsome study, and no metabolites were 
found. In the light of in vivo data, this could be due to the high protein binding. 
Only the supernatant was analyzed, but the amount of the compound in the 
precipitate is not known. At 45 min, 78 ± 10% of the parent [18F]2 was intact in the 
plasma and 69 ± 10% in the brain, based on the radio-TLC. All the observed 
metabolites were hydrophilic (Rf = 0).  
Demethylation and defluoroethylation were observed for 3 in microsome 
incubations. After 45 min, 80% of the parent was still intact. In vivo at the same time 
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point the number was 69 ± 11% in the plasma and 96 ± 0.8% in the brain. All the 
found metabolites were hydrophilic in the nature (Rf = 0–0.3).  
In vivo [11C]verapamil metabolite analysis was not possible due to the low 
radioactivity in the plasma and brain. However, metabolism of (R)-[11C]verapamil is 
known in rats.20 According to that study, at 30 min postinjection, 47% of the parent 
radiopharmaceutical was intact in plasma, and at 60 min, 28%. In the brain at 30 min, 
68% of the intact radiopharmaceutical was found, and at 60 min, 47%. Typical 
metabolites for verapamil are O- and N-demethylated compounds, as well as an N-
dealkylated one.20 These metabolites were found also in our microsome experiment 
where about 60% of the parent compound was intact at 45 min.   
4. Discussion 
Three novel PET radiopharmaceuticals designed for imaging P-glycoprotein function 
were synthesized and evaluated in control and knockout mice. All of the compounds 
were labeled with fluorine-18 to increase their applicability. Compounds were 
characterized in vitro as substrates and were compared in vivo to the best known P-
gp substrate [11C]verapamil. 
Low radiochemical yield of [18F]1a (3.2 %) is limiting its use. In order to improve the 
radiochemical yield, several different reaction temperatures and times were 
investigated. Microwave and microfluidic synthesis modules were also attempted to 
conduct the labeling, but the radiochemical yield remained low. The oxazole ring in 
the para-position is not a very strong activator for the nitro-group of the precursor.  
However, to conduct the current studies, the radiochemical yield was sufficient. 
Other radiopharmaceuticals were synthesized with a decent radiochemical yield of 
about 10 %.  
As expected for a substrate, [18F]3 had higher uptake in the transporter knockout 
mice compared to the control mice. Uptake in the Mdr1a/b(–/–) knockout was a little 
bit lower than in the Mdr1a/b(–/–)Bcrp1(–/–) knockout, indicating that Bcrp is involved 
in the transport. However, the difference in the time-activity curves was not 
statistically significant. In vitro the Bcrp affinity was not observed. The higher uptake 
in Mdr1a/b(–/–)Bcrp1(–/–) mice may be due to the cooperative lack of both P-gp and 




Bcrp, and the pure Bcrp effect would be better investigated with Bcrp1(–/–) knockout. 
This is in contrast to (R)-[11C]verapamil, which has been found to be transported 
only by P-gp and not by Bcrp or Mrp1 at the BBB.29  
Uptake in control mice was higher for [18F]3 compared to (R)-[11C]verapamil, which 
could be advantageous in the cases where P-gp is overexpressed at the BBB. Upon 
up-regulation of P-gp, a very low PET signal can be expected, and since [18F]3 shows 
higher brain uptake under normal physiological condition, its PET signal might be 
significantly larger than that of (R)-[11C]verapamil, assuming that the radioactivity 
uptake in controls is P-gp mediated. 
[18F]1a and [18F]2 failed to show any substrate activity for P-gp in vivo, although these 
compounds were selected from in vitro assays as potential candidates. Neither of 
them showed any difference in the brain uptake between Mdr1a/b(–/–)Bcrp1(–/–)and 
control mice. In addition, [18F]2 had high retention in plasma which could indicate 
strong plasma protein binding. Compound 1a has a 6-fold higher EC50 value than 3, 
which could explain the poor in vivo results. Because 2 has an EC50 value in the 
same range as 3, its in vitro substrate activity cannot explain this result. However, it 
should be noted that metabolism might play an important role in vivo. 
Compound 3 was shown to be metabolically more stable than verapamil. In vivo 
metabolites were analyzed in plasma and brain, and in vitro metabolism was 
investigated in liver microsomes. Although liver microsomes were from a human 
source and in vivo experiments were performed in mice, metabolism rate in 
microsomes was quite predictable for the in vivo situation. More than 96% of the 
parent radiopharmaceutical [18F]3 was still intact in the brain after 45 min, whereas 
(R)-[11C]verapamil produces much more brain entering metabolites, as was found 
previously in rats.20 The in vivo stability of a radiopharmaceutical is of importance 
because PET measures only total radioactivity and cannot distinguish radioactive 
metabolites from the parent compound.  
Both precursors of 2 and 3 (9 and 14) have been previously labeled with carbon-
11.23,30 The carbon-11 analogue of 2, [11C]MC113, was characterized in vitro as an 
inhibitor but in vivo was weakly transported by P-gp. Uptake in the Mdr1a/b(-/-) mice 
was higher than in the control mice. In high and low P-gp expressing tumors 
Chapter 2  
50 
 
[11C]MC113 also failed to show the difference. Change of the methyl group into a 
fluoroethyl in 2 affected the affinity negatively in vivo based on the results presented 
in this Article, although in vitro they were almost the same (MC113, 0.6 µM; 2, 0.54 
µM). Instead of affinity, a reason for this might be the better metabolic stability of 
[11C]MC113.  
The carbon-11 analogue of [18F]3, [11C]MC266, was evaluated in normal rats and in 
rats pretreated with cyclosporine A (CsA).23 Results were comparable to [18F]3 
studies in mice, as described in this Article. Cyclosporine A treatment increased the 
brain uptake of [11C]MC266 2.2-fold (AUC0–60 min). CsA also increased the cerebral 
distribution volume 3-fold. Except brain, CsA treatment did not affect the 
radioactivity concentration in any peripheral organ. 
5. Conclusion 
In search for a new 18F-substrate radiopharmaceutical for imaging functional changes 
of P-gp at the BBB, we evaluated three novel compounds: [18F]1a, [18F]2, and [18F]3. 
Due to the good metabolic stability and brain uptake, [18F]3 is the most promising 
radiopharmaceutical for P-gp PET imaging. Further quantitative in vivo studies in 
rats are needed to assess the cerebral kinetics of the compound. 
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P-glycoprotein (P-gp) is a protective efflux transporter at the blood-brain barrier 
(BBB) showing altered function in many neurological disorders. The purpose of this 
study was to validate [18F]MC225 as a radiotracer for measuring P-gp function with 
positron emission tomography. Three groups of Sprague-Dawley rats were used to 
assess tracer uptake at baseline (group 1), after inhibition of P-gp (group 2), and after 
inhibition of both P-gp and breast cancer resistance protein (Bcrp, group 3). A two-
tissue compartment model with a metabolite-corrected plasma input function 
provided the best fit to the positron emission tomography data, but parameter 
estimates were more reliable in a one-tissue compartment model, which was selected 
as the preferred model. Regional distribution volumes (VT) in the control group 
ranged from 6–11, which is higher than for other radiotracers. [18F]MC225 showed 
transporter selectivity, since inhibition of P-gp caused a 2–4 fold increase in the 
cerebral VT values, but additional inhibition of Bcrp did not cause any further 
increase. Metabolic stability of [18F]MC225 was moderate (at 1 h post-injection 15% 
of plasma radioactivity and 76% of brain radioactivity represented intact parent). 
Thus, [18F]MC225 may be a useful radiotracer to measure especially increases of P-
gp function at the BBB.  
Keywords: blood-brain barrier, brain imaging, breast cancer resistance protein, 









P-glycoprotein (P-gp, Mdr1) and breast cancer resistance protein (Bcrp) are efflux 
transporters expressed at the blood-brain barrier (BBB) and in many other tissues.1,2 
They maintain homeostasis and protect the brain from neurotoxic substances by 
facilitating their efflux back into the blood.3 P-gp and Bcrp belong to the ATP-
binding cassette (ABC) family of transporters. Compounds that are effluxed by these 
transporters are called “substrates”. Particularly, many anti-epileptic drugs4 and 
antidepressants5 are substrates of P-gp. Typical substrates show almost no brain 
uptake in the normal condition, but a strongly increased uptake when transporter 
function is impaired. Labeling such a substrate with a positron emitter, can result a 
tool which allows quantification of transporter function by positron emission 
tomography (PET) imaging. PET imaging of ABC-transporters may be important in 
choosing the correct medication for patients with neurological diseases or in 
identifying subjects at risk of developing a disease. 
ABC-transporters are suspected to be involved in the pathogenesis of Alzheimer’s 
disease (AD).6 Especially the role of P-gp has been studied,7,8 although it is not yet 
known whether observed decreases of P-gp function in Alzheimer patients are a 
cause or a consequence of the disease. Accumulation of neurotoxic amyloid-ß (Aß) 
in the brain is supposed to be an important factor in the development of AD. Aβ is 
a substrate of P-gp and decreases of P-gp function are associated with increases of 
Aβ accumulation in the brain.9,10 Thus P-gp may be a potential target in the treatment 
of AD.  
The ABC-transporters P-gp and Bcrp have comparable function and recognize 
molecules with similar structures. For this reason, it is difficult to design compounds 
with affinity for a single transporter. Tracer selectivity is an important issue, especially 
in human PET studies. In the rodent brain, Bcrp is expressed 3.2-fold less than P-gp, 
but in the human brain, Bcrp expression is 1.3-fold higher than the expression of P-
gp.11,12 For reliable quantification of transporter function, the employed radiotracer 
should be selective and should not have affinity to other targets. Signal changes can 
then be directly related to changes of the function of a particular transporter. P-gp 
and Bcrp are known to play synergistic roles.13,14 Dual substrates (i.e. compounds 




with affinity for both transporters) show a significantly higher brain uptake in 
Mdr1a/b(-/-)Bcrp1(-/-) knockout mice than in Mdr1a/b(-/-) or Bcrp1(-/-) mice.15  
In a previous publication, we reported the synthesis of three radiolabeled P-gp 
substrates and their preclinical evaluation in mice.16 5-(1-(2-[18F]fluoroethoxy))-[3-(6,7-
dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-propyl]-5,6,7,8-tetrahydronaphthalen 
([18F]MC225, Figure 1) was found to be selective to P-gp over Bcrp and displayed a 
good metabolic stability. Based on the data reported in this paper, we selected 
[18F]MC225 for further studies in rats and validated it as a PET radiotracer to 
quantitatively measure P-gp function at the BBB. Arterial blood sampling during the 
scan is possible in rats, which allows the acquisition of a metabolite-corrected input 
function for kinetic modeling. Different modeling approaches were applied and the 
optimal method for PET data analysis was selected. 
In order to evaluate the in vivo selectivity of [18F]MC225 to P-gp,  three different 
groups of Sprague-Dawley rats were involved in the present study. Group 1 (control) 
was used to assess the brain uptake of [18F]MC225 at baseline. In group 2, tariquidar 
was used to inhibit P-gp. At a dose of 8 mg/kg i.v., tariquidar blocks predominantly 
P-gp. Only at higher dosing it also blocks Bcrp17 and doses smaller than 8 mg/kg 
would cause incomplete inhibition of P-gp. In group 3, both P-gp and Bcrp were 
inhibited by combined administration of tariquidar (8 mg/kg i.v.) and specific Bcrp 
inhibitor Ko143 (15 mg/kg i.v.).18 A dose of 15 mg/kg of Ko143 results in complete 
inhibition of Bcrp.17 Ko143 increases the brain uptake of a dual P-gp/Bcrp substrate 
only when P-gp is chemically inhibited or genetically knocked out. For this reason 
we have administered Ko143 in combination with tariquidar. 
 
Figure 1. Molecular structure of [18F]MC225 
 




2. Materials and methods  
2.1. Chemicals  
Tariquidar (N-[2-[[4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-
yl)ethyl]phenyl]carbamoyl]-4,5-dimethoxyphenyl]quinoline-3-carboxamide) was 
purchased from API Services Inc. (Westford, MA, USA) and Ko143 ((3S,6S,12aS)-
1,2,3,4,6,7,12,12a-octahydro-9-methoxy-6-(2-methylpropyl)-1,4-
dioxopyrazino[1′,2′:1,6]pyrido[3,4-b]indole-3-propanoic acid 1,1-dimethylethyl ester) 
from Axon Medchem BV (Groningen, Netherlands). For i.v. injections, tariquidar 
was first dissolved in DMSO (5%) and then to the vehicle solution (95%) (10% TWEEN 
20, 25% Poly(ethylene glycol) 300 (PEG 300), 65% water) in a concentration of 2.6 
mg/mL and injected in a volume of 3 mL/kg. Ko143 was first dissolved in DMSO 
(5%) and TWEEN 20 (9%), PEG 300 (24%) and water (62%) were added separately in 
a concentration of 3.8 mg/mL. Ko143 was injected i.v. in a volume of 4 mL/kg. Other 
reagents and solvents were obtained from Merck (Kenilworth, NJ, USA), Sigma-
Aldrich (St. Louis, MO, USA) and Rathburn (Walkerburn, UK) and were used 
without further purification. 
2.2. Radiosynthesis 
[18F]MC225 was synthesized with a 9 ± 2% radiochemical yield (calculated from end 
of bombardment of [18F]F-) in high radiochemical purity (98 ± 0.5%) and specific 
activity (> 200 GBq/µmol) as previously reported by a two-step reaction using 
[18F]fluoroethyl bromide as an intermediate.16 Quality control was performed with 
ultra performance liquid chromatography (UPLC), using a Waters Acquity H-class 
UPLC system (Milford, CT, USA) with a Berthold FlowStar LB 513 radioactivity 
detector (Bad Wildbad, Germany) and a Waters Acquity UPLC HSS T3 1.8 µm 3.0 
x 50 mm column. The product was eluted with 53% acetonitrile/47% 10 mM 
ammonium bicarbonate pH 9.5 (v/v) at a flow rate of 1.2 mL/min. The UV signal 
was measured at a wavelength of 220 nm. A calibration curve of nonlabeled 
reference MC225 was used to determine the amount of carrier and to calculate the 
specific activity.  
 




2.3. Animal experiments 
Male outbred Sprague Dawley rats (306 ± 24 g, 9–10 weeks) were obtained from 
Harlan (Horst, Netherlands). Rats were acclimatized for at least 7 days in the Central 
Animal Facility of the University Medical Center Groningen before starting the 
experiments. Rats were housed in groups of 2 at a 12 h light-dark regime. Food and 
water were available ad libitum. Animal experiments were approved by the 
Institutional Animal Care and Use Committee of the University of Groningen (DEC 
6456B) and were in accordance with the Animal Welfare Act of the European 
Communities Council Directive. Experiments are reported according to the 
ARRIVE criteria. 
Rats were randomly divided in three groups. Group 1 (n = 6) was the control group 
treated with 1 mL of vehicle solution (i.v.) 30 min before the scan. Group 2 (n = 6) 
was pretreated with 8 mg/kg tariquidar i.v. which was injected 30 min before the 
scan, because at that time point the inhibition of P-gp has been found to be 
maximal.19 In group 3 (n = 6), Ko143 was administered i.v. 1 h before the scan at a 
concentration of 15 mg/kg and P-gp was inhibited with 8 mg/kg of tariquidar 30 min 
before the scan.  
2.4. PET imaging and ex vivo biodistribution 
Rats were anesthetized with 5% isoflurane in medical air and anesthesia was 
maintained with 1.5–2% of isoflurane. Body temperature was maintained with a 
heating pad and an electronic temperature controller. A cannula was inserted into a 
femoral artery in order to collect blood samples during the scan. A femoral vein was 
also cannulated for radiotracer injection. After treatment with drugs or vehicle 
solution, rats were positioned in the microPET camera (microPET Focus 220, 
Siemens Medical Solutions, Malvern, PA, USA) and a transmission scan was 
acquired using a 57Co point source. The radiotracer [18F]MC225 (0.5 mL saline 
solution, 13 ± 4 MBq) was injected using an infusion pump set to a speed of 1 
mL/min. A 60 min PET scan was started simultaneously with the radiotracer injection 
and 0.1 mL arterial blood samples were collected every 10 seconds during the first 
minute and at 1.5, 2, 3, 5, 7.5, 10, 15, 30, 45 and 60 min post-injection (p.i.) for 
determination of radioactivity in whole blood and plasma. Larger blood samples 




(0.3–0.4 mL) were collected at 5, 15, 30, 45 and 60 min for metabolite analysis. Drawn 
blood was replaced by heparinized saline. A 25 μL aliquot of whole blood was 
extracted from each sample for radioactivity measurement. The remainder of each 
sample was centrifuged at 6000 rpm for 5 min (Hettich EBA 20 centrifuge, Tuttlingen, 
Germany) and 25 μl of plasma was collected. Radioactivity in whole blood and 
plasma was measured with a γ-counter (LKB Wallac, Turku, Finland). Animals were 
terminated by extirpation of the heart. Peripheral organs and half of the brain were 
collected for ex vivo biodistribution analysis. These tissue samples were weighed and 
radioactivity was measured with a γ-counter. Radioactivity accumulation was 
expressed as standardized uptake value (SUV), using the following formula: [tissue 
activity concentration (MBq/g)]/[injected dose (MBq)/body weight (g)].   
2.5. Metabolite analysis  
Radioactivity in all the plasma samples was analyzed by thin layer chromatography 
(TLC, F-254 silica gel plates, Sigma-Aldrich, St. Louis, MO, USA). Plasma was 
precipitated by addition of 2 volumes of acetonitrile and centrifuged for 5 min at 
6000 rpm. Samples of the supernatant were spotted on a TLC-plate which was then 
eluted with 10% MeOH in EtOAc. Radioactivity on plates was detected by phosphor 
storage imaging using a Cyclone® system (PerkinElmer Life and Analytical Science, 
Waltham, MA, USA). The fractions of intact radiotracer and radioactive metabolites 
were calculated by region of interest (ROI) analysis using OptiQuant 03.00 software 
(PerkinElmer, Waltham, MA, USA). Metabolites in brain were analyzed by 
homogenizing half of the brain in 1 mL cold acetonitrile using a Heidolph Diax 600 
homogenizer (Schwabach, Germany). The mixture was centrifuged and samples of 
the supernatant were analyzed by TLC, as described above.   
Selected plasma samples (at 5, 15, 30, 45 and 60 min) from half of the animals in 
each group were also analyzed by UPLC. Plasma proteins were precipitated by 
addition of 1.5 volume of acetonitrile and by 3 min of centrifugation in a Hettich 
Mikro 20 centrifuge at maximum speed (13000 rpm). Supernatant was passed 
through a Millex-HV filter (0.45 µm, Millipore, Billerica, MA, USA), and sample was 
injected into a Waters Acquity UPLC H-Class system, using an Acquity UPLC HSS 
T3 1.8 µm 3.0 x 50 mm column and acetonitrile + 0.1% TFA/10 mM ammonium 
bicarbonate pH 9.5 (53:47, v/v) as mobile phase at a flow rate of 1.2 mL/min. 




Fractions were collected every 30 seconds during 7 minutes and were counted in a 
γ-counter. Measured radioactivity (cpm) was plotted as a function of time. The 
fraction of intact radiotracer (parent molecule) was calculated by dividing the area 
under the parent peak (AUC3.5–5.5min) by the total AUC0–7min. The fraction of plasma 
radioactivity representing parent compound was expressed as a function of time and 
one phase decay curves were fitted to this data, using GraphPad Prism 5 software 
(La Jolla, CA, USA). The calculated parameters of the exponential equation were 
used to correct the plasma input function (which was acquired by arterial blood 
sampling) for the presence of radioactive metabolites. A group average was used for 
this purpose. 
2.6. PET image reconstruction and analysis 
The list-mode data from the emission scan were reconstructed into 21 frames (6×10 
s, 4×30 s, 2×60 s, 1×120 s, 1×180 s, 4×300 s, and 3×600 s). Emission sinograms were 
iteratively reconstructed (OSEM 2D, four iterations and 16 subsets) after being 
normalized and corrected for attenuation and decay of radioactivity. PET images 
were analyzed using PMOD v3.5 software (PMOD Technologies, Zürich, 
Switzerland). PET images were automatically coregistered with an MRI template20 
using rigid matching. Predefined brain regions were selected as volumes of interest 
(VOI).  Brain radioactivity concentrations were calculated from these VOIs to 
generate time–activity curves (TACs). Tissue radioactivity (Bq/mL) was corrected for 
injected dose and animal body weight and expressed as SUV. Measured radioactivity 
in whole blood and plasma (Bq/mL) was used as input function for kinetic modeling. 
In addition, plasma radioactivity was corrected for the presence of metabolites. 
Different approaches were used to calculate total distribution volume (VT), which 
represents the ratio of radiotracer concentration in target tissue and plasma at 
equilibrium: a one-tissue-compartment model (1TCM) fit, a two-tissue-compartment 
model (2TCM) fit and Logan graphical analysis. Reference tissue models could not 
be used, since P-gp is expressed throughout the brain21 and a suitable reference 
region is lacking. In a compartment model fit, the observed changes in radiotracer 
concentration are described by rate constants of transport between the 
compartments. The Logan plot is a graphical analysis technique developed for 
reversible ligand binding which allows estimation of VT.22 The slope of the linear 
part of the plot represents VT. A stable fit was acquired after 10 minutes, which was 




thus chosen as the proper fit onset. Data were weighted for frame duration and the 
cerebral blood volume was fixed to 5%.  
2.7. Statistical analysis 
Unless otherwise mentioned, data are presented as mean ± standard deviation (SD). 
One-way analysis of variance (ANOVA) with Bonferroni correction was used to 
assess the differences between the groups. A p-value < 0.05 was considered 
statistically significant. IBM SPSS Statistics version 22 (Armonk, NY, USA) was used 
for the analysis. 
3. Results 
3.1. Ex vivo biodistribution 
Biodistribution results acquired 60 min after injection of [18F]MC225 are presented 
in Figure 2. Results are expressed both as SUV (2A) and as tissue-to-plasma ratios of 
radioactivity (2B, nonmetabolite-corrected total plasma collected at 60 min p.i. used) 
because tariquidar and Ko143 affected the plasma concentration of the radiotracer. 
Statistically significant differences in tissue-to-plasma ratios between group 1 and 
groups 2–3 were found in liver, spleen, pancreas, kidney, small- and large intestine, 
bone and brain. Drug treatment (groups 2–3) decreased ratio in many peripheral 
organs and increased it in the brain. Compared to group 1, the ratio in the brain was 
2-fold higher in group 2 and 3-fold higher in group 3. However, when data is 
expressed as SUV, brain uptake between group 2 and 3 is not significantly different, 
as it is in the tissue-to-plasma ratios. 




Figure 2. Biodistribution results at 60 min expressed as (A) SUV and (B) tissue-to-
total plasma values (n = 6). Data are presented as mean ± SEM. Statistical differences 
are marked with a horizontal capped line (*p < 0.05, **p < 0.01, ***p < 0.001). 
 
 





TLC and UPLC analysis gave comparable results for metabolite assays in plasma 
(Figure 3A). The fraction of parent molecule measured in each group using these 
two different techniques was not significantly different in group wise comparisons of 
area under the curve (AUC5–60min). Drug treatment (groups 2 and 3) increased the 
rate of metabolism of [18F]MC225, especially at early time points. Metabolite curves 
of group 1 and groups 2–3 were significantly different in UPLC analysis (AUC5–60min, 
p = 0.009 group 2, p = 0.04 group 3), but not in TLC (AUC0–60min). In the control 
group, UPLC analysis indicated 57% parent tracer at 10 min, 24% at 30 min and 15% 
at 60 min. All observed metabolites were more hydrophilic than parent, but TLC 
detected a minor amount (< 5% of total radioactivity) of metabolites which were more 
hydrophobic than parent at late time points in some animals. Averaged UPLC 
chromatograms and an example of a radio-TLC chromatogram for group 1 are 
shown in Figure 3C–D. Metabolite identification in UPLC was not possible because 
metabolites eluted all at the same time. However, in previous experiments using 
microsomes, both demethylation and defluoroethylation were observed for 
MC225.16  
Metabolites in cerebral tissue were analyzed by TLC after the PET scan, that is, at 
60 min p.i. (Figure 3B). In control animals, 24% of total brain radioactivity consisted 
of metabolites. Drug treatment decreased the fraction of metabolites (to 11%). After 
inhibition of P-gp, the amount of radiotracer in the brain is higher and therefore also 
the amount of parent molecule in the brain is higher than in the controls. Probably 
majority of the [18F]MC225 metabolites are not P-gp substrates, or otherwise we 
would have expected to see an increased accumulation of metabolites in the brain 
due to the inhibition. 





Figure 3. Metabolism of [18F]MC225. Fraction of total radioactivity representing 
parent radiotracer (mean ± SEM) in (A) plasma (TLC (n=6) and UPLC (n=3)) and 
(B) brain (TLC, n=6). (C) Averaged UPLC fractions of group 1 and (D) example of 
a radio-TLC at time points 1–10 min in group1. 
3.3. SUV analysis 
Metabolite-corrected plasma radioactivity (AUC0–60min) was not significantly different 
between groups (p > 0.05, Figure 4A). Although in the enlarged view for 0–2 min in 
the SUV TACs the plasma radioactivity is highest in the group 1, in the end of the 
scan the plasma radioactivity is higher in groups 2–3. Therefore the area under the 
curve for 0–60 min is similar in each group. Example time-activity curves for the 
whole brain are shown in Figure 4B. When an area under the curve (AUC0–60min) 
was calculated, group 1 had 3.7-fold lower uptake than both treated groups (groups 




2 and 3). No significant difference in brain SUV uptake between groups 2 and 3 was 
found (AUC0–60min). Brain SUV images are presented in Figure 5.  
 
Figure 4. SUV kinetics: (A) Metabolite-corrected plasma radioactivity (mean ± SEM). 
In the inset an expanded view of the first 2 minutes. (B) Whole brain time-activity 
curves (mean ± SEM). 
 
Figure 5. SUV-PET images averaged over the duration of the whole scan and over 
the whole group in group 1 (top), group 2 (middle), and group 3 (bottom). Left axial, 




middle coronal, and right sagittal view. Images were generated using Vinci 4.24 
software (Max Planck Institute, Cologne, Germany). 
3.4. Kinetic modeling 
Three different approaches (one- and two-tissue compartment model fits and Logan 
graphical analysis) were used to calculate kinetic parameters (K1, k2, k3, k4) and tracer 
distribution volumes (VT). Whole blood and metabolite-corrected plasma 
radioactivity were used as input functions, and the most optimal approach for 
[18F]MC225 was selected. Tables 1–3 present results for whole brain, frontal cortex, 
rest of cortex, striatum, hippocampus and cerebellum. 
Fit examples for each approach and each group are presented in Figure 6. A 2TCM 
fitted the whole brain time-activity curve most accurately. A 1TCM slightly 
underestimated the K1. The Akaike information criterion (AIC) is a measure of a fit 
quality; lower values represent a better fit. The AIC values for a 1TCM and a 2TCM 
fit were similar in group 1, but were higher for a 1TCM fit than for a 2TCM fit in 
groups 2–3 (Tables 1–2). In both compartment model fits, the AIC values were the 
lowest in group 1. However, in Logan analysis, the AIC values were lower in groups 
2–3 than in group 1 (Table 3). This is due to a fixed start time for the kinetic analysis 
(10 min). When the delay time is fitted, the AIC values are almost the same in each 
group (data not shown). 
Table 1. One-tissue compartment model fit results with metabolite-corrected plasma 
radioactivity as input (n = 6). Values in brackets are calculated with total plasma 










Group 1     
Brain region K1 (mL/mL/min) k2 (1/min) VT (mL/mL) AIC 
Whole brain 
0.12 ± 0.04 
(0.13 ± 0.06) 
0.015 ± 0.001 
(0.037 ± 0.01) 
7.7 ± 2.6  
(3.7 ± 1.1) 
240 ± 16 
(230 ± 17) 
Frontal cortex 
0.14 ± 0.06 
(0.16 ± 0.08) 
0.013 ± 0.002 
(0.034 ± 0.01) 
11 ± 5.0 
(4.6 ± 1.1) 
260 ± 21 
(260 ± 16) 
Rest of cortex 
0.10 ± 0.04 
(0.11 ± 0.05) 
0.010 ± 0.002 
(0.028 ± 0.01) 
10 ± 3.1 
(4.1 ± 1.3) 
220 ± 14 
(220 ± 8.4) 
Striatum 
0.11 ± 0.04 
(0.13 ± 0.05) 
0.017 ± 0.004 
(0.038 ± 0.01) 
7.1 ± 2.7 
(3.3 ± 0.57) 
250 ± 11 
(250 ± 13) 
Hippocampus 
0.11 ± 0.03 
(0.12 ± 0.04) 
0.016 ± 0.001 
(0.038 ± 0.01) 
6.6 ± 2.1 
(3.3 ± 1.2) 
250 ± 13 
(250 ± 11) 
Cerebellum 
0.15 ± 0.06 
(0.17 ± 0.08) 
0.018 ± 0.003 
(0.043 ± 0.02) 
8.1 ± 2.8 
(4.4 ± 2.1) 
260 ± 19 
(250 ± 14) 
Group 2     
Brain region K1 (mL/mL/min) k2 (1/min) VT (mL/mL) AIC 
Whole brain 
0.81 ± 0.11 
(0.84 ± 0.12) 
0.041 ± 0.01 
(0.13 ± 0.02) 
20 ± 1.8*** 
(6.3 ± 0.76)** 
300 ± 14 
(360 ± 20) 
Frontal cortex 
0.82 ± 0.11 
(0.85 ± 0.12) 
0.036 ± 0.01 
(0.12 ± 0.02) 
23 ± 2.0** 
(7.0 ± 0.79)* 
300 ± 13 
(360 ± 21) 
Rest of cortex 
0.72 ± 0.13 
(0.73 ± 0.13) 
0.037 ± 0.01 
(0.12 ± 0.03) 
20 ± 1.8** 
(6.0 ± 0.70)* 
280 ± 16 
(350 ± 22) 
Striatum 
0.95 ± 0.13 
(0.97 ± 0.14) 
0.038 ± 0.01 
(0.13 ± 0.02) 
25 ± 2.3*** 
(7.8 ± 0.98)*** 
300 ± 13 
(370 ± 20) 
Hippocampus 
0.91 ± 0.13 
(0.95 ± 0.14) 
0.036 ± 0.01 
(0.12 ± 0.02) 
25 ± 2.1*** 
(7.7 ± 0.91)*** 
310 ± 14 
(360 ± 20) 
Cerebellum 
1.0 ± 0.12 
(1.0 ± 0.12) 
0.057 ± 0.01 
(0.17 ± 0.03) 
18 ± 1.8*** 
(6.2 ± 0.85) 
310 ± 14 
(370 ± 18) 
Group 3     
Brain region K1 (mL/mL/min) k2 (1/min) VT (mL/mL) AIC 
Whole brain 
1.1 ± 0.50 
(1.3 ± 0.74) 
0.047 ± 0.02 
(0.17 ± 0.11) 
23 ± 5.1*** 
(7.5 ± 1.5)*** 
400 ± 170 
(450 ± 160) 
Frontal cortex 
1.1 ± 0.48 
(1.3 ± 0.76) 
0.039 ± 0.01 
(0.15 ± 0.10) 
27 ± 5.9*** 
(8.7 ± 1.7)*** 
400 ± 170 
(450 ± 160) 
Rest of cortex 
0.93 ± 0.45 
(1.1 ± 0.67) 
0.040 ± 0.02 
(0.15 ± 0.10) 
23 ± 5.2*** 
(7.3 ± 1.5)** 
380 ± 170 
(440 ± 160) 
Striatum 
1.2 ± 0.55 
(1.4 ± 0.84) 
0.042 ± 0.02 
(0.16 ± 0.10) 
29 ± 7.3*** 
(9.4 ± 2.2)*** 
400 ± 170 
(460 ± 160) 
Hippocampus 
1.2 ± 0.57 
(1.4 ± 0.90) 
0.041 ± 0.02 
(0.16 ± 0.11) 
29 ± 6.6*** 
(9.3 ± 2.0)*** 
410 ± 170 
(450 ± 160) 
Cerebellum 
1.4 ± 0.67 
(1.5 ± 0.84) 
0.068 ± 0.02 
(0.22 ± 0.13) 
20 ± 3.9*** 
(7.1 ± 1.2)* 
400 ± 170 
(460 ± 160) 
Statistics compared to group 1: *p < 0.05, **p < 0.01, ***p < 0.001  
 
 




Table 2. Two-tissue compartment model fit results with metabolite-corrected plasma 
radioactivity as input (n=6). 
Group 1       
Brain region K1 k2 k3 k4 VT AIC 
Whole brain 0.20 ± 0.15 0.34 ± 0.44 0.28 ± 0.26 0.031 ± 0.01 8.9 ± 2.7 200 ± 21 
Frontal cortex 0.19 ± 0.11 0.12 ± 0.09 0.17 ± 0.12 0.027 ± 0.02 18 ± 11 260 ± 14 
Rest of cortex 0.16 ± 0.13 0.39 ± 0.62 0.32 ± 0.44 0.020 ± 0.01 14 ± 5.0 210 ± 21 
Striatum 0.18 ± 0.12 0.33 ± 0.35 0.40 ± 0.27 0.038 ± 0.01 8.0 ± 3.3 240 ± 8.6 
Hippocampus 0.17 ± 0.10 0.21 ± 0.23 0.19 ± 0.18 0.023 ± 0.01 8.9 ± 1.9 240 ± 12 
Cerebellum 0.34 ± 0.32 0.73 ± 1.0 0.37 ± 0.28 0.033 ± 0.01 9.1 ± 3.0 230 ± 15 
Group 2       
Brain region K1 k2 k3 k4 VT AIC 
Whole brain 0.98 ± 0.12 0.13 ± 0.07 0.17 ± 0.15 0.095 ± 0.03 21 ± 1.9** 260 ± 14 
Frontal cortex 1.0 ± 0.19 0.19 ± 0.23 0.28 ± 0.36 0.085 ± 0.02 24 ± 2.1 270 ± 12 
Rest of cortex 0.80 ± 0.15 0.086 ± 0.05 0.12 ± 0.13 0.094 ± 0.02 20 ± 1.9 250 ± 11 
Striatum 1.1 ± 0.18 0.18 ± 0.13 0.34 ± 0.33 0.12 ± 0.03 26 ± 2.4*** 270 ± 15 
Hippocampus 1.2 ± 0.27 0.21 ± 0.24 0.26 ± 0.31 0.082 ± 0.02 26 ± 2.4*** 280 ± 13 
Cerebellum 1.2 ± 0.17 0.13 ± 0.06 0.11 ± 0.11 0.099 ± 0.03 19 ± 1.9*** 270 ± 16 
Group 3       
Brain region K1 k2 k3 k4 VT AIC 
Whole brain 1.3 ± 0.75 0.11 ± 0.08 0.07 ± 0.07 0.23 ± 0.26 23 ± 6.3*** 400 ± 180 
Frontal cortex 1.4 ± 0.89 0.18 ± 0.22 0.22 ± 0.16 0.10 ± 0.03 29 ± 6.3* 380 ± 160 
Rest of cortex 1.1 ± 0.64 0.095 ± 0.07 0.11 ± 0.08 0.10 ± 0.02 24 ± 5.8** 360 ± 160 
Striatum 1.7 ± 1.2 0.25 ± 0.33 0.29 ± 0.18 0.11 ± 0.04 30 ± 7.7*** 380 ± 170 
Hippocampus 1.6 ± 0.91 0.16 ± 0.11 0.17 ± 0.16 0.082 ± 0.02 30 ± 8.0*** 380 ± 170 
Cerebellum 1.6 ± 0.78 0.15 ± 0.09 0.10 ± 0.10 0.11 ± 0.03 20 ± 4.5*** 380 ± 160 
Statistics compared to group 1: *p < 0.05, **p < 0.01, ***p < 0.001  
 
VT values obtained by the different approaches were compared by linear regression 
and Bland-Altman plots (Figure 7). The correlation coefficient of linear regressions 
(7A, 7C) was really good (r2 > 0.9), but Bland-Altman plots revealed more variation 
for 1TCM versus 2TCM (7B) than for 1TCM versus Logan (7D). The average 
difference between 1TCM and 2TCM was negative (-1.09), meaning that VT values 
obtained with 2TCM were higher than with 1TCM fit. In addition, group 3 showed 
more variability than the other two groups (7B). Standard deviations of the influx 
and efflux parameters (K1–k4) were much larger in the 2TCM than in the 1TCM fit 
(Tables 1–2). Values in the 2TCM fit were sometimes irrationally small resulting 
extremely high distribution volumes, thus these values were excluded as outliers. 
Since a 2TCM fit was not sufficiently stable and a 1TCM fit was still reasonably 
accurate, the 1TCM fit was selected as the preferred kinetic modeling method for 




[18F]MC225. Logan graphical analysis, which provides comparable results, can be 
used as a robust alternative to a 1TCM fit. 
Table 3. Logan graphical analysis results with metabolite-corrected plasma 
radioactivity as input (n=6). Values in brackets are calculated with total plasma 
radioactivity as input. 
 Group 1 Group 2  Group 3  
Brain region VT AIC VT  AIC VT  AIC 
Whole brain 8.3 ± 2.9  
(3.7 ± 1.3) 
66 ± 6.4 
(59 ± 9.3) 
20 ± 1.8 *** 
(5.6 ± 0.70)* 
54 ± 3.7 
(73 ± 2.2) 
22 ± 5.4 *** 
(6.1 ± 1.1)* 
50 ± 6.6 
(71 ± 2.3) 
Frontal cortex 11 ± 5.0  
(4.4 ± 1.1) 
85 ± 2.4 
(69 ± 7.9) 
22 ± 2.1**  
(6.2 ± 0.74)* 
54 ± 5.7 
(72 ± 2.3) 
27 ± 6.2***  
(7.1 ± 1.2)** 
51 ± 4.2 
(69 ±2.2) 
Rest of cortex 10 ± 3.4  
(4.0 ± 1.5) 
72 ± 4.9 
(61 ± 4.7) 
19 ± 1.8**  
(5.4 ± 0.64) 
51 ± 5.8 
(72 ± 2.5) 
23 ± 5.5***  
(6.0 ± 1.0) 
45 ± 9.0 
(69 ±2.9) 
Striatum 7.5 ± 3.1  
(3.2 ± 0.65) 
72 ± 8.9 
(65 ± 5.7) 
24 ± 2.3***  
(6.9 ± 0.89)*** 
49 ± 9.8 
(72 ± 2.2) 
28 ± 7.6***  
(7.5 ± 1.4)*** 
51 ± 5.8 
(70 ± 2.6) 
Hippocampus 7.0 ± 2.4  
(3.3 ± 1.4) 
79 ± 3.8 
(68 ± 7.2) 
25 ± 2.2***  
(6.9 ± 0.84)** 
56 ± 7.3 
(71 ± 2.2) 
29 ± 6.9***  
(7.6 ± 1.5)*** 
56 ± 5.1 
(68 ± 2.7) 
Cerebellum 8.8 ± 3.1  
(4.3 ± 2.3) 
68 ± 5.8 
(64 ± 7.1) 
18 ± 1.8*** 
 (5.4 ± 0.76) 
55 ± 3.5 
(77 ± 2.1) 
19 ± 4.1***  
(5.8 ± 0.95) 
51 ± 7.1 
(76 ± 2.8) 
Statistics compared to group 1: *p < 0.05, **p < 0.01, ***p < 0.001  
 
 
Figure 6. Example fits of (A) 1TCM, (B) 2TCM and (C) Logan analysis to whole 
brain time-activity data, using metabolite-corrected plasma radioactivity as input 
 





Figure 7. Comparison of VT data calculated in different ways: Correlation of (A) 
1TCM fit versus 2TCM fit and (C) 1TCM fit versus Logan graphical analysis. All fits 
used metabolite-corrected plasma radioactivity as input. Bland-Altman plots with 95% 
confidence intervals represent the difference of VT versus mean VT for (B) 1TCM fit 
versus 2TCM fit and (D) 1TCM fit versus Logan graphical analysis. 




The effect of cerebral blood volume fraction on AIC values in the whole brain using 
1TCM fit is presented in Figure 8A. Different fixed blood volumes (3, 4 and 5%) 
affected the fit accuracy very little. The lowest AIC values were obtained with 5% 
cerebral blood volume, which was used in all the compartmental (1TCM and 2TCM) 
modeling. 
 
Figure 8. (A) Whole brain AIC-values with different fixed cerebral blood volume 
fractions in 1-tissue compartment model fit with metabolite-corrected plasma input 
(mean ± SEM). (B) Whole brain VT at different scan durations (1TCM, metabolite-
corrected plasma input, mean ± SEM). 
Distribution volumes in group 1, based on the 1TCM fit, were significantly different 
from group 2 and 3 in all brain regions, but volumes between group 2 and 3 were 
not significantly different (p > 0.29, Table 1). After inhibition of P-gp by tariquidar 
(group 2), the VT values increased 1.9- to 3.7-fold, depending on the brain region. 
When both P-gp and Bcrp were inhibited (group 3), these values increased 2.2- to 
4.3-fold. Distribution volumes were highest in the frontal cortex.  
In all groups of animals, the influx constant K1 calculated by a 1TCM fit was higher 
than the efflux constant k2. When P-gp was inhibited (groups 2 and 3), K1 increased 
6- to 11-fold compared to baseline. The efflux constant k2 increased then also 2- to 4-
fold. Since the observed changes in K1 after drug treatment were larger than changes 
in VT, K1 could pose as a more robust measure of P-gp function at the BBB, as 
suggested by Muzi et al. for [11C]verapamil.23  




We investigated also the effect of scan duration (15, 30, 40, 50 and 60 min) on VT- 
and k-values in the whole brain (Table 4) using the 1TCM fit. K1 remained stable 
and was not affected much by the scan duration. k2 values on the other hand, were 
considerably higher at 15 min scan duration compared to a 60 min scan, but 
stabilized at scan durations greater than 30 min. Time-dependent VT values are also 
presented in Figure 8B. In groups 2 and 3, VT was already stable at 30 min, and 
remained within 10% of the VT of 60 min for scans of 30 to 60 min duration. In group 
1, however, VT was stable at scan durations ranging from 30 to 50 min (5.3–5.9), but 
increased when scanning was prolonged to 60 min (7.7). Still, considering the stability 
of other parameters, scan time could be reduced to 30 min. AIC values would also 
support the shortening of the scan, as the AIC values at 60 min were higher than 
during other time points in each group.  
Table 4. Whole brain 1TCM fit results with metabolite-corrected plasma radioactivity 
as input at different scan durations 
Group  Time/min K1 k2 VT AIC 
1 15 0.14 ± 0.06 0.033 ± 0.008 4.1 ± 0.90 160 ± 10 
30 0.13 ± 0.05 0.021 ± 0.002 5.9 ± 1.9 200 ± 12 
40 0.14 ± 0.06 0.026 ± 0.005 5.3 ± 1.3 26 ± 23 
50 0.14 ± 0.06 0.023 ± 0.004 5.8 ± 1.6 29 ± 23 
60 0.12 ± 0.04 0.015 ± 0.001 7.7 ± 2.6  240 ± 16 
2 15 0.89 ± 0.12 0.055 ± 0.006 16 ± 1.4 200 ± 11 
30 0.85 ± 0.11 0.047 ± 0.006 18 ± 1.7 250 ± 13 
40 0.90 ± 0.12 0.051 ± 0.006 18 ± 1.6 18 ± 10 
50 0.89 ± 0.12 0.049 ± 0.006 18 ± 1.6 21 ± 10 
60 0.81 ± 0.11 0.041 ± 0.01 20 ± 1.8 300 ± 14 
3 15 1.2 ± 0.62 0.066 ± 0.03 18 ± 3.1 200 ± 23 
30 1.1 ± 0.55  0.054 ± 0.02  21 ± 4.1 250 ± 25 
40 1.2 ± 0.59 0.055 ± 0.02 21 ± 4.8 70 ± 120  
50 1.2 ± 0.59 0.053 ± 0.02 22 ± 5.1 75 ± 120 
60 1.1 ± 0.50 0.047 ± 0.02 23 ± 5.1 400 ± 170 
 
Tracer kinetic modeling is rather time-consuming since arterial cannulation and 
blood sampling are required. Simplified methods of data analysis are preferred 
especially in the clinic. We investigated if SUV values would correlate with VT values, 
so that SUV could be used instead of VT. SUV values calculated for the last frame 
(50 to 60 min) of the PET data correlated slightly better with VT values from a 1TCM 
fit (Figure 9A) than SUV time-activity curve AUC0–60min values (r2 = 0.829 versus r2 = 




0.803, data not shown). Correlation in groups 2–3 was better than in group 1, but the 
overall correlation was only fair. Therefore, SUV may not be an adequate 
replacement for kinetic modeling. In addition, the use of SUV is only justified when 
there is no change in radiotracer clearance and metabolism between baseline and 
inhibited groups. Statistical significance was not reached in plasma TACs for AUC0–
60min (Figure 2A) or in metabolite analysis in TLC between group 1 and groups 2–3 
(Figure 3A). However, UPLC analysis of metabolites resulted significant differences 
due to inhibition and the amount of metabolites found in the brain was also 
influenced. Therefore, we can say that inhibition affected the metabolism of 
[18F]MC225 which invalidates the use of SUV in this particular study.  
 
Figure 9. (A) Correlation between VT 60 min (1TCM, metabolite-corrected plasma 
input) and SUV 50–60 min. (B) Correlation of metabolite-corrected and total plasma 
input in 1TCM fit (60 min). 
Metabolite analysis is another time-consuming effort. We compared kinetic modeling 
with metabolite-corrected and nonmetabolite-corrected total plasma input. Using the 
total plasma input, VT values produced by a 1TCM fit and Logan analysis were 




reduced (Table 1 and 3), but displayed the same pattern as with metabolite-corrected 
plasma input, although the observed differences between the groups were smaller. 
A 2TCM fit with a noncorrected plasma input did not converge for all animals and 
resulted in many outliers. The standard deviation of the fit parameters was in many 
cases higher than the mean, thus we decided to not report these values. VT values in 
groups 2–3 were 1.4- to 2.8-fold higher than in group 1 in 1TCM analysis, and 1.2- 
to 2.3-fold higher in Logan analysis when a total plasma input was used. Yet, 
statistically significant differences were still observed in most regions (with the 
exception of cerebellum and rest of the cortex in Logan analysis, and in 1TCM fit 
significant differences in the cerebellum were only detected between groups 1 and 
3). As with the metabolite-corrected plasma input, groups 2 and 3 did not show 
significant differences in any brain region with total plasma input. VT values 
calculated by a 1TCM fit using either metabolite-corrected or total plasma were 
moderately correlated (r2 = 0.839, Figure 9B). Therefore use of total plasma serves 
like a scaling factor, but the differences between the groups still remain. K1 values in 
the 1TCM fit were slightly higher in all groups but k2 values doubled in group 1 and 
tripled in groups 2–3 when a total plasma input was used and the standard deviation 
of all parameters increased. The fit quality in group 1 was not impaired by the use 
of a noncorrected plasma input, but in groups 2–3 the AIC values for a 1TCM fit 
were up to 25% higher and up to 50% higher for a Logan analysis. 
4. Discussion  
Thus far, (R)-[11C]Verapamil is the best known and most used radiolabeled P-gp 
substrate. A great advantage of [11C]verapamil is its specificity to P-gp,24 but the 
radiotracer has also several limitations; a very low brain uptake at baseline and 
considerable uptake of radioactive metabolites in the brain. The biggest advantage 
of [18F]MC225 over [11C]verapamil is the limited amount of metabolites present in 
the brain. Radioactive metabolites of [18F]MC225 constituted 11 to 24% of the total 
radioactivity in brain tissue at 60 min p.i., but in case of [11C]verapamil this was over 
50%.25 Radioactive metabolites in the brain can be a complicating factor in PET 
measurements, since a PET camera detects only radioactivity and cannot distinguish 
between the parent molecule and its radioactive metabolites. However, the rate of 
metabolism of [11C]verapamil in rat periphery was slower than that of [18F]MC225, 




measured in plasma.25 At 30 min and 1 h after injection, 47% and 28% of total plasma 
radioactivity in untreated animals represented intact [11C]verapamil, whereas the 
corresponding values for [18F]MC225 were 24% and 15%. A small fraction of the 
[11C]verapamil metabolites found in the brain were identified as N-dealkylated 
[11C]compounds (0.4%) and O-demethylated [11C]compounds (0.8%). Majority of the 
metabolites constituted of [11C]polar fraction, which according to authors was a 
mixture of [11C]formaldehyde, [11C]formaldehyde metabolites, [11C]formyl proteins 
and/or a nonvolatile form of [11C]CO2. The metabolic products of [18F]MC225 are 
not as well known as for [11C]verapamil, but in the microsome experiments 
defluoroethylation and demethylation has been found.16 Formed 
[18F]fluoroethane/ethanol can probably enter the brain. Yet, most likely 
[11C]verapamil metabolism produces more small radioactive polar compounds 
which can easily diffuse into the brain (or are formed in the brain) than [18F]MC225 
metabolism, which is why despite the slower peripheral metabolism of 
[11C]verapamil more metabolites were found in the brain.  
We found that both TLC and UPLC can be used for metabolite analysis of 
[18F]MC225. TLC has the advantage that only small volumes of plasma are needed 
at each time point and many samples can be analyzed on a single TLC-plate. UPLC 
analysis can only be performed for selected samples as the method is more laborious 
and time consuming. However, 4–5 samples taken during the scan are generally 
sufficient to fit a metabolite curve. Even though more blood (300 µL) is needed for 
UPLC analysis as compared to TLC (minimum 10 µL), the required amount of blood 
is still less than usually collected for HPLC analysis. A big advantage of UPLC over 
TLC is the better separation and the possibility of identification of metabolites. 
However, this was not possible in our case since all the metabolites of [18F]MC225 
eluted during the first 1.5 minutes.  
An additional advantage of [18F]MC225 over [11C]verapamil is the longer half-life of 
18F (110 min) compared to 11C (20 min), although either isotope can be preferred 
depending on the particular application. Fluorine-18 radiotracers can be transported 
to remote imaging centers without an onsite cyclotron and more subjects may be 
dosed from a single production batch. 




Based on our results, a one-tissue compartment model fit was selected as the 
preferred kinetic modeling approach for [18F]MC225. The baseline uptake of 
[18F]MC225 was higher than that of other P-gp substrates. [11C]Verapamil has 
baseline VT values ranging from 1.1 to 2.3,19 whereas these were 6.6 to 11 for 
[18F]MC225 (Table 1). The highest uptake of [18F]MC225 was observed in cortical 
areas (particularly in frontal cortex) and cerebellum. A similar regional distribution 
pattern has been observed for [11C]verapamil, with highest uptake in frontal motor 
cortex and cerebellum.19 Inhibition of P-gp results in a maximally 12-fold increase of 
whole brain VT for [11C]verapamil. For [18F]MC225, the maximum increase was 4.3-
fold in the hippocampus and 2.9-fold in the whole brain, when both P-gp and Bcrp 
were inhibited. Thus, [18F]MC225 seems to be a weaker P-gp substrate than 
[11C]verapamil. A direct comparative study using both tracers in a disease model 
might answer the question whether they are capable of detecting small changes in P-
gp function and might assess their limits of quantification. 
We performed kinetic modeling with both metabolite-corrected and nonmetabolite-
corrected total plasma radioactivity as input, as suggested by Lubberink et al.26 The 
reason for testing the two plasma input functions was to account for the presence of 
brain crossing radiolabeled metabolites, which contribute to brain uptake. The 
simplification of using noncorrected plasma input would be otherwise only justified 
when the radiotracer is minimally metabolized, which isn’t the case for [18F]MC225. 
When total plasma radioactivity served as input, the calculated VT data were scaled 
down by a certain factor, but group differences were still observed and the 
conclusions about drug effects were not altered. Even though avoiding metabolite 
analysis would be convenient and the quality of a 1TCM fit with total plasma 
radioactivity input was good, the standard deviation of all parameters was larger, 
thus for our data set a 1TCM fit with metabolite-corrected plasma input worked best.  
The high baseline uptake of [18F]MC225 could be advantageous in cases where P-gp 
is overexpressed, such as in drug-resistant epilepsy.27,28 Increased P-gp function 
would then result in a decreased brain uptake of the radiotracer. Detection of P-gp 
overexpression may not be possible with a radiotracer, which has a very low baseline 
uptake in the brain. There is always a trade-off between the affinity of a substrate for 
P-gp and the brain uptake of such a substrate at baseline. [11C]N-desmethyl-
Loperamide ([11C]dLop) is a potent P-gp substrate with an extremely low brain 




uptake at baseline.29,30 Radiochemical efforts are therefore directed at the synthesis 
of [11C]dLop analogues with lower affinity for P-gp than the original molecule, which 
will hopefully result in a higher baseline uptake and the capability to measure 
increases of P-gp function.31 
However, the high baseline uptake of [18F]MC225 may indicate that this tracer binds 
to an unidentified target in the brain. Based on the molecular structure of the tracer, 
sigma-1 or sigma-2 receptors would be a possible target. However, when the affinity 
of the nonradioactive compound to these receptors was tested in vitro, MC225 was 
found to be inactive.16 Thus, [18F]MC225 cannot be expected to bind to sigma 
receptors.  
The experiments reported in this paper were a continuation of previous work with 
[18F]MC225 in mice.16 The data in our group 2 may be compared to those acquired 
in Mdr1a/b(-/-) mice and the data from our group 3 to those of Mdr1a/b(-/-)Bcrp1(-/-) 
mice. There was no statistical difference in whole brain SUV uptake between 
Mdr1a/b(-/-)Bcrp1(-/-) and Mdr1a/b(-/-) mice. Similarly, additional inhibition of Bcrp with 
Ko143 in rats did not significantly increase the radiotracer SUV or VT uptake as 
compared to inhibition of P-gp only. Thus, in rodents [18F]MC225 seems to display 
selectivity to P-gp as the influence of Bcrp inhibition was negligible. However, the 
peak of tracer uptake in the brain (SUV) was twice as high in drug-treated rats than 
in knockout mice, whereas the baseline uptake in control rats and mice was the same. 
The rate of tracer metabolism was much slower in mice than in rats (69% of plasma 
radioactivity representing parent at 45 min) and even lower amounts of metabolites 
were detected in the mouse brain (4% of total brain radioactivity at 45 min). These 
findings are the opposite to what would be expected, as peripheral metabolism in 
bigger animals is usually slower than in small animals. Biodistribution results in rats 
and mice were similar, with the exception of the liver SUV, which was higher in 
mice. Based on the promising results of [18F]MC225 in mice, we expected good 
results also in rats, but this expectation did not fully come true. 
In conclusion, 1TCM fit with metabolite-corrected plasma input was selected as the 
optimal kinetic modeling method for [18F]MC225. The tracer showed a moderate 
rate of peripheral metabolism measured in rat plasma and the fraction of metabolites 
observed in the brain after the PET scan was small. [18F]MC225 appeared to be 




selective to P-gp, as the influence of additional inhibition of Bcrp on brain uptake of 
the tracer was negligible. The baseline brain uptake of [18F]MC225 was higher than 
that of other P-gp radiotracers such as [11C]verapamil. [18F]MC225 may thus be useful 
for imaging regional increases of P-gp function at the BBB. 
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The blood-brain barrier (BBB) contributes to brain homeostasis by protecting the 
brain from harmful compounds. P-glycoprotein (P-gp) is one of the major efflux 
transporters at the BBB. In the present study, we assessed whether 1) P-gp function 
in the brain is constant or fluctuates across the day and 2) if it is affected by sleep 
deprivation. Four groups of rats were PET scanned with a radiolabeled P-gp substrate 
[18F]MC225, each at a different moment of the 12 h light - 12 h dark cycle to study 
diurnal variations: early sleep phase (ZT3), late sleep phase (ZT9), early active phase 
(ZT15) and late active phase (ZT21). In two additional groups, controls were allowed 
to sleep normally while experimental animals were sleep-deprived for 10 h in a slowly 
rotating drum during the sleep phase. Kinetic modeling with a 1-tissue compartment 
model fit resulted for all brain regions in 1.2–1.8 fold higher distribution volumes 
(VT) at ZT15 than at other time points. VT-values at ZT3, ZT9 and ZT21 were not 
significantly different from each other. Regional tracer distribution volumes in 
controls and sleep-deprived animals were also not significantly different. Our results 
indicate that P-gp function in rats displays a daily rhythm with reduced function at 
the beginning of the active phase. This rhythm is not dependent on sleep since acute 
sleep deprivation had no effect. Knowing the diurnal variation of P-gp function could 
be important for the design of PET studies and for choosing the correct 
administration time for P-gp dependent drugs.  
Keywords: circadian rhythm, efflux transporter, [18F]MC225, pharmacokinetic 











P-glycoprotein (P-gp) is expressed on the luminal side of endothelial cells in the 
blood-brain barrier (BBB).1,2 This transporter protects the brain by pumping a wide 
variety of substances back into the blood. P-gp function is not constant but can be 
modulated by a wide variety of endogenous3,4 and exogenous factors.5–7 However, 
little is known about physiological fluctuations in P-gp function across the day in 
relation to the circadian rhythm. Such fluctuations could be important for selecting 
the optimal time of the day for application of therapeutic drugs. By selecting the 
appropriate hour of administration for a drug which is a (weak) substrate for P-gp, 
the ratio between beneficial effect and undesired side effects could be optimized. 
Many CNS drugs have some affinity for P-gp, e.g. certain anticancer drugs, 
antidepressants and HIV-protease inhibitors.8–11 
Most processes in the mammalian body display a 24 h rhythm, from molecular 
processes to behavior. Many of these rhythms are coordinated by an endogenous 
circadian clock that is located in the suprachiasmatic nuclei (SCN) of the 
hypothalamus.12 Ultimately, rhythms in the regulation of gene expression, protein 
synthesis, hormone levels or neurotransmitter release could affect P-gp expression 
and function. Moreover, the endogenous circadian clock might not only affect P-gp 
function through direct physiological mechanisms, but a daily rhythm in P-gp 
function might also be related to sleep, which is itself under control of the SCN.13,14   
Recent data have indicated that the clearance of harmful substances from the brain 
may be directly related to the sleep-state. Such substances include the 
neurodegenerative marker amyloid-ß (Aß) which is a substrate for P-glycoprotein.15,16 
Cerebral accumulation of Aβ-plaques is a hallmark, and probably also the major 
cause, of Alzheimer’s disease (AD).17 In humans, both a shorter duration and a 
reduced quality of sleep results in increased accumulation of Aβ in the brain.18 In 
mice, natural sleep is associated with a 60 % increase in the volume of the cerebral 
interstitial space, resulting in an increase in convective exchange of cerebrospinal 
fluid with interstitial fluid, which causes an increased rate of Aß clearance during 
sleep.19 Another study showed that acute (6 h) sleep deprivation in wild-type mice 
and chronic (20 h daily during 21 days) sleep deprivation in an AD mouse model 
causes a substantial increase in the Aβ plaque burden in the brain.20 Although these 
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studies did not involve specific measurements of the activity of P-gp, the data suggest 
that the observed fluctuations in Aβ clearance may be related to an altered function 
of this efflux pump. 
In the present study, we used in vivo positron emission tomography (PET) imaging 
and a substrate radiotracer [18F]MC22521,22 to investigate whether P-gp function in 
the brain is constant or if it fluctuates across the day. Decreased function of P-gp 
should correlate with an increased uptake of [18F]MC225, since after passive diffusion 
into the brain the tracer would be less effectively effluxed. We scanned four groups 
of rats each at a different specific zeitgeber time (ZT, hours after light onset) during 
the 24 h cycle. Since P-gp function may be regulated by the sleep-wake cycle rather 
than the time of the day, we also investigated whether P-gp function is affected by 
sleep deprivation. A group of rats was scanned after 10 h of acute sleep deprivation 
during the normal sleep phase. The data of these animals were compared to those 
of a control group which was allowed to sleep normally. 
2. Material and Methods 
2.1. Animals and housing 
Male outbred Sprague Dawley rats (388 ± 35 g, 12–14 weeks) were obtained from 
Harlan (Horst, Netherlands). Rats were acclimatized at least 2 weeks in the Central 
Animal Facility of the University Medical Center Groningen before starting the 
experiments. Rats were housed in groups of 2 in a 12 h light-dark regime and had 
access to standard laboratory food (RMH-B, AB Diets, Woerden, Netherlands) and 
water ad libitum. Animal experiments were approved by the Institutional Animal 
Care and Use Committee of the University of Groningen (DEC 6456D) and were in 
accordance with the Animal Welfare Act of the European Communities Council 
Directive. 
2.2. Experimental groups 
In the first experiment, we determined if there is a daily rhythm in P-gp function by 
scanning 4 groups of rats each at a different time during the light-dark cycle. Since 
rats are nocturnal animals, the light phase is for them the main sleep period and the 
dark phase the main period of activity. The 4 groups were scanned at ZT3 (early 




sleep phase, group 1, n = 8), ZT9 (late sleep phase, group 2, n = 8), ZT15 (early 
active phase, group 3, n = 8) and ZT21 (late active phase, group 4, n = 6). Animals 
in groups 1 and 2 had a light phase from 07:00–19:00 and a dark phase from 19:00–
07:00, whereas for groups 3 and 4, light and dark were reversed. Thus, scan times at 
ZT3 and ZT9 for groups 1 and 2, and ZT15 and ZT21 for groups 3 and 4 both 
corresponded to 10:00 and 16.00, respectively.  
In the second experiment, we assessed whether a daily rhythm in P-gp function might 
be due to the alternation of sleep and wakefulness. Two additional groups of rats 
were scanned at the end of the sleep phase. One group could sleep normally (group 
5, n = 7), while the other group (group 6, n = 7) was sleep deprived for most of the 
light phase (10 h), which in rats is the main sleep phase. Sleep deprivation was 
achieved by placing an animal in a slowly rotating drum (diameter 40 cm, rotation 
speed 40 cm/min) at the beginning of the sleep cycle.23,24 A control animal was placed 
in a non-rotating drum for 10 hours. Food and water were available ad libitum inside 
the wheels. All animals in groups 5–6 were adapted to non-rotating drums 2×45 min 
before the experiments. 
2.3. PET radiotracer 
To assess P-gp function, we performed small animal PET with the preclinically 
validated radiotracer [18F]MC225 (5-(1-(2-[18F]fluoroethoxy))-[3-(6,7-dimethoxy-3,4-
dihydro-1H-isoquinolin-2-yl)-propyl]-5,6,7,8-tetrahydronaphthalen). The tracer was 
synthesized as previously described.21 In the daily rhythm study, the same batch of 
[18F]MC225 was used in the morning and afternoon scans (radiochemical yield 5.2 ± 
1.6 % calculated from end of bombardment of [18F]F-). Specific radioactivity at the 
end of tracer synthesis was >200 GBq/µmol and radiochemical purity >98 %. Tracer 
quality was checked before both scans to confirm the stability of [18F]MC225 (>6 h). 
During the PET scans, 1 mL of radiotracer in saline solution was injected with 18 ± 
5 MBq of radioactivity. In the morning scans, on average 14 ng of non-radioactive 




Chapter 4  
90 
 
2.4. PET imaging and ex vivo biodistribution 
Rats were anesthetized with 5% isoflurane in medical air and anesthesia was 
maintained with 1.5–2% of isoflurane. Body temperature was maintained with a 
heating pad which was connected to an electronic temperature controller (38 °C). A 
cannula was inserted into a femoral artery in order to collect blood samples during 
the scan. A femoral vein was also cannulated for tracer injection. Rats (2 at a time) 
were positioned in the microPET camera (microPET Focus 220, Siemens Medical 
Solutions, Malvern, USA) and a transmission scan was acquired using a 57Co point 
source. The radiotracer was injected at a constant speed of 1 mL/min using an 
infusion pump. Data acquisition for a dynamic PET scan of 60 min duration was 
started simultaneously with the tracer injection. Arterial blood samples (volume 0.1 
mL) were collected every 10 seconds during the first minute and at 1.5, 2, 3, 5, 7.5, 
10, 15, 30 and 60 min. Collected blood was replaced by heparinized saline. A 25 μl 
aliquot of whole blood was extracted from each sample for radioactivity 
measurement. The remainder of each sample was centrifuged at 3460 x g for 5 min 
and 25 μl of plasma was taken for radioactivity measurement. The radioactivity in 
blood and plasma was measured with a gamma counter (LKB Wallac, Turku, 
Finland). Radioactivity in plasma was expressed as standardized uptake value (SUV), 
which is defined as [plasma activity concentration (MBq/mL)]/[injected dose 
(MBq)/body weight (g)]. Radioactive metabolites of [18F]MC225 in plasma were 
measured with thin-layer chromatography (radio-TLC) as described earlier.22 After 
the scan, rats were perfused with 40 mL of ice cold PBS. Some peripheral organs 
were collected for biodistribution analysis. Organs were weighed and radioactivity 
was measured with a gamma counter. Radioactivity in tissue (MBq/g) was divided 
by radioactivity in plasma to express the values as tissue-to-plasma ratio. 
2.5. PET image reconstruction and analysis 
The list-mode data from the emission scan were reconstructed into 21 frames (6×10 
s, 4×30 s, 2×60 s, 1×120 s, 1×180 s, 4×300 s, and 3×600 s). Emission sinograms were 
iteratively reconstructed (OSEM 2D, four iterations and 16 subsets) after being 
normalized and corrected for attenuation and decay of radioactivity. The PET 
images were analyzed using PMOD v3.5 software (PMOD Technologies, Zürich, 
Switzerland). Each PET image was automatically co-registered with an MRI template 




of the rat brain (which is included in the PMOD software package) using rigid 
matching. Predefined brain regions from the template were selected as volumes of 
interest (VOI). Blood and metabolite-corrected plasma radioactivity (Bq/mL) were 
used as input functions for the kinetic modeling. Tracer distribution volume (VT), 
the tissue-to-plasma radiotracer concentration ratio at equilibrium, was calculated 
using a 1-tissue-compartment model (1TCM) fit for each VOI. Data were weighted 
for frame duration and the blood volume in the brain was fixed to 5%.22 
2.6. Statistical analysis 
Unless otherwise mentioned, data are presented as mean ± standard error of the 
mean (SEM). One way analysis of variance (ANOVA) with Bonferroni correction 
was used to assess the differences between 3 or more groups and a 2-tailed unpaired 
t-test for comparisons between 2 groups. A p-value of less than 0.05 was considered 
statistically significant. IBM SPSS Statistics version 22 (Armonk, USA) was used for 
the analysis. 
3. Results 
3.1. Daily rhythm 
Radioactive metabolites of the injected PET tracer in plasma were measured using 
radio-TLC. The rate of tracer metabolism did not differ between groups (Figure 1A). 
Metabolite-corrected plasma time-activity curves (SUV) at ZT15 were significantly 
different from those acquired at ZT3 and ZT9 (p = 0.026 and p < 0.001 respectively, 
Figure 2A) when area under the curve (AUC) 0–60 min was compared. Plasma 
activities were the lowest and tracer uptake in brain tissue was the highest at ZT15 
(Figure 3). For kinetic modeling, 1TCM was fitted to the cerebral time-activity data. 
The 1TCM has been identified as the preferred kinetic model for analysis of 
[18F]MC225 PET data.22 Tracer distribution volume (VT) in all analyzed brain 
regions, was 1.2–1.8 fold higher at ZT15 than at other time points (Figure 3). VT 
values at ZT3, ZT9 and ZT21 were not significantly different from each other. 
Examples of VT-images are presented in Figure 4. VT is calculated as K1/k2, from a 
1TCM fit. The influx parameter K1 largely determined the daily pattern of VT as K1 
displayed the same variation (Table 1). K1 at ZT15 was on average 1.4-fold higher 
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than at other time points. Efflux parameter k2 values were similar in all groups. 
Significant differences in k2-values (between ZT3 and ZT21) were observed only in 
the pons (p = 0.035).  
 
Figure 1. Fraction of plasma radioactivity representing parent [18F]MC225 as a 
function of time measured in radio-TLC in the (A) daily rhythm (n = 6−8 per group) 
and (B) sleep deprivation study (n = 7 per group) 
 
Figure 2. Metabolite-corrected plasma radioactivity expressed as SUV in the (A) daily 
rhythm (n = 6−8 per group) and (B) sleep deprivation study (n = 7 per group). The 
figure inset provides an expanded view of the initial 2 min. 





Figure 3. Regional tracer distribution volumes (VT) in the daily rhythm study 
calculated with 1-tissue compartment model fit (n = 6−8 per group). Significant 
differences are marked with horizontal capped lines (*p < 0.05, **p < 0.01, ***p < 
0.001). 
 
Figure 4. Examples of parametric VT-images in each group of the daily rhythm study 
(ZT3, ZT9, ZT15 and ZT21). Images were generated using a 1TCM (Alpert) fit in 
the PXMOD module of the PMOD software. 
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Table 1. Rate constants obtained with 1-tissue compartment model fit using whole 
blood and metabolite-corrected plasma radioactivity as input (mean ± SD, n = 6−8 
per group) 
Parameter Region ZT3 ZT9 ZT15 ZT21 Control Sleep 
deprived 

















































































































































Tissue samples of several P-gp expressing peripheral organs were collected at 60 min 
post-injection (p.i.) to see if tracer uptake in these organs displays the same diurnal 
rhythm as was observed in the brain. This was indeed the case for liver, adrenal 
gland, kidney, pancreas and testes (Figure 5). The highest tracer tissue-to-plasma 
ratios were again observed at ZT15. 





Figure 5. Ex vivo biodistribution data for the daily rhythm study expressed as tissue-
to-plasma ratios of radioactivity at 60 min p.i. (n = 6−8 per group). Significant 
differences are marked with horizontal capped lines (*p < 0.05, **p < 0.01, ***p < 
0.001). 
3.2. Sleep deprivation 
Significant differences between the two groups in the sleep deprivation study were 
not observed. Radiotracer metabolism (AUC0-60min, Figure 1B), plasma SUV-curves 
(AUC0-60min, Figure 2B) and regional tracer distribution volumes (Figure 6A) in 
controls and sleep-deprived animals were not significantly different. The regional 
pattern of tracer distribution was the same as was reported previously: highest in 
cortical areas and lowest in the pons.22 K1 and k2 values appeared to be higher in 
sleep deprived animals than controls, but these differences were not statistically 
significant (Table 1). The biodistribution of radioactivity in peripheral organs did not 
show any significant difference between sleep-deprived animals and controls (Figure 
6B). 




Figure 6. (A) Regional tracer distribution volumes and (B) ex vivo biodistribution 
data for the sleep deprivation study (n = 7 per group) expressed as tissue-to-plasma 
ratios of radioactivity at 60 min p.i. Significant differences between control and sleep-
deprived animals were not observed.  
4. Discussion 
In the current study, we investigated diurnal fluctuations of P-gp activity in the brain 
and the effect of sleep deprivation in rats, using [18F]MC225 and PET imaging. Brain 
uptake (VT) of a P-gp substrate [18F]MC225 was the highest in the early dark phase 
(ZT15), which is the active phase in these animals. Brain uptake of the tracer at other 
time points of the light-dark cycle (ZT3, ZT9, ZT21), was on average 1.5-fold lower. 
Since P-gp is an efflux transporter, the increased uptake at ZT15 means that P-gp 
function is reduced at this time of day compared to the other time points. The 
observed difference is not related to the time-dependent differences of tracer 
metabolism since metabolite curves in rat plasma at all the time points of the diurnal 
cycle were identical (Figure 1A). In many brain regions the lowest tracer uptake was 
observed at ZT9 (Figure 3), indicating that the greatest change in P-gp function occurs 
at the transition from sleep phase to active phase. 
In contrast to the findings of the diurnal rhythm study, we did not observe any 
difference in regional cerebral tracer uptake between sleep-deprived and control 




animals after 10 h of acute sleep deprivation (during the light phase which is the 
main sleep phase of rats). Therefore, our results suggest that P-gp function in rats 
displays a daily rhythm with reduced function at the beginning of the active phase 
which is not dependent on sleep. P-gp function may be modulated by the 
endogenous circadian clock via other processes than sleep, such as rhythms in 
neurotransmitters, cytokines or hormones. 
One limitation in our study is the use of anesthesia. Since we cannot perform 
microPET scans with naturally sleeping or naturally awake rats, all animals were 
anesthetized with isoflurane during the surgical procedures and scans. All animals 
had been under anesthesia for about an hour prior to the start of the scan, and they 
were kept under anesthesia during the scan. Thus, one could argue that changes in 
P-gp function as a consequence of 10 h of sleep deprivation might partially disappear 
during the period of anesthesia which precedes the PET scan. However, after 10 h 
of sleep deprivation during the sleep phase, rats need not 1, but 6 to 8 h of recovery 
sleep to fully dissipate the accumulated sleep debt, as reflected by prolonged 
elevations of EEG slow-wave deltapower.25 From the perspective of sleep debt, it 
seems unlikely that the brief period of sleep induced by anesthesia could dissipate 
all effects of sleep deprivation. Thus, our data suggest that acute sleep deprivation 
has no major effect on P-gp function in the brain.  
Our observation of a rhythm in P-gp function in the brain appears to be in 
accordance with several studies which have shown rhythms of P-gp mRNA or protein 
expression in other organs. However, the reported shape of these rhythms varies 
between tissues and studies. For example, a 24 h rhythm in mRNA expression of the 
Abcb1a (1 member of a 3-membered P-gp gene family)26 was observed in C57BL/6J 
mouse liver and intestines.27 mRNA expression in the liver peaked at ZT12–ZT16 
and at ZT8–ZT12 in the intestines. However, in the kidney, where P-gp is also 
expressed,26 no daily rhythm in mRNA was found. In addition, mRNA expression 
of the other members of the P-gp gene family, Abcb1b and Abcb4, did not exhibit 
significant 24 h variation in any of the tissues investigated. Levels of P-gp protein also 
exhibited a daily rhythm in the intestine, with a peak occurring in the latter half of 
the sleep phase (ZT8), but not in the liver or kidney. In another study, Abcb1a 
mRNA expression in mouse liver was maximal at ZT17, and 2.9-fold higher than the 
lowest expression which was observed at ZT0.28 In mouse ileum, mRNA expression 
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of Abcb1a peaked at ZT10 and P-gp protein expression displayed almost the same 
pattern.29 So all the studies in mice reported the peak of P-gp mRNA and protein 
expression in the intestine to be in the late sleep phase and in the liver in the early 
or mid-active phase. In contrast in rats, intestinal secretion of the P-gp substrates 
talinolol and losartan was greater during nocturnal activity (ZT13–ZT15) than 
daytime rest (ZT1–ZT3).30 P-gp rhythm has been investigated also in daytime-active 
cynomolgus monkeys.31 mRNA levels of Abcb1 oscillated in both liver and intestine, 
but the daily variation was higher in the intestine being highest at ZT2 (early active 
phase) and lowest at ZT8 (mid-active phase). In contrast, protein expression in the 
liver did not show any obvious circadian oscillation. In the small intestine, an 
opposite behavior was noted to mRNA and protein expression, the latter showing a 
decrease at the early active phase and an increase from the mid-active phase to the 
early sleep phase. Thus, gene expression, protein expression and protein function 
may not show a direct correlation.  
Since different organs were reported to show a different pattern of diurnal changes, 
also P-gp function at the BBB may show its own distinct rhythm. The only publication 
which addressed diurnal rhythmicity of P-gp function in the brain, found on average 
2-fold higher P-gp mediated quinidine transport in rat brain throughout the active 
period than during daytime rest.32 Our PET data is conflicting to these findings, as 
we found that the P-gp function in the brain is the weakest during the early active 
period. [18F]MC225 and quinidine may have different transporter selectivity, which 
could in part explain this result. [18F]MC225 has been evaluated for its specificity in 
transporter knockout mice and in rats with inhibitors.21,22 It is selective to P-gp and 
has only negligible affinity to breast-cancer resistance protein (Bcrp), which is another 
efflux transporter at the BBB and belongs to the same family as P-gp. Quinidine has 
been found to be specific to P-gp in knockout mice.33 The earlier study, however, 
did find that the cerebrospinal fluid (CSF) flux was almost twice as high during the 
resting period (ZT8) compared to active period (ZT20).32 We also used different 
techniques for measuring the P-gp substrates, Kervezee et al ex vivo measurements 
and microdialysis, whereas we used PET imaging. The strength of PET is that it 
measures regional distribution of a tracer non-invasively and quantitatively in time-
dependent manner, but it measures only total radioactivity and cannot distinguish 
between bound and unbound tracer concentrations.  




The data reported in this paper may have important implications for the design of 
PET studies of P-gp function in human subjects. The light phase is for humans the 
active phase, as opposed to rodents. Thus, it may matter whether humans are 
scanned in the morning or in the afternoon, since differences in P-gp function 
between the early and late active phase can be expected. Treatment groups should 
not be scanned at different time points during the day (e.g. group 1 in the morning 
and group 2 in the afternoon) in order to avoid differences which are related to 
diurnal variation rather than to treatment. If scanning all subjects at the same time 
point is not feasible, the scans should be randomized across the day. In a test-retest 
study in humans performed with a P-gp substrate [11C]verapamil, subjects were 
scanned initially at 10:30 and a second time at 14:00. In the scans performed in the 
afternoon, a significantly lower tracer uptake (VT) in grey matter of the entire brain 
was observed by Logan graphical analysis.34 The authors explained this observed 
difference by changes of cerebral blood volume, but our data suggest that diurnal 
variation of P-glycoprotein activity could also play a role. In rats, on average 20 % 
higher cerebral blood flow has been measured during the active cycle compared to 
the sleep cycle.35,36 We scanned rats at two separate time points during the active 
phase, but only at ZT15 the tracer uptake was significantly increased, although the 
cerebral blood flow remains high throughout the active cycle. Therefore, it is unlikely 
that variations in blood flow alone can explain the increase of [18F]MC225 uptake in 
the early active phase.  
Daily fluctuations of P-gp activity in human beings could have important implications 
for therapy design. The P-gp rhythmicity could be exploited depending on the 
question whether the aim is to limit or increase the CNS distribution of a drug. A 
potential strategy to improve therapeutic effectiveness and to minimize side effects 
would be careful timing of a CNS drug administration, so that the drug is 
administered at the time point when P-gp function is minimal. If our results in rats 
would be translatable to humans, the most optimal time point to take a P-gp 
dependent CNS medication would be early in the morning, at the onset of our daily 
activities. Treatment scheduling according to a circadian or other rhythm, known as 
“chronotherapy”, is already considered important for the treatment of various 
disorders such as epilepsy,37 cardiac diseases38,39 and cancer.40–42 These schedules 
are based on the observation that treatment-related parameters such as the 
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occurrence of seizures, heart rate, blood pressure, the activity of vasodilating 
hormones and cellular proliferation show diurnal rhythms.  
5. Conclusion 
P-gp function in the rat brain displays a daily rhythm with a reduced function at the 
beginning of the active phase. This rhythm is not dependent on sleep since acute 
sleep deprivation had no effect. P-gp function may be modulated by the endogenous 
circadian clock via other processes than sleep, such as rhythms in neurotransmitters, 
cytokines or hormones. 
Acknowledgements 
This study was funded by the Dutch Technology Foundation STW (project number 
11741). We thank Jürgen Sijbesma for his help during the microPET scans, Ronald 
Boellaard for suggestions in the data analysis and David Vállez García for help in 
making parametric images. 
6. References 
(1)  Schinkel, A. H. P-Glycoprotein, a Gatekeeper in the Blood-Brain Barrier. Adv. Drug 
Deliv. Rev. 1999, 36, 179–194. 
(2)  Liu, X.; Chen, C.; Smith, B. J. Progress in Brain Penetration Evaluation in Drug 
Discovery and Development. J. Pharmacol. Exp. Ther. 2008, 325 (2), 349–356. 
(3)  Sukhai, M.; Piquette-Miller, M. Regulation of the Multidrug Resistance Genes by 
Stress Signals. J. Pharm. Pharm. Sci. 2000, 3 (2), 268–280. 
(4)  Miller, D. S.; Bauer, B.; Hartz, A. M. S. Modulation of P-Glycoprotein at the Blood-
Brain Barrier: Opportunities to Improve Central Nervous System Pharmacotherapy. 
Pharmacol. Rev. 2008, 60, 196–209. 
(5)  Chan, G. N. Y.; Saldivia, V.; Yang, Y.; Pang, H.; de Lannoy, I.; Bendayan, R. In 
Vivo Induction of P-Glycoprotein Expression at the Mouse Blood-Brain Barrier: An 
Intracerebral Microdialysis Study. J. Neurochem. 2013, 127 (3), 342–352. 
(6)  Moerman, L.; Wyffels, L.; Slaets, D.; Raedt, R.; Boon, P.; De Vos, F. Antiepileptic 
Drugs Modulate P-Glycoproteins in the Brain: A Mice Study with 11C-
Desmethylloperamide. Epilepsy Res. 2011, 94, 18–25. 
(7)  Yousif, S.; Chaves, C.; Potin, S.; Margaill, I.; Scherrmann, J.-M.; Declèves, X. 
Induction of P-Glycoprotein and Bcrp at the Rat Blood-Brain Barrier Following a 
Subchronic Morphine Treatment Is Mediated through NMDA/COX-2 Activation. J. 




Neurochem. 2012, 123 (4), 491–503. 
(8)  Benish, R. L.; Rodriguez, B.; Zimmerman, P. A.; Mehlotra, R. K. Comparative 
Description of Haplotype Structure and Genetic Diversity of MDR1 (ABCB1) in HIV-
Positive and HIV-Negative Populations. Infect. Genet. Evol. 2010, 10 (1), 60–67. 
(9)  Breedveld, P.; Beijnen, J. H.; Schellens, J. H. M. Use of P-Glycoprotein and BCRP 
Inhibitors to Improve Oral Bioavailability and CNS Penetration of Anticancer Drugs. 
Trends Pharmacol. Sci. 2006, 27 (1), 17–24. 
(10)  Doran, A.; Obach, R. S.; Smith, B. J.; Hosea, N. A.; Becker, S.; Callegari, E.; Chen, 
C.; Chen, X.; Choo, E.; Cianfrogna, J.; Cox, L. M.; Gibbs, J. P.; Gibbs, M. A.; Hatch, 
H.; Hop, C. E. C. A.; Kasman, I. N.; Laperle, J.; Liu, J.; Liu, X.; Logman, M.; Maclin, 
D.; Nedza, F. M.; Nelson, F.; Olson, E.; Rahematpura, S.; Raunig, D.; Rogers, S.; 
Schmidt, K.; Spracklin, D. K.; Szewc, M.; Troutman, M.; Tseng, E.; Tu, M.; van 
Deusen, J. W.; Venkatakrishnan, K.; Walens, G.; Wang, E. Q.; Wong, D.; Yasgar, A. 
S.; Zhang, C. The Impact of P-Glycoprotein on the Disposition of Drugs Targeted 
for Indications of the Central Nervous System: Evaluation Using the mdr1a/1b 
Knockout Mouse Model. Drug Metab. Dispos. 2005, 33 (1), 165–174. 
(11)  O’Brien, F. E.; Dinan, T. G.; Griffin, B. T.; Cryan, J. F. Interactions between 
Antidepressants and P-Glycoprotein at the Blood-Brain Barrier: Clinical Significance 
of in Vitro and in Vivo Findings. Br. J. Pharmacol. 2012, 165 (2), 289–312. 
(12)  Hastings, M. H.; Reddy, A. B.; Maywood, E. S. A Clockwork Web: Circadian Timing 
in Brain and Periphery, in Health and Disease. Nat. Rev. Neurosci. 2003, 4 (8), 649–
661. 
(13)  Mistlberger, R. E. Circadian Regulation of Sleep in Mammals: Role of the 
Suprachiasmatic Nucleus. Brain Res. Brain Res. Rev. 2005, 49, 429–454. 
(14)  Beersma, D. G. M.; Gordijn, M. C. M. Circadian Control of the Sleep-Wake Cycle. 
Physiol. Behav. 2007, 90 (2, 3), 190–195. 
(15)  Ohtsuki, S.; Ito, S.; Terasaki, T. Is P-Glycoprotein Involved in Amyloid-β Elimination 
across the Blood-Brain Barrier in Alzheimer’s Disease? Clin. Pharmacol. Ther. 2010, 
88 (4), 443–445. 
(16)  Cirrito, J. R.; Deane, R.; Fagan, A. M.; Spinner, M. L.; Parsadanian, M.; Finn, M. B.; 
Jiang, H.; Prior, J. L.; Sagare, A.; Bales, K. R.; Paul, S. M.; Zlokovic, B. V; Piwnica-
Worms, D.; Holtzman, D. M. P-Glycoprotein Deficiency at the Blood-Brain Barrier 
Increases Amyloid-β Deposition in an Alzheimer Disease Mouse Model. J. Clin. 
Invest. 2005, 115 (11), 3285–3290. 
(17)  Castello, M. A.; Soriano, S. On the Origin of Alzheimer’s Disease. Trials and 
Tribulations of the Amyloid Hypothesis. Ageing Res. Rev. 2014, 13 (1), 10–12. 
(18)  Bilgel, M.; Zhou, Y.; Wong, D. F.; Ferrucci, L.; Resnick, S. M. Self-Reported Sleep 
and β-Amyloid Deposition in Community-Dwelling Older Adults. JAMA Neurol. 
2013, 70 (12), 1537–1543. 
(19)  Xie, L.; Kang, H.; Xu, Q.; Chen, M. J.; Liao, Y.; Thiyagarajan, M.; Donnell, J. O.; 
Christensen, D. J.; Nicholson, C.; Iliff, J. J.; Takano, T.; Deane, R.; Nedergaard, M. 
Chapter 4  
102 
 
Sleep Drives Metabolite Clearance from the Adult Brain. Science. 2013, 342 (6156), 
373–377. 
(20)  Kang, J.; Lim, M. M.; Bateman, R. J.; Lee, J. J.; Smyth, L. P.; Cirrito, J. R.; Fujiki, N.; 
Nishino, S.; Holtzman, D. M. Amyloid-β Dynamics Are Regulated by Orexin and 
the Sleep-Wake Cycle. Science. 2009, 326 (5955), 1005–1007. 
(21)  Savolainen, H.; Cantore, M.; Colabufo, N. A.; Elsinga, P. H.; Windhorst, A. D.; 
Luurtsema, G. Synthesis and Preclinical Evaluation of Three Novel Fluorine-18 
Labeled Radiopharmaceuticals for P-Glycoprotein PET Imaging at the Blood–brain 
Barrier. Mol. Pharm. 2015, 12 (7), 2265–2275. 
(22)  Savolainen, H.; Windhorst, A. D.; Elsinga, P. H.; Cantore, M.; Colabufo, N. A.; 
Willemsen, A. T. M.; Luurtsema, G. Evaluation of [18F]MC225 as a PET Radiotracer 
for Measuring P-Glycoprotein Function at the Blood-Brain Barrier in Rats: Kinetics, 
Metabolism, and Selectivity. J. Cereb. Blood Flow Metab. 2017, 37, 1286–1298. 
(23)  Meerlo, P.; Koehl, M.; van der Borght, K.; Turek, F. W. Sleep Restriction Alters the 
Hypothalamic-Pituitary-Adrenal Response to Stress. J. Neuroendochrinology 2002, 
14 (5), 397–402. 
(24)  Novati, A.; Roman, V.; Cetin, T.; Hagewoud, R.; den Boer, J. A.; Luiten, P. G.; 
Meerlo, P. Chronically Restricted Sleep Leads to Depression-like Changes in 
Neurotransmitter Receptor Sensitivity and Neuroendocrine Stress Reactivity in Rats. 
Sleep 2008, 31 (11), 1579–1585. 
(25)  Tobler, I.; Borbely, A. A. Sleep EEG in the Rats as a Function of Prior Waking. 
Electroencephalogr. Clin. Neurophysiol. 1986, 64 (1), 74–76. 
(26)  Schinkel, A. H.; Smit, J. J. M.; van Tellingen, O.; Beijnen, J. H.; Wagenaar, E.; van 
Deemter, L.; Mol, C. A. A. M.; van der Valk, M. A.; Robanus-Maandag, E. C.; Te 
Riele, H. P. J.; Berns, A. J. M.; Borst, P. Disruption of the Mouse mdr1a P-
Glycoprotein Gene Leads to a Deficiency in the Blood-Brain Barrier and to Increased 
Sensitivity to Drugs. Cell 1994, 77 (4), 491–502. 
(27)  Ando, H.; Yanagihara, H.; Sugimoto, K.; Hayashi, Y.; Tsuruoka, S.; Takamura, T.; 
Kaneko, S.; Fujimura, A. Daily Rhythms of P-Glycoprotein Expression in Mice. 
Chronobiol. Int. 2005, 22 (4), 655–665. 
(28)  Zhang, Y. K.; Yeager, R. L.; Klaassen, C. D. Circadian Expression Profiles of Drug 
Processing Genes and Transcription Factors in Mouse Liver. Drug Metab. Dispos. 
2008, 37 (1), 106–115. 
(29)  Murakami, Y.; Higashi, Y.; Matsunaga, N.; Koyanagi, S.; Ohdo, S. Circadian Clock-
Controlled Intestinal Expression of the Multidrug-Resistance Gene mdr1a in Mice. 
Gastroenterology 2008, 135 (5), 1636–1644. 
(30)  Okyar, A.; Dressler, C.; Hanafy, A.; Baktir, G.; Lemmer, B.; Spahn-Langguth, H. 
Circadian Variations in Exsorptive Transport: In Situ Intestinal Perfusion Data and 
in Vivo Relevance. Chronobiol. Int. 2012, 29 (4), 443–453. 
(31)  Iwasaki, M.; Koyanagi, S.; Suzuki, N.; Katamune, C.; Matsunaga, N.; Watanabe, N.; 
Takahashi, M.; Izumi, T.; Ohdo, S. Circadian Modulation in the Intestinal 




Absorption of P-Glycoprotein Substrates in Monkeys. Mol. Pharmacol. 2015, 88 (1), 
29–37. 
(32)  Kervezee, L.; Hartman, R.; van den Berg, D.-J.; Shimizu, S.; Emoto-Yamamoto, Y.; 
Meijer, J. H.; de Lange, E. C. M. Diurnal Variation in P-Glycoprotein-Mediated 
Transport and Cerebrospinal Fluid Turnover in the Brain. AAPS J. 2014, 16 (5), 
1029–1037. 
(33)  Kodaira, H.; Kusuhara, H.; Ushiki, J.; Fuse, E.; Sugiyama, Y. Kinetic Analysis of the 
Cooperation of P-Glycoprotein (P-gp/Abcb1) and Breast Cancer Resistance Protein 
(Bcrp/Abcg2) in Limiting the Brain and Testis Penetration of Erlotinib, Flavopiridol, 
and Mitoxantrone. J. Pharmacol. Exp. Ther. 2010, 333 (3), 788–796. 
(34)  Lubberink, M.; Luurtsema, G.; van Berckel, B. N. M.; Boellaard, R.; Toornvliet, R.; 
Windhorst, A. D.; Franssen, E. J. F.; Lammertsma, A. A. Evaluation of Tracer Kinetic 
Models for Quantification of P-Glycoprotein Function Using (R)-[11C]verapamil and 
PET. J. Cereb. Blood Flow Metab. 2007, 27 (2), 424–433. 
(35)  Wauschkuhn, C. A.; Witte, K.; Gorbey, S.; Lemmer, B.; Schilling, L. Circadian 
Periodicity of Cerebral Blood Flow Revealed by Laser-Doppler Flowmetry in Awake 
Rats: Relation to Blood Pressure and Activity. Am J Physiol Hear. Circ Physiol 2005, 
289 (4), H1662–H1668. 
(36)  Endo, Y.; Jinnai, K.; Endo, M.; Fujita, K.; Kimura, F. Diurnal Variation of Cerebral 
Blood Flow in Rat Hippocampus. Stroke 1990, 21 (10), 1464–1469. 
(37)  Glauser, T. A.; Pippenger, C. E. Chronotherapy in the Treatment of Epilepsy. 
ChronoPhysiology Ther. 2014, 4, 109–123. 
(38)  Takeda, N.; Maemura, K. Cardiovascular Disease, Chronopharmacotherapy, and the 
Molecular Clock. Adv. Drug Deliv. Rev. 2010, 62 (9, 10), 956–966. 
(39)  Singh, V.; Deshpande, A. The Emergence of Time Programmed Drug Delivery 
System: Chronotherapy of Cardio Vascular Diseases. Int. J. Pharm. Pharm. Sci. 2014, 
6 (10), 56–60. 
(40)  Kondratov, R. Circadian Clock and Cancer Therapy: An Unexpected Journey. Ann. 
Med. 2014, 46 (4), 189–190. 
(41)  Fu, L.; Lee, C. C. The Circadian Clock: Pacemaker and Tumor Suppressor. Nat. 
Rev. 2003, 3 (5), 350–361. 
(42)  Ortiz-Tudela, E.; Mteyrek, A.; Ballesta, A.; Innominato, P. F.; Levi, F. Cancer 
Chronotherapeutics: Experimental, Theoretical, and Clinical Aspects. Circadian 






















Comparison of in vitro assays in selecting 





Renske M. Raaphorst1,*, Heli Savolainen2,*, Mariangela 
Cantore3,4, Evita van de Steeg5, Aren van Waarde2, Nicola 
A. Colabufo3,4, Philip H. Elsinga2, Adriaan A. Lammertsma1,  
Albert D. Windhorst1 and Gert Luurtsema2 
 
 
1 Department of Radiology & Nuclear Medicine, VU University Medical Center,  
De Boelelaan 1085C, 1081 HV Amsterdam, Netherlands  
2 Department of Nuclear Medicine and Molecular Imaging, University of Groningen,  
University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, Netherlands  
3 Dipartimento di Farmacia-Scienze del Farmaco, Università Degli Studi di Bari, via 
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Positron emission tomography (PET) imaging of P-glycoprotein (P-gp) in the blood-
brain barrier can be important in neurological diseases where P-gp is affected, such 
as Alzheimer´s disease. Radiotracers used in the imaging studies are present at very 
small, nanomolar, concentration, whereas in vitro assays where these tracers are 
characterized, are usually performed at micromolar concentration, causing often 
discrepant in vivo and in vitro data. We had in vivo rodent PET data of 
[11C]verapamil, (R)-N-[18F]fluoroethylverapamil, (R)-O-[18F]fluoroethyl-norverapamil, 
[18F]MC225 and [18F]MC224 and we included also two new molecules [18F]MC198 
and [18F]KE64 in this study. To improve the predictive value of in vitro assays, we 
labeled all the tracers with tritium and performed bidirectional substrate transport 
assay in MDCKII-MDR1 cells at three different concentrations (0.01, 1 and 50 µM) 
and also inhibition assay with P-gp inhibitors. As a comparison, we used 
nonradioactive molecules in transport assay in Caco-2 cells at a concentration of 10 
µM and in calcein-AM inhibition assay in MDCKII-MDR1 cells. All the P-gp 
substrates were transported dose-dependently. At the highest concentration (50 µM), 
P-gp was saturated in a similar way as after treatment with P-gp inhibitors. Best in 
vivo correlation was obtained with the bidirectional transport assay at a concentration 
of 0.01 µM. One micromolar concentration in a transport assay or calcein-AM assay 
alone is not sufficient for correct in vivo prediction of substrate P-gp PET ligands. 
Keywords: apical and basolateral membrane, bidirectional transport, blood-brain 











P-glycoprotein (P-gp, ABCB1, MDR1) is an efflux transporter expressed with varying 
abundance in different tissues of the body, which affects the absorption, distribution, 
metabolism and elimination (ADME) of many drugs. P-gp is involved in liver 
canalicular biliary excretion, kidney apical renal secretion, intestinal luminal 
secretion and blood-brain barrier (BBB) efflux.1 At the BBB, P-gp is expressed mainly 
in the capillary endothelial cells, where it transports its substrates out of the brain 
into the bloodstream. P-gp has a similar function and overlapping substrate specificity 
with breast cancer resistance protein (BCRP, ABCG2), another BBB efflux 
transporter.2 P-gp can also work synergistically with metabolizing enzymes (e.g., 
cytochrome P450 (CYPs)), which are not only present in the liver, but also in cerebral 
endothelium, and as such can affect drug metabolism.3 Because of its widespread 
influence on ADME profiles of drugs, P-gp has been identified as a prominent 
transporter protein that affects drug pharmacokinetics. All drug candidates for 
regulatory submissions need to be screened for substrate affinity and inhibitory 
potency of transporters, particularly P-gp.4  
Different cell lines are used to predict membrane permeability, oral absorption of 
drugs and interaction with P-gp.5,6 Measurement of bidirectional transport in a 
transwell system using cell lines (over)expressing human P-gp is one of the most 
common and reliable in vitro assays to study P-gp interactions. This assay is typically 
performed in polarized cell lines that form monolayer and tight junctions, such as 
Madin-Darby canine kidney (MDCKII) and porcine renal epithelial (LLC-PK1) cells, 
transfected with the human MDR1 gene, or human epithelial colorectal 
adenocarcinoma (Caco-2) cells, which endogenously express human P-gp.7 In 
addition to P-gp, Caco-2 cells also express Bcrp8 and multidrug resistance-associated 
protein 2 (Mrp2).9 Transport of a compound from the apical (A) to the basolateral 
(B) direction represents passive diffusion and transport from B to A P-gp mediated 
efflux, if P-gp is the only protein involved in the transport. An efflux ratio (ER), 
calculated as apparent permeability (Papp) from B to A divided by apparent 
permeability from A to B, is generally used to describe the substrate potential. This 
ratio is the net result of passive diffusion and the action of P-gp and thus may reflect 
the contribution of P-gp to restrict flux across the membranes, rather than active 
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efflux only. Feng et al. identified a cutoff value of 1.7 for ER in MDCK-MDR1 versus 
MDCK wild-type cells.10 Compounds having a value higher than 1.7 were classified 
as potential P-gp substrates. The same authors identified an in vivo cutoff value of 4 
for brain-to-plasma area under the curve (AUC) ratios between P-gp knockout and 
wild-type mice. More widely used is an in vitro cutoff value of 2, which has been 
reported in several publications.11,12 By using an in vitro ER cutoff value of 2 and an 
in vivo ER of 3, 74% of the class 1 compounds of the Biopharmaceutics Drug 
Disposition Classification System (BDDCS) and 81% of the class 2–3 compounds 
were correctly classified as P-gp substrates.12 Zhang et al. indicated that a drug is 
likely to be a P-gp substrate if its ER in vitro is higher than 2 and two or three known 
P-gp inhibitors significantly reduce the ER.1  
Another common in vitro test for determining interaction of a compound with P-gp 
is a calcein-AM assay. A non-fluorescent hydrophobic dye and P-gp substrate, calcein 
acetoxymethyl (AM) derivative, is normally kept out of the cells by P-gp. When P-
gp is inhibited by a test compound, influx of calcein-AM will increase. Calcein-AM 
hydrolyzes into hydrophilic fluorescent calcein, which is then measured.10 The 
calcein-AM assay is therefore a P-gp inhibition and not a substrate assay. The calcein-
AM and transport assays are both useful across a broad range of apparent 
permeability values of test compounds, but Polli et al. showed that the transport assay 
is more prone to fail at high permeability, whereas the calcein-AM assay is more 
prone to fail at low permeability.11 
Positron emission tomography (PET) is a powerful method to investigate the 
functionality of P-gp in various organs in vivo. PET is a non-invasive imaging 
technique that can measure the concentration of a positron emitting radiolabeled 
molecule in a region of interest, for example in the brain. To date, several 
radiolabeled P-gp substrates have been used to image P-gp function at the human 
BBB.13 Substrate behavior can be useful, e.g., in the case of Alzheimer’s disease 
(AD), where diminished P-gp function has been measured, resulting in increased 
brain accumulation of a PET tracer and neurotoxic compounds, such as amyloid-
β.14 On the other hand, overexpression of P-gp in the brain has been reported in 
epilepsy patients suffering from multidrug resistance.15 In this case, anti-epileptic 
drugs that are substrates of P-gp are not able to reach the brain. For PET imaging of 
regional P-gp expression (as opposed to P-gp function), a PET tracer is required 




which binds tightly to P-gp, instead of being transported. Several attempts were made 
to radiolabel compounds that showed such inhibitory binding in vitro, but the PET 
tracers based on these compounds, such as [11C]tariquidar and [11C]elacridar, still 
showed substrate behavior in vivo.16 In vitro assays usually are performed in the 
micromolar concentration range, whereas in vivo PET studies are carried out at 
nanomolar concentrations. A possible explanation is that the mechanism of 
interaction of the tested compounds with the P-gp protein is concentration 
dependent. 
The purpose of the present study was to investigate the usefulness of in vitro assays 
for predicting the in vivo behavior of PET tracers, with a focus on the concentration 
dependency of ligand behavior. Previously, several fluorine-18 labeled PET ligands 
for in vivo measurements of P-gp function at the BBB have been developed in our 
labs. Fluorine-18 tracers have the advantage over carbon-11 due to a longer half-life 
(110 min vs. 20 min) that they can be transported to imaging facilities without an on-
site cyclotron. We had existing in vivo data in mice and/or in rats for the standard 
substrate (R)-[11C]verapamil17,18 and its derivatives (R)-N-[18F]fluoroethylverapamil 
(N-[18F]FeVer) and (R)-O-[18F]fluoroethylnorverapamil (O-[18F]FeVer) and the 
isoquinoline derivatives [18F]MC224 and [18F]MC225 (Figure 1).19–22 In this study, we 
included also two new fluorine-18 labeled isoquinoline derivatives, [18F]MC198 and 
[18F]KE64 (Figure 1), which were evaluated in vivo in mice. MC198 and KE64 are 
structural analogs of MC225 and MC224, respectively.  
Originally, MC224 and MC225 were selected from large libraries, based on bi-
directional transport data in Caco-2 cells and calcein-AM inhibition data in MDCKII-
MDR1 cells, which had been acquired with nonradioactive molecules. In this study, 
by labeling all the molecules with tritium (3H, half-life 12.3 years), we could have a 
measurable signal even in a very low test compound concentration. Bi-directional 
transport assays were performed with tritiated molecules in MDCKII-MDR1 cells at 
three different concentrations (0.01, 1 and 50 µM). The lowest concentration (0.01 
µM) best reflects the conditions seen during in vivo PET studies, whereas the higher 
concentrations are generally used in in vitro experiments. This set-up made it 
possible to evaluate whether measured ER values decreased with increasing 
concentration of the test compound. If so, this would indicate dose-dependent 
substrate transport and saturation of P-gp. In parallel experiments, cells were treated 
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with the P-gp inhibitors ketoconazole and tariquidar (TQD) for further study of the 
substrate behavior of the test compounds.23,24 The standard substrate [3H] digoxin 
was added as a control in this experiment.25 In addition, MC224 was used as a 
negative control in all the transport experiments, as it did not show substrate behavior 
in vivo. Finally, the acquired in vitro data was compared with the in vivo data. 
 
Figure 1. Chemical structures of all test compounds 
 
 




2. Material and methods 
2.1. Chemicals 
All reagents and solvents were obtained from commercial suppliers: Merck 
(Darmstadt, Germany), Sigma-Aldrich (St. Louis, MO, USA), Rathburn 
(Walkerburn, UK), Selleckchem, (Houston, TX, USA), B. Braun (Melsungen, 
Germany) and ThermoFisher (Waltham, MA, USA). (R)-Norverapamil was a gift 
from Abbott Laboratories (Chicago, IL, USA). [3H]Methyl nosylate (3.08 GBq/µmol) 
and [3H]digoxin (1.47 GBq/µmol) were purchased from PerkinElmer Inc. (Boston, 
MA, USA). [3H]Fluoroethyl tosylate (1.13 GBq/µmol) was purchased from Novandi 
Chemistry AB (Södertälje, Sweden). 
2.2. Organic synthesis 
2.2.1. General methods 
Column chromatography was performed with 1:30 (mg crude product: g silica gel) 
silica gel 60 Å (63–200 μm, Merck, Darmstadt, Germany) as the stationary phase. 
Melting points were determined in an open capillary on a Gallenkamp 
electrothermal apparatus (Loughborough, UK). 1H-NMR spectra were recorded in 
CDCl3 at 300 MHz with a Mercury-VX (Varian, Palo Alto, CA, USA) or at 250 MHz 
on an Avance (Bruker Billerica, MA, USA) spectrometer. All chemical shift values 
are reported in ppm (δ) relative to the solvent peak (7.27 for CHCl3). Recording of 
mass spectra was carried out on an HP 6890-5973MSD gas chromatograph/mass 
spectrometer (Agilent, Santa Clara, CA, USA); only significant m/z peaks, with their 
percentage of relative intensity in parentheses, are reported. Electrospray ionization 
mass spectrometry (ESI-MS) analyses were performed on an Agilent 
1100LC/MSDtrap systemVL. Electrospray ionisation-high resolution mass 
spectrometry (ESI-HRMS) was carried out using a Bruker microTOF-Q instrument 
in positive ion mode (capillary potential of 4500 V). Elemental analyses (C, H, N) 
were performed on an Euro EA 3000 analyzer (Eurovector, Milan, Italy); the 
analytical results were within ±0.4% of the theoretical molecular formula values. 




methoxyphenethyl)amino)-2-isopropylpentane-nitrile (2).  
(R)-2-(3,4-Dimethoxyphenyl)-2-isopropyl-5-oxopentanenitrile (1, 95 mg, 0.34 mmol) 
was dissolved in MeOH (2 mL) and added to a suspension of 4-(2-aminoethyl)-2-
methoxyphenol (110 mg, 0.55 mmol) and Na2SO4 (1.5 g, 11 mmol) in MeOH (2 
mL). The reaction mixture was stirred overnight at room temperature under argon. 
Next, sodium triacetoxyhydroborate (120 mg, 0.55 mmol) was added and stirred for 
3.5 h at room temperature. The reaction mixture was quenched with a few drops of 
1 M NaOH, extracted with EtOAc and washed with H2O and brine. The solvent 
was concentrated under reduced pressure and the product was purified by flash 
column chromatography on a Buchi (Flawil, Switzerland) Sepacore system 
(comprising of a C-620 control unit, a C-660 fraction collector, 2 C601 gradient 
pumps and a C640 UV detector) equipped with a Buchi Sepacore prepacked flash 
column of 12 g Silica using a gradient (2–5% MeOH/CH2Cl2 over 30 min) to obtain 
the desired product 2 as a colorless oil (30 mg, 70 µmol, 20%). ESI-HRMS: calculated 
for C25H34N2O4: 426.2519; 427.2657 [M + H]+ found. 1H-NMR (CDCl3) δ: 6.63–6.94 
(m, 6H, CHAR), 3.90 (s, 3H, OCH3), 3.86 (s, 3H, OCH3), 3.85 (s, 3H, OCH3), 2.89 
(s, 2H, CH2CH2CH2NH), 2.78 (t, 2H, J = 6.7 Hz, CH2CH2CH2NHCH2CH2), 2.24 
(m, 2H, CH2CH2CH2NH), 2.08 (m, 3H, CH2CH2CH2NHCH2CH2 and CH(CH3)2), 
1.70 (m, 2H, CH2CH2CH2NHCH2CH2), 1.18 (d, 3H, J = 6.6 Hz, CH(CH3)2), 0.78 (d, 
3H, J = 6.6 C(CH3)2). 
2.2.3. (6-Hydroxy-7-methoxy-3,4-dihydroisoquinolin-2(1H)-yl)(4′-
hydroxybiphenyl-4-yl)methanone (5a).  
4-(4-Hydroxyphenyl)-benzoic acid 3 (2.0 g, 14 mmol) was refluxed with SOCl2 (2.0 
mL, 0.30 mmol) in the presence of Et3N (1.0 mL, 13 mmol) for 1 h. After evaporation 
of SOCl2, the resulting acyl chloride 4 was reacted with 7-methoxy-1,2,3,4-
tetrahydroisoquinolin-6-ol (2.5 g, 14 mmol) in a mixture of NH4OH (8 M), H2O and 
CH2Cl2 (1:1:1 v/v/v, 45 mL), and this mixture was stirred at room temperature for 4 
h. The organic layer was separated from the aqueous layer and washed with 2 M 
NaOH (3 × 10 mL). The organic solution was dried over Na2SO4 and evaporated 
under reduced pressure. The residue was purified by silica gel column 
chromatography (CH2Cl2/MeOH 95:5 v/v). The yield of brown solid 5a was 3.3 g 




(8.8 mmol, 64%). ESI−/MS m/z calculated for C23H21NO4: 375; found 374 [M − H]−. 
ESI−/MS/MS m/z: 359 (97), 223 (57), 212 (98). 
2.2.4. 2-((4′-Hydroxybiphenyl-4-yl)methyl)-7-methoxy-1,2,3,4-
tetrahydroisoquinolin-6-ol (6a).  
A suspension of LiAlH4 (170 mg, 4.4 mmol) in dry THF (50 mL) was stirred for 10 
min. A solution of amide 5a (550 mg, 1.5 mol) in dry THF (20 mL) was added to the 
suspension. The mixture was refluxed for 2 h. Water (20 mL) was added until the 
effervescence ceased. The aqueous layer was extracted with Et2O (3 × 20 mL), the 
organic layer was separated, dried over Na2SO4 and evaporated under reduced 
pressure. The residue was purified by silica gel column chromatography 
(CH2Cl2/MeOH 9:1 v/v). The yield of white solid 6a was 490 mg (1.3 mmol, 92%). 
ESI−/MS m/z calculated for C23H23NO3: 361; found 360 [M − H]−. ESI−/MS/MS m/z: 
345 (100), 168 (26). 
2.2.5. 2-((4′-(2-Fluoroethoxy)biphenyl-4-yl)methyl)-7-methoxy-1,2,3,4-
tetrahydroisoquinolin-6-ol (7a).  
A suspension of NaH (60%, 24 mg, 1.0 mmol) in dry DMF (3 mL) was stirred at room 
temperature for 10 min. A solution of phenol precursor 6a (1.0 mmol) in DMF (1 
mL) was added and the solution was stirred for 1 h. A solution of 2-fluoroethyl 
tosylate was added (440 mg, 2.0 mmol) in DMF (1 mL) and the reaction mixture was 
stirred for 4 h. The synthesis of 2-fluoroethyl tosylate has been described previously.20 
Water was added until effervescence ceased. The solvent was evaporated under 
reduced pressure and the residue was partitioned between H2O (20 mL) and CHCl3 
(20 mL). The organic phase was separated, the aqueous phase was extracted with 
CHCl3 (3 × 50 mL) and the collected organic fractions were dried over Na2SO4 and 
evaporated under reduced pressure. The residue was purified on silica gel column 
chromatography (CHCl3/MeOH 19:1 v/v) and recrystallized from MeOH/Et2O. The 
yield of white solid 7a was 220 mg (0.54 mmol, 56%). ESI+/MS m/z calculated for 
C25H26FNO3: 407; found 408 [M + H]+. ESI+/MS/MS m/z: 229 (100), 183 (94). 
 




methoxy-1,2,3,4-tetrahydroisoquinol-in-6-ol (11a).  
A solution of chloride 10 (180 mg, 0.80 mmol), isoquinoline (450 mg, 1.7 mmol) and 
Na2CO3 (270 mg, 2.5 mmol) in DMF (10 mL) was refluxed overnight. The solvent 
was evaporated under pressure and the residue was dissolved in water (20 mL) and 
CHCl3 (20 mL). The organic phase was separated, the aqueous phase was extracted 
with CHCl3 (3 × 50 mL) and the collected organic fractions were dried over Na2SO4 
and evaporated under reduced pressure. The residue was purified on silica gel 
column chromatography (CHCl3/MeOH 19:1 v/v) and recrystallized from 
MeOH/Et2O. The yield of white solid 11a was 130 mg (0.33 mmol, 45%). ESI+/MS 
m/z calculated for C23H27NO3: 365; found 386 [M + Na]+, ESI+/MS/MS m/z: 371 (100), 
198 (16). 
2.2.7. 2-(3-(5-Hydroxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl)-7-methoxy-
1,2,3,4-tetrahydroisoquinolin-6-ol (12a).  
A solution of 11a (140 mg, 0.36 mmol) in EtOH (50 mL) and a pinch of Pd/C 10% 
were stirred overnight at room temperature under hydrogen. The catalyst was filtered 
off and the solvent was evaporated under pressure. The residue was purified by silica 
gel column chromatography (CHCl3/MeOH 9:1 v/v). The yield of white solid 12a 
was 110 mg (0.50 mmol, 85%). ESI+/MS m/z calculated for C23H29NO3: 367; found 
368 [M + H]+. ESI+/MS/MS m/z: 218 (41), 187 (100), 165 (62). 
2.2.8. 2-(3-(5-(2-Fluoroethoxy)-1,2,3,4-tetrahydronaphthalen-1-yl)propyl)-7-
methoxy-1,2,3,4-tetrahydroisoquinol-in-6-ol (13a).  
Compound 13a was prepared in the same way as reported above for compound 7a. 
The residue was purified on silica gel column chromatography (CHCl3/MeOH 9:1 
v/v). The yield of yellow solid 13a was 320 mg (0.77 mmol, 22%). ESI−/MS m/z 
calculated for C25H32FNO3: 413; found 412 [M − H]−. ESI−/MS/MS m/z: 392 (100). 
1H-NMR (CDCl3) δ: 6.84–7.10 (m, 2H, aromatic tetrahydro-naphtalene), 6.58–6.63 
(m, 2H, aromatic), 6.52 (s, 1H, aromatic), 5.6 (bs, 1H, OH), 4.83 (t, 1H, J = 3 Hz, 
OCH2CH2F), 4.66 (t, 1H, J = 3 Hz, OCH2CH2F), 4.24 (t, 1H, J = 3 Hz, OCH2CH2F), 
4.14 (t, 1H, J = 3 Hz, OCH2CH2F), 3.83 (s, 3H, CH3), 3.55 (s, 2H, NCH2 isoquinoline), 




2.60–2.84 (m, 8H, NCH2CH2CH2CH, CH2CH2CH2CH tetrahydronaphtalene, 
NCH2CH2 isoquinoline),1.63–1.85 (m, 9H, NCH2CH2CH2CH, CH2CH2CH2CH 
tetrahydronaphthalene). 
2.2.9. (E)-2-(3-(5-(2-Fluoroethoxy)-3,4-dihydronaphthalen-1(2H)-
ylidene)propyl)-7-methoxy-1,2,3,4-tetrahydro-isoquinolin-6-ol (14a).  
Compound 14a was prepared in the same way as reported above for compound 7a. 
The residue was purified on silica gel column chromatography (CHCl3/MeOH 9:1 
v/v). The yield of yellow solid 14a was 280 mg (0.71 mmol, 12%). ESI−/MS m/z 
calculated for C25H30FNO3: 411; found 410 [M − H]−. ESI−/MS/MS m/z: 390 (100), 
364 (52). 1H-NMR (CDCl3) δ: 6.48–7.2 (m, 5H, aromatic), 6.0 (t, 1H, J = 6 Hz, 
NCH2CH2CH=C), 5.6 (bs, 1H, OH), 4.83 (t, 1H, J = 3 Hz, OCH2CH2F), 4.66 (t, 1H, 
J = 3 Hz, OCH2CH2F), 4.24 (t, 1H, J = 3 Hz, OCH2CH2F), 4.14 (t, 1H, J = 3 Hz, 
OCH2CH2F), 3.83 (s, 3H, CH3), 3.55 (s, 2H, NCH2 isoquinoline), 2.60–2.84 (m, 8H, 
NCH2CH2CH=C, CH2CH2CH2C tetrahydronaphtalene, NCH2CH2 isoquinoline), 
1.63–1.85 (m, 6H, NCH2CH2CH=C, CH2CH2CH2C tetrahydronaphtalene). 
2.2.10. (E)-2-(3-(5-(2-Fluoroethoxy)-3,4-dihydronaphthalen-1(2H)-
ylidene)propyl)-6,7-dimethoxy-1,2,3,4-tetra-hydroisoquinoline (MC198).  
MC198 was prepared in the same way as reported above for compound 7a. The 
residue was purified on silica gel column chromatography (CHCl3/MeOH 9:1 v/v). 
The yield of yellow oil MC198 was 230 mg (0.87 mmol, 15%). ESI+/MS m/z calculated 
for C26H32FNO3: 425; found 426 [M + H]+. ESI+/MS/MS m/z: 262 (33), 235 (100), 179 
(65). 1H-NMR (CDCl3) δ: 6.48–7.30 (m, 5H, aromatic), 6.0 (t, 1H, J = 6 Hz, 
NCH2CH2CH=C), 4.83 (t, 1H, J = 3 Hz, OCH2CH2F), 4.66 (t, 1H, J = 3 Hz, 
OCH2CH2F), 4.24 (t, 1H, J = 3 Hz, OCH2CH2F), 4.14 (t, 1H, J = 3 Hz, OCH2CH2F), 
3.83 (s, 3H, CH3), 3.55 (s, 2H, NCH2 isoquinoline), 2.40–2.84 (m, 8H, 
NCH2CH2CH=C, CH2CH2CH2C tetrahydronaphtalene, NCH2CH2 isoquinoline), 
1.73–1.80 (m, 6H, NCH2CH2CH=C, CH2CH2CH2C tetrahydronaphtalene). 
2.2.11. Methyl 4-(4′-hydroxybiphenyl-4-yloxy)butanoate (17).  
Dihydroxybifenyl (1.5 g, 8.0 mmol) dissolved in dry DMF (5 mL) was added to a 
suspension of NaH (100 mg, 4.1 mmol) in dry DMF (5 mL). The mixture was stirred 
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at room temperature for 20 min. Methyl-4-chlorobutanoate (3.5 g, 28 mmol) was 
added and the mixture was refluxed overnight. Water (20 mL) was added until the 
effervescence ceased. The aqueous layer was extracted with CH2Cl2 (3 × 20 mL), the 
organic layer was separated, dried over Na2SO4 and evaporated under reduced 
pressure. The residue was purified on silica gel column chromatography (CH2Cl2). 
The yield of yellow solid 17 was 450 mg (1.57 mmol, 20%). ESI−/MS m/z calculated 
for C17H18O4: 286; found 285 [M − H]−. ESI−/MS/MS m/z: 184 (100). 
2.2.12. Methyl 4-(4′-(2-Fluoroethoxy)biphenyl-4-yloxy)butanoate (18).  
Compound 18 was prepared in the same way as reported above for compound 7a. 
The residue was purified on silica gel column chromatography (CH2Cl2). The yield 
of white solid 18 was 230 mg (0.78 mmol, 45%). ESI+/MS m/z calculated for 
C19H21FO4: 332; found 355 [M + Na]+, ESI+/MS/MS m/z: 295 (10), 205 (18). 
2.2.13. 4-(4′-(2-Fluoroethoxy)biphenyl-4-yloxy)-1-butanol (19).  
Compound 19 was prepared by reduction with LiAlH4, following the same 
procedure as reported above for 6a. The residue was purified on silica gel column 
chromatography (CHCl3/AcOEt 1:1 v/v). The yield of white solid 19 was 320 mg 
(0.13 mmol, 40%). ESI+/MS m/z calculated for C18H21FO3: 304; found 327 [M + Na]+, 
ESI+/MS/MS m/z: 245 (100). 1H-NMR (CDCl3) δ: 7.40–7.62 (m, 4H, aromatic, 
OCH2CH2F), 6.80–7.13 (m, 4H, aromatic), 5.2 (bs, 1H, OH), 4.83 (t, 1H, J = 3 Hz, 
OCH2CH2F), 4.66 (t, 1H, J = 3 Hz, OCH2CH2F), 4.24 (t, 1H, J = 3 Hz, OCH2CH2F), 
4.14 (t, 1H, J = 3 Hz, OCH2CH2F), 3.65–3.84 (m, 4H, CH2CH2CH2CH2), 1.43–2.02 
(m, 4H, CH2CH2CH2CH2). 
2.2.14. 4-(4′-(2-Fluoroethoxy)biphenyl-4-yloxy)butyl methanesulfonate (20).  
A mixture of alcohol 19 (390 mg, 1.5 mmol), MsCl (680 mg, 6.0 mmol) and Et3N 
(400 mg, 4.0 mmol) in CH2Cl2 (30 mL) was stirred at room temperature for 3 h. The 
organic phase was washed with saturated solution of NaHCO3 (3 × 30 mL) and 3 N 
HCl (3 × 30 mL). The organic phase was dried over Na2SO4 and evaporated under 
reduced pressure. The residue was purified on silica gel column chromatography 
(CHCl3/AcOEt 1:1 v/v). The yield of yellow solid 20 was 540 mg (1.8 mmol, 95%). 




ESI+/MS m/z calculated for C19H23FO5S: 382; found 405 [M + Na]+, ESI+/MS/MS m/z: 
287 (100). 
2.2.15. 2-(4-(4′-(2-Fluoroethoxy)biphenyl-4-yloxy)butyl)-7-methoxy-1,2,3,4-
tetrahydroisoquinolin-6-ol (21a).  
Compound 21a was alkylated with 6-hydroxy-7-methoxyisoquinoline as reported 
above for 11a. The residue was purified on silica gel column chromatography 
(CHCl3/MeOH 19:1 v/v). The yield of white solid 21a was 480 mg (1.5 mmol, 68%). 
ESI+/MS m/z calculated for C28H32FNO4: 465; found 466 [M + H]+, ESI+/MS/MS m/z: 
316 (66), 287 (87), 245 (100), 165 (99). 1H-NMR (CDCl3) δ: 7.40–7.62 (m, 4H, 
aromatic biphenyl), 6.80–7.13 (m, 4H, aromatic biphenyl), 6.6 (s, 1H, aromatic 
isoquinoline), 6.4 (s, 1H, aromatic isoquinoline), 5.2 (bs, 1H, OH), 4.83 (t, 1H, J = 3 
Hz, OCH2CH2F),), 4.66 (t, 1H, J = 3 Hz, OCH2CH2F), 4.24 (t, 1H, J = 3 Hz, 
OCH2CH2F), 4.14 (t, 1H, J = 3 Hz, OCH2CH2F), 3.95–4.15 (m, 2 H, NCH2 
isoquinoline), 3.65–3.84 (m, 5H, CH3 and OCH2CH2CH2CH2N), 2.72–3.20 (m, 6 H, 
OCH2CH2CH2CH2N and NCH2CH2), 1.63–2.02 (m, 4H, OCH2CH2CH2CH2N).  
2.2.16. 2-(4-(4′-(2-Fluoroethoxy)biphenyl-4-yloxy)butyl)-6,7-dimethoxy-1,2,3,4-
tetrahydroisoquinoline (KE64).  
KE64 was prepared by alkylation with 6-hydroxy-7-methoxyisoquinoline as reported 
above for 11a. The residue was purified on silica gel column chromatography 
(CHCl3/MeOH 19:1 v/v). The yield of yellow solid KE64 was 79 mg (0.27 mmol, 
11%). ESI+/MS m/z calculated for C29H34FNO4: 479; found 502 [M + Na]+, 
ESI+/MS/MS m/z: 248 (100), 179 (16).1H-NMR (CDCl3) δ: 7.40–7.62 (m, 4H, aromatic 
biphenyl), 6.80–7.13 (m, 4H, aromatic biphenyl), 6.4 (s, 1H, aromatic isoquinoline), 
6.6 (s, 1H, aromatic isoquinoline), 4.83 (t, 1H, J = 3 Hz, OCH2CH2F), 4.66 (t, 1H, J 
= 3 Hz, OCH2CH2F), 4.24 (t, 1H, J = 3 Hz, OCH2CH2F), 4.14 (t, 1H, J = 3 Hz, 
OCH2CH2F), 4.2–4.3 (m, 2H, NCH2 isoquinoline), 3.84 (s, 3H, CH3), 3.82 (s, 3H, 
CH3), 3.63–3.59 (m, 2H OCH2CH2CH2CH2N), 2.42–2.80 (m, 6H, 
OCH2CH2CH2CH2N and NCH2CH2), 1.63–2.02 (m, 4H, OCH2CH2CH2CH2N). 
 
 




2.3.1. General methods in tritium labeling 
[3H]Methyl nosylate stock solution (100–300 µL, 717 MBq/mL, 10:2 hexane/EtOAc) 
or [3H]fluoroethyl tosylate stock solution (300 µL, 139 MBq/mL, 6:4 heptane/EtOAc) 
was dried at 40 °C under a flow of argon. Precursor (R)-norverapamil, 2, 7a, 13a, 
14a or 21a was dissolved in MeCN (0.2 mL) and 5 M NaOH (5 µL) was added. This 
precursor solution was added to the dried [3H]methyl nosylate or [3H]fluoroethyl 
tosylate. Reaction temperatures and times varied for each compound. The reaction 
mixture was cooled down and diluted with 0.6 mL of MeOH/H2O (70:30) and 
purified by preparative HPLC. HPLC analysis was performed with an Agilent 1200 
Series auto injector (Agilent Technologies, Waldbronn, Germany) and a single Jasco 
PU-2080Plus pump (Jasco Ltd., Great Dunmow, UK). A Reprosphere 100 C18-DE 
column (50 × 8 mm, 5µm) from Dr. Maisch GmbH (Ammerbuch, Germany) was 
used for preparative HPLC with MeOH/H2O/DIPA 70:30:0.1 as an eluent at a 
flowrate of 3 mL/min. The column eluate was monitored continuously using a Jasco 
UV-2075Plus absorbance UV/Visible spectrophotometer set at 254 nm and a β-Ram 
radiochemical detector (LabLogic, Sheffield, UK). Fractions of the eluate (3 mL) 
were collected and analyzed for radioactivity by liquid scintillation counting (LSC) 
(LKB/Wallac 1219 Rackbeta, Mount Waverley, Australia) using 5 mL of Optiphase 
‘Highsafe 3’ scintillation liquid (PerkinElmer) for a 3 µL sample of an HPLC fraction. 
Collected fractions were diluted with 50 mL of sterile water and passed over a Waters 
tC18 Sep-Pak cartridge (Waters, Etten-Leur, The Netherlands), preconditioned with 
5 mL of EtOH followed by 10 mL of water. The cartridge was washed with 20 mL 
of water, followed by elution of the product with 1.5 mL of 96% ethanol. All products 
were analysed for purity by analytical HPLC using a Platinum C18 column (250 × 
4.6 mm, 100 Å, 5 µm) from Grace (Columbia, MD, USA) with a flow rate of 1 
mL/min (MeCN/H2O/TFA 40:60:0.1) and the identity was confirmed by co-elution 
with a reference compound.  
2.3.2. [3H]Verapamil  
[3H]Methyl nosylate (250 µL) was reacted overnight at room temperature with the 
precursor (R)-norverapamil (0.60 mg, 1.4 µmol) according to the general method. 




The product was purified with preparative HPLC (MeOH/H2O/DIPA 60:40:0.1 v/v/v) 
and [3H]verapamil (41 MBq) was obtained with 25% radiochemical yield (RCY) and 
>99% radiochemical purity.  
2.3.3. [3H]N-FeVer  
Precursor (R)-norverapamil (0.6 mg, 1.4 µmol) was dissolved in 0.2 mL of MeCN 
and 10 µL of 5 M NaOH was added. This solution was added to the dried 
[3H]fluoroethyl tosylate and heated at 120 °C for 45 min. The crude mixture was 
purified with preparative HPLC (MeOH/H2O/DIPA 55:45:0.1 v/v/v)) and [3H]N-
FeVer (2.3 MBq) was obtained with 5.7% radiochemical yield and >99% 
radiochemical purity, as determined on analytical HPLC (MeCN/H2O/TFA 50:50:0.1 
v/v/v)).  
2.3.4. [3H]O-FeVer  
Precursor 2 (0.2 mg, 0.47 µmol) was reacted with [3H]fluoroethyl tosylate for 45 min 
at 120 °C, according to the general procedure. The crude mixture was purified with 
HPLC (MeOH/H2O/DIPA 55:45:0.1 v/v/v)) to give the desired product [3H]O-FeVer 
(6.0 MBq) with 14% radiochemical yield and >99% radiochemical purity. 
2.3.5. [3H]MC224  
[3H]MC224 was prepared using the general method, with the exception that 
precursor 7a (0.5 mg, 1.2 µmol) was dissolved in DMSO (0.2 mL instead of MeCN. 
Compound 7a was reacted with [3H]methyl nosylate (100 µL) at room temperature 
overnight. Product [3H]MC224 (18 MBq) was obtained with 26% radiochemical yield 
and >99% radiochemical purity, as determined on analytical HPLC 
(MeCN/H2O/TFA 50:50:0.1 v/v/v)). 
2.3.6. [3H]MC225  
Precursor 13a (0.35 mg, 0.85 µmol) was reacted with [3H]methyl nosylate (100 µL) 
for 15 min at 60 °C, according to the general method. [3H]MC225 (7.0 MBq) was 
obtained with 10% radiochemical yield and >99% radiochemical purity, as 
determined on analytical HPLC (MeCN/H2O/TFA 50:50:0.1 v/v/v)). 
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2.3.7. [3H]MC198  
[3H]MC198 was prepared according to the general method, by reacting precursor 
14a (0.2 mg, 0.49 µmol) with [3H]methyl nosylate (200 µL) for 30 min at 60 °C. The 
product (5.0 MBq) was synthesized with 3.7% radiochemical yield and high 
radiochemical purity (>99%). 
2.3.8. [3H]KE64  
[3H]methyl nosylate (150 µL) was reacted with the precursor 21a (0.2 mg, 0.43 µmol) 
for 60 min at 60 °C according to the general method to give the desired product 
[3H]KE64 (2.3 MBq) with 2.3% radiochemical yield and >99% radiochemical purity, 
as determined on analytical HPLC (MeCN/H2O/TFA 50:50:0.1 v/v/v)). 
2.3.9. Radiosynthesis of [18F]MC198 and [18F]KE64  
Production and work-up of fluoride-18 was performed as described previously.20 
Radiolabeling was performed by a two-step distillation method as reported earlier 
using [18F]fluoroethyl bromide as an intermediate. Briefly, 2-bromoethyl tosylate (15 
µL, 21 mg, 75 μmol) in 1,2-dichlorobenzene (1.0 mL) was added to the dried fluoride 
complex. Formed [18F]fluoroethyl bromide was distilled directly after addition of 2-
bromoethyl tosylate at 90 °C during 15 min with a helium gas flow (40 mL/min) to 
the second vial at room temperature. For [18F]MC198, [18F]fluoroethyl bromide was 
reacted with precursor 11b (2 mg, 5.3 µmol) and NaH (60% dispersion in mineral oil, 
2 mg, 50 µmol) in DMF (0.5 mL) at 80 °C for 5 min. [18F]KE64 was prepared in the 
same way using 16 (1.5 mg, 3.5 µmol) and NaH (3.0 mg, 75 µmol) in DMF (0.5 mL) 
in a 10 min reaction at 80 °C. After completion of the reactions, HPLC eluent (0.1 
M NaOAc/MeCN 6:4 (v/v), 0.5 mL) for [18F]MC198 or 1:1 for [18F]KE64) was added. 
The mixture was filtered through an Acrodisc syringe filter (0.4 µm, Pall, Port 
Washington, NY, USA) and subjected to HPLC purification utilizing a 
Symmetryshield RPS 5 µm 7.8 × 300 mm column (Waters, Milford, MA, USA) at a 
flow of 3 mL/min (UV detection at 254 nm, Rt of [18F]MC198 = 17 min and [18F]KE64 
= 9 min). The product was collected into a bottle containing 80 mL of sterile water. 
Formulation was performed as described previously.20 
 




2.4. In vitro experiments with tritiated molecules 
2.4.1. Cell culture 
Madin-Darby canine kidney (MDCK) II cells expressing cDNAs encoding human 
MDR1 (MDCKII-MDR1 cells) were obtained by TNO from the Netherlands Cancer 
Institute. Transfected MDCKII cells were seeded on semi-permeable (pore size 0.4 
µm) filter inserts (12-well Transwell plates 3401, Costar Corp, Cambridge, MA, USA) 
at approximately 4 × 105 cells per filter insert (growth area of 1.13 cm2) and cultured 
according to the standard procedure for this cell line.26 Cells were counted using an 
automatic cell counter (Millipore, Bedford, MA, USA). Cells on the inserts were 
cultured for three days in a total volume of 2.3 mL culture medium per well (0.5 mL 
apical and 1.8 mL basolateral) at approximately 37 °C in a humidified incubator 
containing approximately 95% air/5% CO2. The medium was refreshed after 48 h. It 
has been shown, that under these conditions the human transporter protein MDR1 
localizes on the apical plasma membrane of the cells.27,28  
2.4.2. Assessment of monolayer integrity 
After three days of cell culture on Transwell, the MDCKII-MDR1 monolayers are 
expected to have developed a transepithelial electrical resistance (TEER) of 
approximately 70 Ωcm2 higher than background (empty filter without cells).29 At the 
start of each study, TEER was measured to assess the integrity of the monolayers of 
MDCKII-MDR1 cells in culture medium using the Millicell-ERS epithelial 
voltohmmeter (Millipore). Monolayers with a TEER value less than 55 Ωcm2 above 
background (empty filter) were excluded from the transport assay. TEER values 
ranged from 205 to 294 Ωcm2, with a mean of 253 Ωcm2, including the background 
of 125 Ωcm2. Cell monolayers were also inspected with a microscope before starting 
the experiments. 
2.4.3. Bidirectional transport of tritiated compounds in MDCKII-MDR1 cells 
Transcellular transport studies were performed as described previously with minor 
modifications.30 In brief, a stock solution of digoxin (0.1 mM) was prepared in 
DMSO. [3H]digoxin was mixed with a non-radiolabeled compound to achieve a final 
concentration of 0.05 µM digoxin in HBSS/HEPES in the transwells, and a 
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radioactivity concentration of 10 kBq/mL. Stock solutions of test compounds 
verapamil, N-FeVer, O-FeVer, MC224, MC225, MC198 and KE64 (0.01, 1 and 100 
mM) were prepared in DMSO, mixed with the tritium labeled analogs and diluted 
with HBSS/HEPES to final concentrations of 0.01, 1 and 50 µM, with a radioactive 
tracer concentration of 10 kBq/mL in the transwells. 
After the integrity assessment, culture medium was removed from the filter inserts 
(apical compartment (A)). The inserts were washed once with warm (37 °C) HBSS, 
transferred to new 12-well plates which were preincubated with HBSS/HEPES for 18 
h at 37 °C, to reduce non-specific binding to the plastic, and washed with warm 
HBSS. The MDR1-mediated apical to basolateral (A → B) transport in MDCKII-
MDR1 cell monolayers was determined by addition of 0.65 mL of a tritiated 
compound in concentrations of 0.01, 1 and 50 µM to the apical compartment in 
triplicate. A volume of 1.8 mL of HBSS/HEPES was added to the basolateral 
compartment. To determine basolateral to apical (B → A) transport, 1.95 mL of a 
tritiated compound at concentrations of 0.01, 1 and 50 µM was added to the 
basolateral compartment and 0.5 ml of HBSS/HEPES to the apical compartment. A 
150 µL aliquot of the apical (A → B) or basolateral (B → A) compartment was taken 
at the start of the experiment to measure the initial concentration and to calculate 
the recovery of radioactivity. Incubations were performed on a rocker platform 
(rotation approximately 60 rpm) at 37 °C for 2 h in a humidified incubator containing 
approximately 95% air/5% CO2. Aliquots of the apical and basolateral samples (150 
and 1600 µL for A → B and 400 and 150 µL for B → A, respectively) and samples 
of the initial concentration were mixed with 10 mL of liquid scintillant Ultima 
GoldTM (PerkinElmer Inc.). Radioactivity was determined by LSC on a Tri Carb 
3100TR liquid scintillation counter using QuantaSmartTM software (PerkinElmer 
Inc.) in which all counts were converted to disintegrations per minute (DPM) using 
tSIE/AEC (transformed spectral index of external standards coupled to automatic 
efficiency correction). Background values were measured for each sample sequence 
using liquid scintillant without test samples. Recovery of radioactivity was calculated 
as percentage of measured total radioactivity after the experiment versus initial 
radioactivity. 
Subsequently, the effects of MDR1-inhibitors ketoconazole and tariquidar on the 
bidirectional transport of the tested tritiated compounds were examined. Stock 




solutions of the inhibitors ketoconazole (10 mM) and tariquidar (10 mM) were 
prepared in DMSO. On the day of the experiment, inhibitors were added to 
HBSS/HEPES solutions of the tritiated test compounds in a concentration of 0.01 µM 
or [3H]digoxin in a concentration of 0.05 µM to reach a final concentration of 25 µM 
ketoconazole or 10 µM tariquidar. These concentrations were based on IC50 values 
that are known to block P-gp completely.16,25 The assay was performed in an identical 
manner as described above, except that all apical (in A → B experiment) and 
basolateral (in B → A experiment) solutions contained 25 µM ketoconazole or 10 
µM tariquidar from the start of the experiment, keeping the concentrations of test 
compounds (0.01 or [3H]digoxin 0.05 µM, 10 kBq/mL) and organic solvent 
concentration (≤1%) constant for all samples. 
2.4.4. Calculations 
Papp representing A to B permeability and B to A of a test compound was calculated 
according to the following equation: 
Papp = (dQ/dt)/(A × C0) (1) 
where dQ/dt indicates the appearance rate of a test compound at the receiver side 
calculated from total DPM at t = 120 min, corrected for background (DPM/s). A is 
the surface area of the filter insert (cm2) and C0 the measured initial concentration, 
calculated from total DPM on the donor side at t = 0 min (DPM/L). 
To determine the ER for the test compounds, the following equation was used: 
ER = Papp B → A/Papp A → B (2) 
2.5. In vitro experiments with nonradioactive molecules 
The transport assay with nonradioactive compounds in Caco-2 cells was performed 
in 96-well plates as described previously.31 The initial concentration of the test 
compounds in the donor well was 10 µM and the concentration in the acceptor well 
was measured after 2 h using UV spectroscopy. Samples from one compound were 
pooled in order to have a sufficient volume for the UV detection. 
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The calcein-AM experiment was performed in MDCKII-MDR1 cells according to 
methods described previously.32 Calcein cell accumulation in the absence and in the 
presence of test compounds (0,1, 1, 10, 30, 50 and 100 µM) was evaluated and the 
basal level of fluorescence was measured in untreated cells. EC50 values were 
determined by fitting the fluorescence increase (in %) versus log[dose]. 
2.6. Animal experiments with [18F]MC198 and [18F]KE64 
All animal studies were in compliance with the local ethical guidelines. Protocols 
(DEC 6456C) were approved by the Institutional Animal Care and Use Committee 
of the University of Groningen. Male FVB wild type mice (33 ± 2 g, 11–12 weeks) 
and Mdr1a/b(−/−)Bcrp1(−/−) constitutive knockout mice (31 ± 3 g, 11–12 weeks) 
developed from the FVB line were purchased from Taconic (Hudson, NY, USA). 
After arrival, animals were housed individually and acclimatized for at least 7 days 
in the Central Animal Facility of the University Medical Center Groningen before 
experiments. Mice had access to food and water ad libitum and were kept under a 
12 h light-dark cycle. During experiments, mice were anesthetized with 2% isoflurane 
in medical air and kept at a constant temperature using electronically controlled 
heating pads.  
2.6.1. PET procedure and data analysis 
Mice were injected with radiotracers (3.5 ± 1.6 MBq, 0.1 mL, [18F]MC198 or 
[18F]KE64) in the penile vein under isoflurane anesthesia. Injections were performed 
with the mice in the microPET camera (microPET Focus 220, Siemens Medical 
Solutions, Malvern, PA, USA), simultaneously starting a 30 min dynamic emission 
scan. After each emission scan, a transmission scan of 515 s with a 57Co point source 
was performed to correct the emission data for attenuation and scatter. Mice were 
terminated by cervical dislocation. Several organs and tissues were excised, weighed 
and radioactivity was measured in a γ-counter (LKB Wallac, Turku, Finland). 
Radioactivity accumulation in the organs was expressed as SUV, using the following 
formula: [tissue activity concentration (MBq/g)]/[injected dose (MBq)/body weight 
(g)]. Metabolites in the terminal plasma and brain samples were determined using a 
radio-TLC method described elsewhere.20 TLC-plates were eluted with 
ethylacetate/methanol 9:1 v/v (Rf [18F]MC198 = 0.45, Rf[18F]KE64 = 0.62). PET data 




were reconstructed as described previously.20 Inveon Research Workplace software 
version 4.0 (Siemens, Erlangen, Germany) was used for data analysis. All frames 
were summed, and PET images were co-registered with an MRI template.33 A whole 
brain volume of interest (VOI) based on the MRI template was generated. 
Radioactivity concentrations were converted to SUV values and plotted as time-
activity curves (TAC). 
2.7. Statistical analysis 
The statistical significance of differences between two groups was calculated by two-
sided unpaired Student’s t test, using IBM SPSS Statistics version 22 (Armonk, NY, 
USA). One-way analysis of variance (ANOVA) with Bonferroni correction was used 
to assess differences between three or more groups. A p value of less than 0.05 was 
considered statistically significant. 
3. Results 
3.1. Organic synthesis 
As depicted in Scheme 1, compound 2 was prepared by reductive amination using  
4-(2-aminoethyl)-2-methoxyphenol and aldehyde 1, which was synthesized in a 
stereoselective manner as described before.19 
 
Scheme 1. Synthesis of 2. Reagents: (i) NaBH(OAc)3, Na2SO4, MeOH. 
Compound 7a and MC224 were synthesized as reported in Scheme 2. Carboxylic 
acid 3 was transformed into the corresponding acyl chloride 4 that was reacted with 
hydroxyisoquinoline to obtain amide 5a. Final amine 7a was obtained by reduction 
of amide 5a, followed by fluoroethylation of 6a. Synthesis of compounds 5b–6b and 
MC224 has been reported previously and spectral data of these compounds were 
identical to those described previously.20 




Scheme 2. Synthesis of 7a and MC224. Reagents and Conditions: (i) SOCl2, Et3N; 
(ii) NH4OH, CH2Cl2; (iii) LiAlH4, THF dry; (iv) NaH, DMF.  
 
Scheme 3. Synthesis of 13a, MC225, 14a and MC198. Reagents and Conditions: (i) 
CH3SO2Cl, Et3N, CH2Cl2, −10 °C; (ii) cyclopropylmagnesium bromide, 3 N HCl, 
THF; (iii) Na2CO3, DMF; (iv) H2, Pd/C (5%); (v) 2-fluoroethyl tosylate, NaH, DMF. 
Compounds 13a, MC225, 14a and MC198 were prepared as reported in Scheme 3. 
Synthesis of compounds 9, 10, 11b, 12b and MC225 has been reported previously 
and spectral data of these compounds were identical to those reported.20,34 
Compounds 11a,b were obtained by alkylation of chloride derivative 10 with 
isoquinoline. Compound 13a was obtained by hydrogenation of 11a and consequent 




fluoroethylation of compound 12a. Compounds 14a and MC198 were obtained by 
direct fluoroethylation of compounds 11a,b. 
 
Scheme 4. Synthesis of 16, 21a and KE64. Reagents and Conditions: (i) 1-bromo-4-
chlorobutane, NaH, toluene; (ii) Na2CO3, DMF; (iii) NaH, THF; (iv) NaH, DMF; (v) 
LiAlH4, THF; (vi) MsCl, Et3N, CH2Cl2.  
Synthesis of compounds 16, 21a and KE64 is depicted in Scheme 4. 
Dihydroxybiphenyl was reacted with methyl-4-chlorobutanoate to obtain ester 17. 
Compound 18 was prepared by fluoroethylation of ester 17 and the ester function 
was then reducted into alcohol yielding compound 19. Compound 19 was mesylated 
(compound 20) and then condensed with 7-methoxy-1,2,3,4-tetrahydroisoquinolin-6-
ol or 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline to obtain final compounds 21a 
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and KE64, respectively. Synthesis of compounds 15 and 16 has been previously 
reported and spectral data of these compounds were identical to those reported 
previously.35 
3.2. Radiosynthesis 
3.2.1. Tritium Labeling 
Radiolabeling with tritium was first pursued using conditions from previous 
experiments with [3H]methyl nosylate.36 For [3H]verapamil labeling, the precursor 
was first dissolved in MeCN with 5 M NaOH and reacted with [3H]methyl nosylate 
at 60 °C for 15 min (Scheme 5). However, milder conditions were required to reduce 
the formation of byproducts and therefore an overnight reaction at room temperature 
was used instead (25% radiochemical yield (RCY)). For the radiosynthesis of [3H]N-
FeVer and [3H]O-FeVer, [3H]fluoroethyl tosylate was used as a labeling agent at 60 
°C for 45 min, but these conditions did not yield any product. Therefore, a higher 
temperature of 120 °C for 45 min was used to promote the reaction towards 5.7% 
RCY for [3H]N-FeVer and 14% RCY for [3H]O-FeVer (Scheme 6). [3H]MC224 was 
dissolved in DMSO with 5 M NaOH and reacted with [3H]methyl nosylate at 60 °C 
for 15 min. This resulted in low yield with an unidentified byproduct. Therefore, the 
reaction was repeated overnight at room temperature and the yield increased under 
these milder conditions (26% RCY). The highest yield for [3H]MC225 labeling was 
obtained according to the standard protocol in MeCN for 15 min at 60 °C (10% 
RCY). For [3H]MC198 and [3H]KE64, a longer reaction time (30 min and 60 min, 
respectively) was needed to reach sufficient yields (3.7% and 2.3% RCY respectively). 
The low yield of [3H]MC198 was mainly due to the formation of byproducts. Most 
likely one of them was the isomerized form of [3H]MC198, as observed in the 
fluorine-18 labeling. The reaction mixture of [3H]KE64 also showed multiple 
unidentified byproducts. Fortunately, the two desired products could easily be 
purified by preparative-HPLC.  
3.2.2. Radiolabeling of [18F]MC198 and [18F]KE64 
[18F]MC198 was challenging to label (Scheme 7), because, under basic reaction 
conditions, which are required for the labeling, the double bond of precursor 11b 
can isomerize from the alkyl chain into the tetrahydronaphthalene ring. When the 




amount of NaH was increased, the amount of isomerization also increased. On the 
other hand, when the amount of NaH was reduced, the radiochemical yield 
remained low. An amount of 2 mg of NaH for 2 mg of precursor 11b was found to 
yield a sufficient amount of [18F]MC198 (2.5% radiochemical yield, calculated from 
end of bombardment of 18F−) to conduct the in vivo studies.  
 
Scheme 5. General tritium labeling of verapamil, MC224, MC225, MC198 and KE64 
with [3H]methyl nosylate. 




Scheme 6. General tritium labeling of N-FeVer and O-FeVer with [3H]fluoroethyl 
tosylate. 
 
Scheme 7. General fluorine-18 labeling of MC198 and KE64 with [18F]fluoroethyl 
bromide. 
Use of tetrabutylammonium hydroxide (TBAOH) solution (40% in water, 1 µL 
TBAOH and 0.5 mg of precursor) instead of NaH was also attempted, but no 
product was formed at all. Radiosynthesis was also attempted by starting with 
ethylene di(p-toluenesulfonate), which was first reacted with dried fluoride complex. 
However, the formed [18F]fluoroethyl tosylate was difficult to purify and using it in 




unpurified form could lead to side products together with the precursor and 
unreacted ethylene ditosylate. A Sep-Pak Silica Plus cartridge, a Sep-Pak C-18 
cartridge and HPLC were used for purification, but all methods were time consuming 
and HPLC and silica Sep-Pak produced the intermediate in large volume. In 
addition, the separation in the Sep-Paks was poor. Radiosynthesis progressed more 
easily and faster, and produced higher yields when the distillation employing 
bromoethyl tosylate as precursor was used. Using 0.1 M NaOAc/MeCN 6:4 (v/v) as 
an HPLC eluent, the product and the isomer could be partially separated, but 
baseline separation was not reached with this or with other eluents tested. 
Identification was based on the retention time of nonradioactive MC198 in HPLC. 
[18F]MC198 was produced in 83 min with >95% radiochemical purity and >100 
GBq/µmol molar radioactivity. Log D7.4 was measured as 2.3 according to a method 
reported earlier.20 A distillation method was used without any difficulties also for 
[18F]KE64. It was generated with 6.7 ±0.5% radiochemical yield, >97% radiochemical 
purity and 32 ± 17 GBq/µmol molar radioactivity in 72 min. Log D7.4 was determined 
to be 3.2. 
3.3. In vitro experiments 
Bidirectional transport of the tritiated test compounds ([3H]verapamil, [3H]N-FeVer, 
[3H]O-FeVer, [3H]MC224, [3H]MC225, [3H]MC198 and [3H]KE64) was investigated 
in MDCKII-MDR1 cells. Papp values for concentration dependent transport in both 
A → B and B → A direction and the ER (B → A/A → B) are shown in Figure 2. 
The effect of P-gp-mediated transport inhibition by ketoconazole and tariquidar is 
shown in Figure 3. The well-known P-gp substrate [3H]verapamil showed high B → 
A transport values (>40 × 10−6 cm/s) and lower A → B transport (>8 × 10−6 cm/s) at 
0.01 µM with an ER of 5, indicating proper function of the MDCKII-MDR1 cells. 
With increasing concentrations of verapamil, the B → A transport and ER values 
decreased significantly, indicating saturation of P-gp. On the other hand, the A → B 
transport did not show any change from 0.01 to 1 µM, only at 50 µM the A → B 
transport increased significantly and the Papp values corresponded to the values 
observed with inhibitors ketaconazole and tariquidar. B → A transport of 
[3H]verapamil decreased significantly in combination with the inhibitors whereas A 
→ B transport increased and consequently the ER values decreased below 2, 
indicating full inhibition of P-gp. 





Figure 2. Bidirectional transport (Papp and ER) of (A) [3H]verapamil, (B) [3H]N-FeVer, 
(C) [3H]O-FeVer, (D) [3H]MC224, (E) [3H]MC225, (F) [3H]MC198 and (G) [3H]KE64 
in MDCKII-MDR1 cells (mean ± SEM) tested at different concentrations: 0.01 µM 
(n = 6), 1 µM (n = 3) and 50 µM (n = 3). * Symbol represents a significant difference 
with 0.01 µM (*p < 0.05, **p < 0.01, ***p < 0.001) and # symbol a significant 
difference with 1 µM (#p < 0.05, ##p < 0.01, ###p < 0.001). 





Figure 3. Bidirectional transport (Papp and ER) of (A) [3H]verapamil, (B) [3H]N-FeVer, 
(C) [3H]O-FeVer, (D) [3H]MC224, (E) [3H]MC225, (F) [3H]MC198, (G) [3H]KE64 
and (H) [3H]digoxin in MDCKII-MDR1 cells (mean ± SEM) using baseline 
concentration of 0.01 µM (n = 6) with co-incubation of the P-gp inhibitor 
ketoconazole at 25 µM (0.01 µM + keto, n = 3) and tariquidar at 10 µM (0.01 µM + 
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TQD, n = 3). * Symbol represents a significant difference with 0.01 µM (*p < 0.05, 
**p < 0.01, ***p < 0.001) and # symbol a significant difference with 0.01 µM + keto 
(#p < 0.05, ##p < 0.01, ###p < 0.001). 
A similar behavior as with [3H]verapamil was observed also for [3H]N-FeVer. The 
only difference was that a significant change in B → A transport compared to 0.01 
μM was observed only at 1 μM. [3H]O-FeVer also behaved like a P-gp substrate, 
with low A → B Papp values (<2 × 10−6 cm/s) at 0.01 µM and 1 µM, but this increased 
significantly at 50 µM and in the presence of inhibitors. The big difference in A → 
B and B → A resulted in a very high ER (>30) at 0.01 µM and 1 µM, and was still 
higher than 2 at 50 µM or after inhibition with ketoconazole.  
[3H]MC224 had low Papp values in both directions (<9 × 10−6 cm/s) compared with 
[3H]verapamil. Different concentrations of [3H]MC224 did not affect the B → A 
transport much, but transport in both directions increased significantly due to 
inhibition of P-gp. The ER was <2 under all conditions, even at a tracer concentration 
of 0.01 µM, indicating that MC224 is not a substrate of P-gp. [3H]MC225 showed 
increased A → B and B → A values and decreased ER values at increasing 
concentrations and in combination with inhibitors, suggesting substrate behavior. 
With [3H]MC198, no change was observed between 0.01 and 1 µM, but A → B and 
B → A values increased significantly at 50 µM concentration and in combination 
with inhibitors. The ER of [3H]MC198 at 0.01 µM was slightly above 2, but below 
this cut-off at higher concentrations, indicating some affinity but very low capacity 
for P-gp mediated transport. [3H]KE64 did not show a clear pattern due to increasing 
concentrations or P-gp inhibition and in addition all Papp values were very low (<3 × 
10−6 cm/s). 
[3H]Digoxin transport across monolayers of MDCKII-MDR1 cells was investigated 
only at a concentration of 0.05 μM and in combination with inhibitors. B → A 
transport was high (>15) and A → B transport very low (<1) causing a really high ER 
(>30). Both transport values decreased significantly (to <3) due to inhibition. With 
both model substrates, [3H]verapamil and [3H]digoxin, A → B transport increased 
and B → A transport decreased due to inhibition. The difference between the two 
compounds was that with [3H]verapamil, both transport values remained high (>20). 
Ketoconazole and tariquidar inhibited the P-gp transport in a very similar way for all 




the tested compounds tested. There were only small differences within a test 
compound in A → B and B → A values after inhibition by either ketoconazole or 
tariquidar, which could be due to different P-gp binding sites of these inhibitors. 
Recovery of radioactivity was determined after each experiment. [3H]Verapamil, 
[3H]N-FeVer, [3H]O-FeVer and [3H]digoxin showed good recovery (≥76% in all 
experiments, both in A → B and B → A directions). The recovery values for the 
remaining compounds were lower, ranging from 30 to 74% for [3H]MC224, 45 to 86% 
for [3H]MC225, 36 to 75% for [3H]MC198 and 40 to 100% for [3H]KE64. These low 
recovery values could be due to the lipophilicity of the molecules, resulting in 
extensive nonspecific binding to surface membrane and/or intracellular components. 
Log D7.4 values for MC224, MC225, MC198 and KE64 were 2.9, 3.0, 2.3 and 3.2, 
respectively, and for verapamil, N-FeVer and O-FeVer 2.6, 2.0 and 1.6, 
respectively.20  
 
Figure 4. (A) Bidirectional transport (Papp and ER) of the test compounds in Caco-2 
cells after 2 h transport using concentration of 10 µM (n = 1) and (B) correlation with 
ER values in MDCKII-MDR1 cells (verapamil: ●, O-FeVer: +, N-FeVer: ■, MC224: 
▲, MC225: ▼, MC198: ♦, KE64: ×). 
In addition, the bidirectional transport of the nonradioactive molecules was 
evaluated in Caco-2 cells (Figure 4A). All of the compounds showed very similar 
results, with ER values ≥2, indicating affinity for P-gp. Remarkably, MC224 showed 
lower A → B and B → A values than other molecules, but still the highest ER, 
indicating the strongest P-gp substrate potential, although this was not observed in 
the in vivo data or in vitro with the tritiated molecule. Bi-directional transport of the 
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tested compounds across monolayers of Caco-2 and MDCKII-MDR1 cells was very 
different. ER values obtained in Caco-2 cells did not correlate with ER of MDCKII 
cells at test compound concentrations of 0.01 and 1 µM. A poor correlation (r2 = 
0.35) was observed between data acquired at 50 µM in MDCKII cells and at 10 µM 
in Caco-2 cells (Figure 4B).  
A calcein-AM inhibition experiment was performed in MDCKII-MDR1 cells with 
nonradioactive test compounds. The lowest EC50 value (0.014 µM) was obtained with 
KE64 and the highest with O-FeVer (2.4 µM, Table 1), indicating that KE64 has the 
greatest P-gp inhibition potential.  
Table 1. In vitro and in vivo results of the P-gp radiotracers tested 
 In vitro In vivo  
 MDCKII-
MDR1 cells 


















    Mice Rats Mice Rats  
Verapamil 5.5 1.1 + 7.12  6.21 
3.72 
7.13 + 
N-VeFer 2.8 1.1 +  5.83 1.21 3.73 + 
O-FeVer 37 2.4 + 6.51  5.91 2.43 + 
MC224 1.8 0.54 − 1.42  1.12  − 





MC198 2.1 0.27 + 2.22  1.72  + 
KE64 1.9 0.014 − 2.12  1.62  + 
Definition as substrate (+) in vitro was ER > 2 and in vivo brain-to-plasma or AUC ratio > 2 
in at least one strain.  
1 Mdr1a/b(−/−) 60 min scan (verapamil, N-FeVer and O-FeVer) or 30 min scan (MC225, 45 
min time point in brain-to-plasma).19,20  
2 Mdr1a/b(−/−)Bcrp1(−/−) 30 min scan, 45 min time point in brain-to-plasma.20  
3 Wistar rats treated with tariquidar (15 mg/kg). N-Fever, 15 min time point in brain-to-plasma 
ratio and treatment with tariquidar 15 min prior to the radiotracer. All other values, treatment 
30 min before tracer injection and 60 min PET scan.19  
4 Sprague-Dawley rats treated with tariquidar (8 mg/kg) 30 min prior to the radiotracer, 60 
min scan.21 
 




3.4. In vivo evaluation of [18F]MC198 and [18F]KE64 
 
Figure 5. (A,B) Whole brain time-activity curves and (C,D) biodistribution profile 45 
min p.i. of [18F]MC198 and [18F]KE64. Data are presented as mean ± SEM. Statistical 
differences are marked with a horizontal capped line (*p < 0.05, **p < 0.01).  
Radiotracer uptake in the brain was evaluated in wild-type and Mdr1a/b(−/−)Bcrp1(−/−) 
knockout mice with microPET imaging. Both [18F]MC198 (control n = 5, knockout 
n = 4) and [18F]KE64 (control n = 5, knockout n = 6) had higher brain uptake in the 
knockout mice than in wild-type, indicating that they are substrates for P-gp and/or 
Bcrp in vivo (Figure 5A,B). The difference in whole brain time-activity curves 
between strains, expressed in standardized uptake value (SUV), was 1.7-fold  
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(p < 0.001, comparing areas under the curve (AUC) from 0 to 30 min) for [18F]MC198 
and 1.6-fold (p = 0.072) for [18F]KE64. The biodistribution profile of both compounds 
(at 45 min post-injection (p.i.)) was similar, with the highest uptake in liver, kidney, 
pancreas and small intestine (Figure 5C,D). Radioactive metabolites in plasma and 
brain at 45 min p.i. were analyzed using radio-TLC. Both compounds showed 
significant and rather rapid metabolism, the fraction of intact parent compound in 
the plasma at 45 min was only 34% and 26% for [18F]MC198 and [18F]KE64, 
respectively. In the brain, more metabolites were detected for [18F]MC198 than for 
[18F]KE64, i.e., 11 versus 5% metabolites of total radioactivity, respectively. 
3.5. In vitro—in vivo correlation 
In vivo evaluation was performed in control and P-gp knockout mice and for some 
compounds also in rats which were treated with P-gp inhibitors (Table 1).19–21 
Experiments were performed in different institutions where different animal models 
were available and some compounds were involved in more experiments than 
others. The in vivo P-gp substrate potential was defined by difference in brain uptake 
between knockout and control animals. For radiolabeled compounds, the brain 
uptake can be determined either by PET imaging (time-activity curves) or by 
biodistribution studies (brain-to-plasma ratios). Brain-to-plasma ratios (Table 1) in 
knockout mice divided by brain-to-plasma ratios in control mice correlated nicely 
with in vitro ER values in MDCKII-MDR1 cells at both test compound 
concentrations of 0.01 µM (r2 = 0.89, Figure 6A) and 1 µM (r2 = 0.83, data not 
shown,). AUC ratios of whole brain SUV time-activity curves also correlated with ER 
values at these same concentrations. Correlation was slightly better at a concentration 
of 0.01 µM (r2 = 0.79, Figure 6B) than at 1 µM (r2 = 0.72, data not shown). [3H]O-
FeVer had such high ER values at both concentrations (0.01 and 1 µM) that they 
were not in the same range as the others and therefore they were not included in the 
correlation analysis. ER of [3H]O-FeVer at a concentration of 0.01 µM was also a 
significant outlier according to Grubb’s test (p < 0.05). At a concentration of 50 µM, 
the correlation of ER values with both brain-to-plasma and AUC ratios was lost for 
all compounds. ER values obtained in Caco-2 cells (using a concentration of 10 uM) 
showed no correlation with the results obtained in the in vivo studies. 




Figure 6. Correlation of in vitro ER values with (A) brain-to-plasma ratios and (A) 
AUC ratios between knockout and control mice. Brain-to-plasma ratios were 
calculated based on the biodistribution data 45 min p.i. using Mdr1a/b(−/−)Bcrp1(−/−) 
knockout and control mice dosed with [11C]verapamil (●), [18F]MC224 (▲), 
[18F]MC198 (♦) and [18F]KE64 (×). For [18F]MC225 (▼), values from both 
Mdr1a/b(−/−)Bcrp1(−/−) (closed symbols) and Mdr1a/b(−/−)(open symbols) mice were 
included. AUC ratios are calculated from whole brain SUV time-activity curves in 
the same strains as mentioned above, except that Mdr1a/b(−/−) mice were used for 
[18F]N-FeVer (■) and these mice were used also for [11C]verapamil (o) in addition to 
Mdr1a/b(−/−)Bcrp1(−/−) mice (●). 
4. Discussion 
This study investigated how accurately standard in vitro assays, i.e., bidirectional 
monolayer transport and calcein-AM assays, can predict in vivo behavior of potential 
P-gp substrates. For this purpose, seven different P-gp PET radiotracers were used: 
(R)-[11C]verapamil, [18F]N-Fever, [18F]O-Fever, [18F]MC224, [18F]MC225, [18F]MC198 
and [18F]KE64. In vivo evaluation was performed in transporter knockout and control 
mice and/or in rats treated with the P-gp inhibitor tariquidar. Initial in vitro 
characterization was performed using nonradioactive compounds in combination 
with both the calcein-AM assay in MDCKII-MDR1 cells and the bidirectional 
transport assay in Caco-2 cells. The main finding was that in vivo behavior was not 
the same for all compounds as that observed in vitro for their nonradioactive analogs. 
Therefore, an attempt was made to improve the predictive value of the in vitro data 
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by identifying more appropriate assays, focusing on the use of a bidirectional 
transport assay with tritium labeled compounds in MDCKII-MDR1 cells. 
Due to differences between the Caco-2 and MDCK-MDR1 cell lines, the P-gp 
mediated transport of compounds may differ, as was observed for example with 
higher efflux of [3H]digoxin in  MDCK-MDR1 cells than in Caco-2 cells.6 The 
transport assay in Caco-2 cells, performed only at a relatively high test compound 
concentration (10 µM), did not sufficiently assess the differences between test 
compounds and incorrectly classified MC224 as a P-gp substrate (Figure 4). 
4.1. Verapamil, N-FeVer and O-FeVer behavior 
Verapamil and its derivatives N-FeVer and O-FeVer showed comparable results in 
the transport experiments. Passive diffusion (A → B transport) increased with 
increasing concentrations of the compound and after treatment with inhibitors, which 
is an indirect consequence of the inhibition of P-gp. More compound is able to pass 
through the cell, without interference of P-gp, since it is not directly transported back 
to the apical side, resulting in a higher A → B transport. The increased A → B 
transport caused a decrease in the ER (Figures 2 and 3). In the concentration assay, 
O-FeVer transport was affected substantially only at a concentration of 50 µM and 
in the Calcein-AM measurement it had the highest EC50 value (2.4 µM. Table 1). P-
gp efflux, the B → A transport, and ER values were the highest of all the tested 
compounds at concentrations of 0.01 and 1 µM. This means that O-Fever was the 
strongest substrate and weakest inhibitor of P-gp in vitro. Only at 50 µM a decrease 
in ER was found, which implies that, for a full assessment of the concentration 
dependent behavior, more concentrations between 1 and 50 µM would be needed 
for this compound. Compared with N-FeVer and verapamil, low A → B transport 
(<2 × 10−6 cm/s) of O-FeVer at 0.01 and 1 µM indicates low passive diffusion and/or 
high P-gp affinity, which could be explained by the low log D7.4 of 1.6. This effect is 
also observed in vivo with slowly increasing brain uptake and absence of an initial 
peak of activity.19 However, verapamil was still the strongest substrate in vivo as it 
had the highest brain-to-plasma and AUC ratios, both in mice and rats (Table 1). N-
FeVer actually showed a rather low AUC ratio in mice (1.2), but this was higher in 
rats (3.7), indicating species differences. With O-FeVer, it was the other way around. 
Both N-FeVer and O-FeVer showed rapid in vivo metabolism. After 5 min, only 46 




and 20% of the total activity in plasma represented parent N- and O-FeVer, 
respectively, whilst for verapamil it was 88%. However, the formed metabolites are 
not expected to interact with P-gp, since they are not fluorine-18 analogs of the known 
[11C]verapamil metabolite and P-gp substrate [11C]D617.19,37 
4.2. MC224, MC225, MC198 and KE64 behavior 
Compounds MC224, MC225, MC198 and KE64 are all structural analogs. The 
difference between MC225 and MC198 is only a double bond in MC198 in the 
middle of the molecule versus a single bond in MC225 (Figure 1). The transport 
assay in MDCKII-MDR1 cells yielded very similar ER values for both compounds, 
although A → B and B → A values were a bit higher for MC225 (Figures 2E,F and 
3E,F)). The calcein-AM assay identified MC198 as a slightly more potent P-gp 
inhibitor (Table 1). However, MC225 had higher knockout/control brain-to-blood 
and AUC ratios in mouse brain in vivo than MC198, it was metabolically more stable 
and showed fewer radioactive metabolites in the brain.20 MC198 was also difficult to 
label due to isomerization of the double bond. Thus, MC225 had better 
characteristics for in vivo PET imaging than MC198, although the in vitro assays 
predicted them to be fairly equal. 
MC224 has a shorter alkyl chain, with only one carbon atom separating the 
isoquinoline and biphenyl structures, than KE64 which has a 4-membered alkyl chain 
connected with an ether bond (Figure 1). In case of P-gp substrates, the in vitro ER 
values are expected to decrease after inhibition of P-gp. This was not observed for 
either MC224 or KE64. There was also no clear concentration dependent transport. 
The calcein-AM assay yielded EC50 values for MC224, which were in the same range 
as for MC225 and MC198 (Table 1). KE64, on the other hand, had the lowest EC50 
value of all tested compounds (0.014 µM), suggesting the best inhibitory properties. 
MC224 was the only compound showing negative results both in vitro and in vivo. 
KE64, on the other hand, was the only compound out of the seven tested molecules 
that had conflicting in vitro and in vivo results. It was not a clear substrate in vitro, 
but at tracer concentrations, higher brain uptake (1.6-fold) was observed in 
Mdr1a/b(−/−)Bcrp1(−/−) compared with wild-type mice, indicating that KE64 is a 
moderate P-gp substrate in vivo. However, the in vitro transport results of KE64 may 
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not be very reliable due to low Papp values obtained and extensive binding to cellular 
components and consequently low recovery values. 
4.3. Calcein-AM assay 
A calcein-AM experiment alone would not have been sufficient to classify the 
molecules as P-gp substrates or inhibitors, as it can falsely indicate affinity for P-gp, 
especially in case of compounds with low Papp values, such as for MC224.11 However, 
if the calcein-AM assay is performed in combination with a transport experiment at 
different concentrations of the test compound, the calcein-AM assay can give 
valuable additional information. Solely based on the calcein-AM experiment, KE64 
would have been classified as a P-gp inhibitor. As no in vivo inhibition experiments 
with increasing concentrations of KE64 or any other compounds were performed, it 
is difficult to predict whether they could be used as inhibitors at high dose. In vitro 
almost all molecules showed a decrease in ER at high concentrations, indicating 
saturation of transport. When the concentration is high enough, P-gp will be saturated 
and efflux is decreased. At least 3 different concentrations should be used to see a 
trend in the ER values. An advantage of the calcein-AM assay is that it can be 
automated, as it produces a readout (fluorescence) that is suitable for high throughput 
screening. The transport assay is more laborious. However, tritiated molecules are 
very easy to use in this assay, as their concentration can be determined by liquid 
scintillation counting, which increases throughput. Due to the high sensitivity of this 
technique, it is possible to use very low concentrations of the tritiated molecules in 
the assays. In addition, calculation of the recovery of radioactivity after the 
experiment provides an indication of the extent of nonspecific binding. On the other 
hand, the synthesis of precursor molecules for tritium labeling and the development 
of a labeling method resulting in sufficient radiochemical purity and yield of the 
labeled product may be time consuming. Concentrations of the nonradioactive 
compounds usually are measured with liquid chromatography (LC) combined with 
mass spectrometry (MS), which requires the development of an analytical method 
and measurement of a standard curve. Of course, both transport and calcein-AM 
assays predict only interaction with P-gp, but they do not take into account other 
factors important for PET tracers such as BBB penetration and metabolism. 
 




4.4. In vitro and in vivo correlation 
The in vitro transport assay in MDCKII-MDRI cells, in combination with an ER 
cutoff value of 2 at a test drug concentration of 0.01 µM, predicted substrate behavior 
in vivo. In vitro and in vivo ER values were nicely correlated (Figure 6), even though 
the cell line is transfected with a human P-gp gene and the in vivo data are obtained 
in rodents. Similar results have also been reported by Adachi et al. in Caco-2 and 
LLC-MDR1 cells.38 Feng et al. reported a good correlation of ER values determined 
in human and mouse mdr-transfected MDCK cell lines,10 but Yamazaki et al. found 
that results obtained in mice were better correlated with apparent permeability 
determined in a mouse than in a human cell line.39 It is unclear whether these results 
reflect true species differences or solely the absence of mdr1b in the cells, since the 
mouse P-gp isoforms mdr1a and mdr1b are known to possess distinct functional 
characteristics.40  
Deciding on a clear cutoff value for P-gp substrates was more difficult in vivo than in 
vitro, as only a small number of compounds was included in the present study and 
differences in brain-to-plasma and AUC ratios were observed not only between 
different compounds, but also between animal strains and species. All compounds 
had higher brain-to-plasma than AUC ratios. Brain-to-plasma values were calculated 
only at one time point, whereas AUC represents the whole time frame of the PET 
scan. In this study, a cutoff value of 2 was used for both brain-to-plasma and AUC 
ratios to identify P-gp substrates. N-FeVer and MC225 had AUC ratios lower than 
this in Mdr1a/b(−/−) mice, but since the brain-to-plasma ratios and AUC ratios in rats 
and in Mdr1a/b(−/−)Bcrp1(−/−) mice were higher than 2, they can still be considered as 
substrates. MC198 and KE64 can be considered as weak substrates. 
5. Conclusions 
In vitro prediction of in vivo results is always challenging, but this is especially the 
case for P-gp ligands, as their behavior appears to be concentration dependent. 
Neither the bidirectional transport assay in Caco-2 cells with the nonradioactive 
compounds verapamil, N-FeVer, O-FeVer, MC224, MC225, MC198 and KE64 in a 
single concentration nor the calcein-AM inhibition assay in MDCKII-MDR1 cells 
was sufficiently correlated with in vivo results in rodents by PET imaging. The 
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predictive value of the in vitro data improved when the bidirectional transport assay 
in MDCKII-MDR1 cells was performed with tritium-labeled compounds at three 
different concentrations and in combination with P-gp inhibitors. Based on the data 
of all experiments, the order of in vitro substrate strength was: O-FeVer > verapamil 
> N-FeVer > MC225 ~ MC198 > MC224 ~ KE64 and in vivo: verapamil > O-FeVer 
> MC225 > N-FeVer > MC198 > KE64 > MC224. 
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The goal of this thesis was to develop new fluorine-18 labeled PET tracers to image 
the efflux transporter P-glycoprotein (P-gp) function at the blood-brain barrier (BBB). 
These tracers should be specific to P-gp, have good metabolic stability and optimal 
lipophilicity to cross the BBB, have high yielding GMP-compliant radiosynthesis and 
high molar activity. Over 300 compounds have been identified as P-gp substrates.1 
It still remains a mystery, why so many unrelated molecules are all effluxed by P-gp. 
Especially, since P-gp does have distinct sites for drug binding and does not simply 
rely on a non-specific hydrophobic adsorptive surface.1 The crystal structure of P-gp 
has been solved, but still we are not much closer in knowing on beforehand which 
compounds would, or would not have, affinity to P-gp. However, there are new 
developments as during recent years there have been several publications studying 
the structure and function of transporters via molecular modeling.2–5 Better 
knowledge of P-gp structure could help to design specific P-gp tracers. The problem 
with many P-gp tracers is that they have affinity also to other transporters, especially 
to breast cancer resistance protein (BCRP).  
In chapter 2, we started experiments by developing three new isoquinoline 
derivatives [18F]MC210, [18F]MC224 and [18F]MC225, in the chapter referred to as 
[18F]1, [18F]2 and [18F]3, respectively. Fluorine-18 labeling was developed for these 
tracers and they were evaluated in transporter knockout and wild-type mice. 
[18F]MC210 and [18F]MC224 were not P-gp substrates in vivo, despite being classified 
as such in vitro. A small change in the molecule structure can cause a loss of P-gp 
affinity. [11C]MC113, as mentioned in chapter 2, is a carbon-11 analogue of 
[18F]MC224, so it has a methyl group instead of a fluoroethyl moiety. [11C]MC113 
was weakly transported by P-gp in vivo, whereas [18F]MC224 was not at all.6 On the 
other hand, [18F]MC225, and its carbon-11 analogue [11C]MC266, had very similar 
in vivo results.7 In addition, as described in chapter 5, [18F]MC225 analogue 
[18F]MC198 showed very similar in vitro but inferior in vivo results as [18F]MC225. 
Difference in the structures is only one double bond in the linker region separating 
aromatic moieties (Figure 1). Common feature in the compounds that were not P-gp 
substrates in vivo, [18F]MC210 and [18F]MC224, is that they have only one carbon 
atom between isoquinoline moiety and phenyloxazole or biphenyl structures. 
Therefore, it seems that the linker needs to be longer and/or more flexible with this 




type of compounds to allow optimum interaction of the molecule with the binding 
pocket of P-gp. [18F]KE64 has four carbons and one oxygen atom in the linker and 
it was weakly transported by P-gp, as described in chapter 5, although it otherwise 
has the same structure as [18F]MC224. [18F]MC225, which was performing the best 
out of these new tracers, has a propyl linker between isoquinoline and 
tetrahydronaphthalen structures.  
 
Figure 1. Structures of the new 18F-labeled compounds. Linker region is shown in 
red.  
[18F]MC225 had promising results in mice and it was therefore further evaluated in 
rats treated with P-gp and Bcrp inhibitors in chapter 3. Rats are preferred in the 
quantification of P-gp function in vivo due to the possibility to collect several arterial 
blood samples during the PET scans which enables metabolite analysis and kinetic 
modeling. In addition, the size of a rat brain is larger than mouse brain, which 
facilitates accurate data analysis. Metabolite analysis showed, that [18F]MC225 had 
faster peripheral metabolism than the most used P-gp substrate tracer (R)-
[11C]verapamil, according to literature, but less radioactive metabolites measured in 
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the brain (24 % vs. 50 % at 1 h p.i.), although still more than desirable. A PET camera 
measures only total radioactivity and cannot distinguish between parent and its 
formed radioactive metabolites. Therefore, low diffusion of peripherally formed 
radioactive metabolites across the BBB is an important aspect of good neuro PET 
tracers. If radioactive metabolites can cross the BBB, or are formed in the brain, 
regardless whether they are also P-gp substrates or they reflect non-P-gp mediated 
transport, they will complicate the quantification of the P-gp function.   
[18F]MC225 showed higher baseline brain uptake than [11C]verapamil and increases 
in the brain uptake after P-gp inhibition were smaller. [18F]MC225 is therefore clearly 
a weaker P-gp substrate than [11C]verapamil. Weaker substrates are less efficiently 
effluxed out of the brain and therefore the baseline uptake is higher than for 
[11C]verapamil. However, a weaker substrate might be advantageous in cases where 
P-gp function is expected to increase, such as in epilepsy and stroke.8,9 In case of a 
tracer with high affinity for P-gp (strong P-gp substrate), the brain uptake in normal 
brain tissue is low and in case of P-gp overexpression it would become even lower 
and might not be even measurable any more. On the other hand, when a tracer with 
less affinity for P-gp (weaker substrate) is used, such as [18F]MC225, it may still 
provide a measurable signal. Advantage of a weak P-gp substrate is therefore that it 
could be used to measure both increases and decreases of P-gp function. Another 
undesirable explanation for the high baseline uptake, which cannot be excluded at 
this point, could be unspecific binding in the brain. MC225 has been found to be 
inactive towards sigma receptors in vitro, but affinity to other targets in the brain, 
other than ATP binding cassette (ABC) transporters, has not been investigated. 
[18F]MC225 has similar distribution in the brain as [11C]verapamil. Uptake is highest 
in the frontal cortex and cerebellum, but otherwise uptake in the brain is quite 
uniform, which does not point to any specific secondary target in the brain.  
Not much is known about the physiological fluctuations in P-gp function across the 
day in relation to circadian rhythm and during sleep. [18F]MC225 was used to 
investigate daily rhythm of P-gp function and the effect of acute sleep deprivation in 
chapter 4. There have been varying reports in the literature about the daily rhythm 
of P-gp, and rhythms between the gene- and protein expression and protein function 
in different organs have been found to be distinct. In general, there is not sufficient 
knowledge about the correlation between the P-gp expression and its function. P-gp 




function, which was measured with [18F]MC225, was found to be the weakest in the 
early active phase and the greatest change occurred at the transition from sleep phase 
to active phase. Acute sleep deprivation had no effect on the P-gp function. Acute 
10 h sleep deprivation, during the normal sleep period of rats, was chosen to study 
the role of sleep in the regulation of P-gp function. Chronic sleep deprivation was 
not investigated, but it is possible that P-gp function could have been affected in that 
case. Instead of sleep deprivation, better option to study the role of sleep itself, not 
the consequence of the lack of sleep, would have been to compare naturally sleeping 
and naturally awake animals, but with PET this was not feasible. Knowing the rhythm 
in P-gp function, could help patients to administer a P-gp dependent medication at 
the right time. If the results in rats would be directly translatable to humans, then 
CNS drugs with affinity towards P-gp, should be taken in the morning to reach their 
target most efficiently, whereas this time point should be avoided if an opposite effect 
is desired. P-gp fluctuations should be also taken into consideration for design of PET 
studies, in order to measure real differences between the subjects instead of time-of-
day variation. Correct timing of PET scans would be especially important in humans 
which are scanned during the active period, whereas rats are usually scanned during 
the sleep cycle, where we did not find differences between early and late sleep phase. 
Correlation of in vitro and preclinical in vivo results was investigated in chapter 5 
with (R)-[11C]verapamil, (R)-N-[18F]fluoroethylverapamil (N-FeVer), (R)-O-
[18F]fluoroethyl-norverapamil (O-FeVer), [18F]MC224, [18F]MC225, [18F]MC198 and 
[18F]KE64. It was shown that the transport measured in vitro was concentration 
dependent. In vitro transport assay should be always performed at several 
concentrations and in combination with inhibitors. Use of only one concentration 
does not give enough information of the compound behavior and may lead to wrong 
conclusions, as was found with [18F]MC224 in chapter 1. Choice of assay is also 
important. Calcein-AM assay, for example, is an inhibition assay, which makes it 
difficult to translate the results of substrate PET tracers to in vivo. The best correlation 
with in vivo PET and biodistribution data was obtained in the bidirectional transport 
assay at the lowest test compound concentration, at 0.01 µM. These low 
concentrations may be difficult to measure without using radiolabeled test 
compounds. We labeled all the molecules with tritium (3H) which has a long half-life 
and samples can be measured rapidly by scintillation counting. Development of 
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reliable in vitro methods for prediction of P-gp interaction is very important since all 
new drugs need to be screened for transporters before regulatory submissions.  
Future perspectives 
P-gp induction 
In epilepsy and stroke, for example, P-gp expression has been shown to be elevated, 
but it is not clear to what extent increases in transporter expression reflect induction 
of P-gp by prescribed drugs.10–13 P-gp expression and/or function can be modulated 
by different endogenous and exogenous stimuli, such as inflammation, disease state, 
stress signals and environmental factors but also by pharmaceuticals and dietary 
components.14 Antidepressant venlafaxine and antiepileptic drugs levetiracetam, 
topiramate, phenytoin and valproic acid have been reported to induce P-gp 
expression and/or function in some animal models.15–18 The induction of P-gp 
activity, has been proposed as a new treatment strategy to limit CNS toxicity19 and 
to reduce the amount of accumulated amyloid-β (Aβ) in the brain in Alzheimer’s 
disease (AD).20,21 In AD, there is an imbalance between production and clearance 
of Aβ. P-gp is one of the transporters clearing Aβ, but in AD its function has been 
found to be reduced. Induction of P-gp would restore its function and could help 
delay the progression of the disease. For all these indications, accurate P-gp activity 
assessment is important to understand the role of P-gp. This can only be achieved 
with PET and a proper P-gp PET tracer.  
ABC-transporters such as P-gp, can be induced by mechanisms similar to those of 
metabolizing cytochrome P450 (CYP) enzymes.22 A nuclear pregnane X receptor 
(PXR in rodents, SXR in humans) has been found to regulate P-gp expression.23 
Steroidal antiglucocorticoid pregnenolone-16α-carbonitrile (PCN), anti-inflammatory 
and immunosuppressant glucocorticoid dexamethasone, antibiotic rifampin, herbal 
antidepressant St. John’s Wort and many antiretroviral drugs used in HIV 
pharmacotherapy are all nuclear pregnane X receptor ligands which have been 
reported to induce P-gp expression and/or function. 20,21,24–27 Another nuclear 
receptor, constitutive androstane receptor (CAR), which is a target in the 
pharmacotherapy of pain and inflammation, has been also identified as a regulator 
of P-gp expression at the BBB.28 CAR ligands, pain medicine acetaminophen and 




antiepileptic drug phenobarbital have been found to induce P-gp expression and/or 
function in rats.28,29 
Next, it would be interesting to perform an induction study with [18F]MC225 in 
healthy rats with a known inducer, such as dexamethasone, to establish if increased 
P-gp function could indeed be measured with [18F]MC225. An induction study in an 
AD animal model would be also interesting. There are many models available, but 
it is difficult to know in which ones P-gp would be affected. Animal models always 
represent just some aspects of the disease, and it could be that a model which would 
be otherwise a good representation of the disease, does not exhibit reduced P-gp 
function. In addition, most genetically modified animal models exist only in mice, 
whereas for PET imaging a rat model would be preferred, as discussed earlier. 
Therefore, before planning an induction study in an AD model, some models would 
have to be screened first for their applicability for such study. 
New tracers and targets 
Instead of using a tracer that is a substrate for P-gp, the use of an inhibitor would be 
a preferred strategy to study changes of P-gp expression. Inhibitors are binding with 
high affinity to the pump itself without being transported. Increased P-gp expression 
would result in increase in the tracer accumulation, instead of decrease as in the case 
of substrates. Then, also wild-type animals would have higher brain uptake than 
knockouts and non-radioactive inhibitors would displace radioactive inhibitor from 
its binding site and the brain uptake would decrease. So far, despite a lot of effort, 
no PET tracer has indisputably demonstrated this behavior at a tracer concentration. 
We also did not find any inhibitor tracers in our studies. Kannan et al. speculate that 
concentration of P-gp in the whole brain low is so low (Bmax = 1.3 nM in human 
brain) that very high affinity inhibitors (picomolar concentration, 1/KD) would be 
required in order to reach sufficient binding potential (Bmax/KD) and measurable PET 
signal.30 In addition, very lipophilic compounds, such as [11C]tariquidar and 
[11C]elacridar, have a very small free fraction which is available to bind to P-gp, since 
majority is bound to plasma proteins.   
ABC-transporter tracer development has been heavily focused on P-gp. BCRP is 
much less studied, but it could be an important target for PET imaging as well, as it 
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has been shown to possess similar function as P-gp. [18F]MC225 had negligible 
interaction with Bcrp in rodents, but it could be that BCRP binding would be a 
problem in humans, where BCRP expression is higher than P-gp expression.31,32 So 
far, there are no specific radiolabeled PET tracers developed for BCRP imaging, 
even though some BCRP inhibitors have been identified, such as Ko143 and 
gefitinib.33–35 Development of tracers for Bcrp imaging would be also challenging to 
study in rodents due to low expression levels in the brain. However, Bcrp function 
can be studied by bioluminescence imaging in luciferase expressing transgenic mice, 
as D-luciferin, substrate of firefly luciferase, is a specific substrate for Bcrp.36,37   
Clinical applicability of [18F]MC225 
[18F]MC225 radiolabeling by [18F]fluoroethylation via the two-step distillation method 
was reliable and consistent. However, for performing a first-in-man study with this 
tracer, it is necessary to set up a GMP-compliant production. Current efforts in the 
GMP production of radiopharmaceuticals are focused on disposable cassette-based 
synthesis units and kit-type reagents. For this reason, it is desirable to simplify the 
[18F]MC225 radiosynthesis into one-step approach. An option would be to insert for 
example ethyl tosylate or mesylate group already into the precursor, in which case 
[18F]F- could displace the leaving group directly. However, this might make the 
precursor molecule less stable because elimination or hydrolysis can occur.   
[18F]MC225 could be a useful PET radiotracer to image both increases and decreases 
of P-gp function also in humans. However, when planning P-gp inhibition studies, it 
should be noted that P-gp inhibitors have been found to cause a much smaller 
increase in humans in the brain exposure of PET tracers in clinically relevant doses 
than in preclinical setting. For example, [11C]verapamil with the tariquidar dose of 8 
mg/kg had 2.4-fold increase in the brain uptake in humans compared to 11-fold in 
rats, even though tariquidar had very similar half-maximum-effect concentrations in 
both rats and humans.38 This discrepancy has been explained by the inability of 
inhibitors to achieve sufficient unbound systemic concentrations, by higher cerebral 
blood flow in rats than humans and possibly higher fraction of brain-penetrating 
metabolites in rats.39 In addition, it is not known if the P-gp at the human BBB was 
fully inhibited, despite the observed plateau in concentration levels.38 A dose-
response study with [18F]MC225, ideally either in non-human primates or in healthy 




volunteers, could help to assess the sensitivity of this tracer to measure small changes 
in the P-gp function. To test the clinical applicability of [18F]MC225, it would be 
interesting to include patient groups where P-gp function is expected to be decreased 
(AD) or increased (epilepsy). However, it is controversial whether changes in the P-
gp function generally measured in neurological diseases (<25%) are clinically 
significant or not.39 On the other hand, P-gp is recognized for its role in limiting 
distribution and bioavailability of several drugs and it is consequently one of the 
most studied transporters. [18F]MC225 could be therefore also used to investigate 
drug-drug interactions (DDI) at the BBB.40  
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This thesis describes the development of new 18F-labeled radiotracers for 
quantification of P-glycoprotein (P-gp, ABCB1, MDR1) function at the blood-brain 
barrier (BBB). Chapter 1 gives an introduction about BBB structure, P-gp function 
and other ATP binding cassette (ABC) transporters. P-gp is an efflux transporter 
protein expressed at the BBB and many other tissues. It is involved in tissue 
homeostasis by removing harmful compounds, but it is also limiting entry of various 
drugs and thereby contributing in multidrug resistance. P-gp has similar function as 
breast cancer resistance protein (BCRP in human, Bcrp in rodents, ABCG2), which 
is another ABC-transporter at the BBB. P-gp function at the BBB has been found to 
be altered in many neurological diseases, which makes it an interesting target for 
imaging. Substrate tracers are efficiently effluxed by P-gp in a normal condition. 
Therefore, they have higher uptake in the brain when P-gp is inhibited or knocked 
out than when P-gp is functioning normally. Several positron emission tomography 
(PET) radiotracers have been developed to image P-gp function. Majority of them 
have been labelled with 11C, while labeling with 18F would increase the applicability 
due to longer half-life. 18F-labeled tracers can be transported to other imaging centers 
without an on-site cyclotron.  
In chapter 2, the organic synthesis, radiosynthesis, and in vivo evaluation in mice of 
three novel 18F-labeled tracers for imaging P-gp at the BBB is described. Two of them 
failed to show affinity to P-gp, but one compound, [18F]MC225, showed promising 
results in wild-type and in combined P-gp and Bcrp knockout mice and was therefore 
further evaluated also in P-gp knockout mice. Brain uptake in knockout mice was 2-
fold higher than in the wild-type, indicating substrate behavior. [18F]MC225 was 
selective to P-gp, had good metabolic stability and very little metabolites were 
measured in the brain. [18F]MC225 was produced with good radiochemical purity, 
molar activity and sufficient radiochemical yield. 
Chapter 3 describes PET studies with [18F]MC225 in rats treated with P-gp and Bcrp 
inhibitors. Comparison of kinetic modeling methods identified one-tissue 
compartment model fit with whole blood and metabolite corrected plasma values as 
input as the preferred method to calculate the influx and efflux parameters and 
distribution volume (VT) due to its accuracy and reliability. Baseline uptake of 
[18F]MC225 was higher than for other known P-gp substrate tracers. Up to 4-fold 





gp and Bcrp were inhibited. [18F]MC225 was selective to P-gp over Bcrp also in rats. 
However, metabolic stability was decreased in rats compared to mice and more 
radioactive metabolites were detected in the brain.  
In chapter 4, [18F]MC225 was used to study the daily rhythm of P-gp function in the 
brain in rats, and the effect of sleep deprivation. The weakest P-gp function, and 
consequently the highest brain uptake of [18F]MC225, was measured in the early 
active phase. No significant differences were found between the other investigated 
time points, early and late sleep phase and late active phase. Acute sleep deprivation 
of 10 h did not cause any change in the [18F]MC225 brain uptake compared to 
controls. Therefore, it was concluded that the daily rhythm in P-gp function was not 
directly dependent on sleep. Knowing the rhythm in P-gp function can be important 
in choosing a correct administration time for P-gp dependent drugs and to properly 
design PET studies.   
Chapter 5 compares in vitro assays in selecting radiotracers for in vivo P-gp imaging. 
In vivo rodent PET data of seven different tracers, including [18F]MC225, were 
compared to in vitro data. Initial in vitro experiments, bidirectional transport in Caco-
2 cells and calcein-AM assay in MDCKII-MDR1 cells, performed with 
nonradioactive compounds, did not correctly classify all the molecules and did not 
sufficiently assess differences between them. In vivo predictability was improved 
when bidirectional transport assay was repeated in MDCKII-MDR1 cells with 3H-
labeled compounds at three different concentrations. The best correlation with in 
vivo PET data was obtained at a concentration of 0.01 µM.   
In conclusion, [18F]MC225, a new specific 18F-labeled P-gp substrate radiotracer, was 
developed and evaluated in several preclinical studies. This tracer may be used to 
































Chapter 8  
166 
 
Positron emissie tomografie (PET) is een beeldvormende techniek die gebruik maakt 
van diverse radioactieve gelabelde geneesmiddelen, ook wel tracers of radiofarmaca 
genoemd. Met deze techniek, is het mogelijk om in vivo verschillende 
stofwisselingsprocessen te visualiseren en te meten. Dit proefschrift beschrijft de 
ontwikkeling en eerste toepassing van nieuwe 18F-gelabelde tracers voor het 
kwantificeren van de P-glycoproteïne (P-gp, ABCB1, MDR1) functie in vivo in de 
bloed-hersen barrière (BHB) met PET. In hoofdstuk 1, wordt een inleiding gegeven 
van de BHB-structuur en diverse efflux transporters, zoals P-gp en andere ATP-
bindingscassette (ABC) transporters. 
P-gp wordt tot expressie gebracht in de BHB, maar komt ook voor in andere 
weefsels. De transporter is betrokken bij het handhaven van de homeostase in de 
hersenen door schadelijke verbindingen te verwijderen, maar beperkt ook de 
toegang van verschillende geneesmiddelen en draagt daardoor bij aan 
geneesmiddelen resistentie. Tevens is een veranderde P-gp-functie in de BHB bij 
diverse neurologische ziekten geconstateerd. Door de ontwikkeling van nieuwe 
specifieke P-gp PET tracers, wordt de mogelijkheid gecreëerd om de rol van dit 
target in relatie tot hersenziekten, maar ook de interactie met geneesmiddelen in vivo 
te bestuderen. 
Tracers die substraat zijn voor P-gp, worden onder normale condities, efficiënt 
getransporteerd uit de hersenen. Een hogere hersenopname van de tracer wordt 
gekregen wanneer P-gp wordt geremd of uitgeschakeld. Verschillende tracers zijn 
ontwikkeld om de P-gp-functie te meten. Het merendeel is gelabeld met koolstof-11 
(halfwaardetijd 20 min), terwijl het labelen met fluor-18 ( halfwaardetijd 110 min) de 
toepasbaarheid zou verhogen vanwege de langere halfwaardetijd. Bovendien, 
kunnen 18F gelabelde tracers naar andere PET centra worden getransporteerd. 
In hoofdstuk 2 worden voor drie nieuwe 18F-gelabelde tracers de organische 
synthese, radiosynthese en in vivo evaluatie bij muizen voor het meten van P-gp in 
de BHB beschreven. Twee ervan lieten, ondanks gemeten in vitro affiniteit, in vivo 
geen P-gp transport zien. Echter, één verbinding, [18F]MC225, toonde veelbelovende 
resultaten in wildtype muizen en in muizen met gecombineerde P-gp en Bcrp gen 
knock-out (deze muizen hebben geen P-gp en Bcrp transporters in de BHB).   




De hersenopname van [18F]MC225 in knockout-muizen was 2 maal zo hoog dan in 
de wildtype, wat wijst op in vivo P-gp transport over de BHB van [18F]MC225. Ook 
is uit diverse studies gebleken dat [18F]MC225 selectief is voor P-gp. Verder is 
demetabole stabiliteit goed, De perifeer gevormde radioactieve metabolieten zijn 
slechts in kleine hoeveelheden aanwezig en kunnen de BHB niet passeren. De 
ontwikkelde radiochemische synthese van [18F]MC225 verloopt met voldoende 
opbrengst. Zowel de radio-chemische zuiverheid als de molaire activiteit is hoog, en 
dus geschikt voor het uitvoeren van PET studies.  
Hoofdstuk 3 beschrijft een PET studie met [18F]MC225 in ratten die werden 
behandeld met P-gp en Bcrp-remmers. Om het P-gp transport in vivo te meten, is 
een kinetisch model nodig, die het gedrag van [18F]MC225 in vivo kan beschrijven. 
Om het optimale model te vinden, zijn verschillende kinetische modellen met elkaar 
vergeleken. Uit de vergelijkende studie is gebleken dat een één-weefselcompartiment 
model, met vol bloed en metaboliet gecorrigeerde plasmawaarden als input,  de 
voorkeur heeft voor het berekenen van diverse kinetische parameters en het 
distributievolume (VT).  
De baseline-opname van [18F]MC225 in het brein van een gezonde rat, was hoger 
dan bij andere bekende P-gp tracers. Een 4-voudige toename van de hersenopname 
(VT) werd waargenomen wanneer zowel P-gp als Bcrp werden geremd. Ook is 
gebleken dat [18F]MC225 selectief is voor P-gp ten opzichte van Bcrp bij ratten. Uit 
metabolietenanalyse in plasma is gebleken dat de metabole stabiliteit van de tracer 
bij ratten minder is dan in vergelijking met muizen. Tevens werden meer 
radioactieve metabolieten in de hersenen gedetecteerd. Echter, dit is wel minder dan 
bij de huidige generatie P-gp C-11 tracers. 
In hoofdstuk 4 is [18F]MC225 gebruikt om het dagelijkse ritme van de P-gp-functie 
en het effect van slaapdeprivatie in ratten te bestuderen. Een verminderde P-gp-
functie, en dus hogere brein opname van [18F]MC225, werd gemeten in de vroege 
actieve fase. Er werden geen significante verschillen gevonden tussen de andere 
onderzochte tijdstippen, vroege en late slaapfase en late actieve fase. Een acuut 
slaapgebrek van 10 uur had geen invloed op de hersen opname van [18F]MC225 in 
vergelijking met de controles. Daarom werd geconcludeerd dat, in dit model, het 
dagelijkse ritme in de P-gp-functie niet direct afhankelijk was van slaap. Het feit dat 
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er een dagelijkse ritme lijkt te zijn in de P-gp functie in de BHB, is een belangrijke 
ontdekking. Dit geldt met name voor het kiezen van een juiste toedieningstijd voor 
P-gp-afhankelijke geneesmiddelen en voor een juist design van PET-onderzoeken. 
In hoofdstuk 5 wordt een studie beschreven over de voorspelbaarheid van het 
selecteren van potentiele P-gp tracers m.b.v. in vitro screening. Het in vivo gedrag 
van zeven verschillende P-gp tracers, waaronder [18F]MC225, is vergeleken met in 
vitro gegevens. Initiële in vitro experimenten zoals bi-directioneel transport in Caco-
2-cellen en calceïne-AM-assay in MDCKII-MDR1-cellen, zijn uitgevoerd met niet-
radioactieve P-gp tracers, en het is gebleken dat dit geen goede in vivo voorspelling 
opleverde. De in vivo voorspelbaarheid werd verbeterd wanneer een bidirectionele 
transportassay werd herhaald in MDCKII-MDR1-cellen met 3H-gelabeld 
verbindingen in drie verschillende concentraties. De beste correlatie met in vivo 
PET-gegevens werd verkregen bij een concentratie van 0.01 μM. 
In conclusie, [18F]MC225, een nieuw specifiek 18F-gelabelde P-gp substraat tracer, 
werd ontwikkeld en is geëvalueerd in verschillende preklinische studies. Deze 
nieuwe tracer kan worden gebruikt om in het brein zowel regionale verschillen, als 
de toename als afname, van de P-gp-functie in de BHB in beeld te brengen. 
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